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In the modern age of personalized medicine and patient stratification, biomolecular 
markers and accompanying molecular profiling techniques have become deeply 
embedded in clinical research and molecular pathology (Cristofanilli et al., 2004; 
Hurvitz et al., 2013; Oviaño et al., 2016; Pecoraro et al., 2016). Specifically analytical 
chemistry methods are applied to pathological tissues in order to obtain the identity, 
quantity and localization of disease-specific molecular features. One of these 
techniques is mass spectrometry imaging (MSI), which is a mass spectrometry-based 
technique that allows the spatially-correlated analysis of biomolecular ions directly from 
thin tissue sections (Caprioli et al., 1997). This introduction will cover the basics of the 
mass spectrometry required for understanding the MSI research described in this thesis 
and to place it in the context of wider MSI research.  
 
Figure 1-1: (A) A schematic overview of the layout of a mass spectrometer with its core components. From left to 
right, the ion source, one (or more) mass analyzers, a detector, and a data acquisition computer. (B) Example of a 
mass spectrum, with the horizontal axis representing the mass-to-charge ratio, and the vertical axis representing the 
(relative) abundance, or signal intensity.  
1.2 Mass spectrometry 
Mass spectrometry (MS) is an analytical chemistry technique that allows the detection, 
identification and quantification of ionized molecular species. Since the recording of the 
first mass spectrum in 1912 by Sir J.J. Thomson (Thomson, 1912), numerous 
technological advances have made MS one of the most sensitive and fast molecular 
analysis techniques available with a great variety of application areas including 
petrochemistry, forensic science, pharmaceutical research, food sciences and 
biomedical research (te Brake et al., 2015; Dekker et al., 2014; Esteve et al., 2015; 
Frese et al., 2017; Groeneveld et al., 2015; Maleki et al., 2016; Smith et al., 2008). 
 Mass spectrometers employ a range of different technologies but share the same 
basic layout (Figure 1-1A); ion source, one or multiple mass analyzers, and a detector 
and acquisition computer. In the ion source, the molecular analytes are converted from 
the liquid or solid phase into gas-phase ions. The mass analyzer separates the ions 
based on their mass-to-charge (m/z) ratio. Finally, the separated ions and their relative 
abundance, are recorded by the detector. The molecular content of the analyzed 
sample is visualized in a mass spectrum. Consisting of two perpendicular axes, a mass 
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spectrum is usually displayed with the x-axis representing the m/z or ‘mass’ in Daltons 
(Da) per unit charge, and the y-axis representing intensity of the signal (Figure 1-1B) 
(Glish and Vachet, 2003). 
1.2.1 Ion source  
A large number of different ionization techniques are available, each with different 
characteristics that make them more/less suitable to specific application areas. The 
choice of ionization method can have a large effect on the quantitative and qualitative 
outcome of the analysis. For example, the analysis of the metabolic content of serum 
by electrospray (ESI) MS, atmospheric pressure chemical ionization (APCI) MS, and 
matrix-assisted laser desorption/ionization (MALDI) MS led to the detection of different 
sets of small molecules (Nordström et al., 2008). Also, the linearity and lower limit of 
quantification for the same compound were shown to be heavily influenced by the 
choice of ionization method (Buse et al., 2014). Therefore, a careful understanding of 
the different ionization methods is essential to determine the application areas most 
suited to the ionization methods available within any single laboratory. Present day 
biomolecular MS utilizes soft ionization techniques that are capable of transferring large 
molecules, such as proteins, from the liquid or solid phase to the gas phase without 
excessive fragmentation. The two most common ionization techniques in biomolecular 
MS are ESI, and MALDI (Domon and Aebersold, 2006). 
1.2.1.1 Electrospray ionization  
ESI, first reported by Yamashita and Fenn in 1984 (Yamashita and Fenn, 1984) and 
later demonstrated to enable protein analysis by mass spectrometry (Fenn et al., 
1989), is a continuous ionization mechanism, based on the nebulization of a dissolved 
sample in an atmospheric pressure environment. The analyte molecules are dissolved 
in an aqueous solution containing an organic solvent (e.g. methanol or acetonitrile) 
and, in the case of positive ion analysis, a small amount of acid (e.g. formic, or acetic 
acid). The sample solution is introduced into a needle, which is held at a high electrical 
potential relative to the mass spectrometer’s sampling capillary. Upon leaving the 
needle, the solution experiences the strong electric field between the needle and the 
mass spectrometer’s sampling capillary, and forms a Taylor cone from which small, 
highly charged droplets are released. The formation of molecular ions from the charged 
droplets is depicted in Figure 1-2 (Wilm, 2011). 
 The strong electric field between the needle and the sampling capillary attracts ions 
to the solution surface, forming the Taylor cone and a steady stream of charge-
enriched droplets. Solvent evaporation then takes place (the ratio of the surface area 
to volume of the droplets is high and so evaporation takes place quickly). During 
solvent evaporation charge repulsion between the excess charges on the droplets leads 
to deformation; when localized repulsion exceeds the local surface tension of the 
droplet (Rayleigh instability), asymmetric fission occurs in which the smaller droplets 




Rayleigh instability continues until only very small droplets remain. In the charge 
residue model, which is believed to be the dominant mechanism for the formation of 
multiply charged ions of large molecules, this process continues until a single, solvated, 
and multiply charged analyte ion is produced. In the ion evaporation model, which is 
believed to explain the formation of ions of small molecules, the (solvated) ions are 
desorbed out of the small droplets owing to the very strong electric field in the ion 
source (Awad et al., 2015; Beaudry et al., 1999; Fenn et al., 1990; Nordström et al., 
2008).  
 Multiple charging and multiple charge states, e.g. lysozyme being detected in 
charge states +5 to +25, are characteristic of ESI (Krusemark et al., 2009; Valentine et 
al., 1997). This has two distinct benefits; (i) it brings the m/z of the protein ions into 
the m/z range that can be analyzed by most mass analyzers with higher mass 
resolution and sensitivity, and (ii) it enables peptide/protein ion fragmentation and the 
detection of complementary fragments, both of which promote their structural 
characterization (Wysocki et al., 2005).  
 The continuity of the ESI method makes it highly suitable for use in a hyphenated 
system where the mass spectrometer is coupled to a chromatographic separation, such 
as liquid chromatography (LC), or capillary electrophoresis (CE). 
Figure 1-2: Schematic overview of the ion formation in electrospray ionization, visualizing both the charge residue 
model and the ion evaporation model. 
1.2.1.2 Matrix-assisted laser desorption/ionization  
In contrast to the continuity of ESI, MALDI is a pulsed ionization process. Developed by 
Karas and Hillenkamp (Karas and Hillenkamp, 1988; Karas et al., 1987) the MALDI 
method requires the analyte molecules to be embedded in an excess amount of a 
chemical matrix. The matrix is typically a small organic acid and a strong absorber of 
UV light. In a MALDI experiment a solution of the analyte is mixed with an excess of a 
matrix solution. During solvent evaporation the matrix crystalizes, incorporating the 
analyte (proteins) or coming in to close contact with the analyte (small molecules). The 
matrix crystals have been shown to segregate salts away from the analytes, thereby 
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effectively helping to de-salt the samples and improve detection sensitivity. Irradiation 
of the analyte doped matrix crystals with a pulsed UV laser leads to efficient production 
of molecular ions. MALDI involves the super excitation of the laser-absorbing matrix 
with the laser (MALDI requires laser fluence thresholds of 30 J/m2 and pulse lengths <5 
ns, so that the laser energy does not have sufficient time to dissipate during 
irradiation). Above laser fluence threshold the super heating causes an almost 
explosive phase transition, with rapid collective motion of the matrix substrate into the 
gas phase. The analyte molecules are brought into the gas phase by being entrained 
within this collective motion. This process of the explosive phase change leads to the 
formation of neutral and charged matrix and analyte molecules, as well as clusters. All 
molecules that form gas-phase ions, anions by deprotonation or cations by available 
protons (H+) or metals (e.g. Na+, K+, Ag+), are accelerated toward the mass analyzer 
by means of an electric (Figure 1-3) (Dreisewerd, 2014; Hanton et al., 1999; McDonnell 
and Heeren, 2007). 
 Careful selection of the matrix is key to the success of a MALDI-MS analysis, as the 
physiochemical properties of the MALDI matrix will affect its co-crystallization with the 
analytes, their co-desorption on laser irradiation and the efficiency of the ionization 
process (Dreisewerd, 2003, 2014; Zenobi and Knochenmuss, 1998). Over the years 
many compounds have been empirically determined to be suitable MALDI matrices; 
some for very specific applications, such as 1H-pteridine-2,4-dione (lumazine), 2-
aminobenzaminde, 2-aminobenzoic acid, β-carboline alkaloids, and graphene (Calvano 
et al., 2010; Dong et al., 2010; Nonami et al., 1997; Shroff and Svatoš, 2009; 
Smargiasso et al., 2012), while other matrices are more generally applicable. For 
example, α-cyano-4-hydroxycinnamic acid (CHCA), 2,5-dihydroxybenzoic acid (DHB), 
and sinapinic acid (SA) are matrices that are commonly used for the analysis of 
peptides, lipids, and proteins in positive ion mode. 9-aminoacridine (9-AA) is commonly 
used for the negative ion analysis of small molecules. 
 The experimental conditions of the ion source and the MALDI sample preparation 
determine the accessible ion yield of the analyte. The ion source instrumentation 
includes how the laser interacts with the sample. Optimization of the irradiation 
conditions can affect the ion flux towards the mass analyzer; too low of a laser fluence 
(energy per illuminated surface) will result in poor MALDI signals, too high of a laser 
fluence will cause extensive in-source fragmentation of the analyte molecules 
(Dreisewerd et al., 1995). The focus of the laser is also important, in that it must be 
tuned along with the laser fluence to ensure that the on-target laser fluence is above 
threshold but not too high that it leads to extensive fragmentation. Furthermore, the 
MALDI matrix crystals of the sample preparation can lead to heterogeneity in the 
sample preparation, mostly observed in dried-droplet sample preparations. In order to 
effectively average this crystal-derived heterogeneity older MALDI instruments used 




 In the last decade, MALDI instruments have moved toward fast, tightly focused 
laser beams, and even include structured laser spots. Qiao et al. demonstrated that 
with careful control of the laser fluence tightly focused laser beams delivered more 
signal per unit area (Qiao et al., 2008), and Holle et al. demonstrated that increased 
signal intensity and reduced analyte depletion was observed if a larger laser beam was 
converted into an array of tightly focused point-illumination beams (Holle et al., 2006). 
These technologies have now combined to offer high speed, high sensitivity MALDI 
ionization systems. Part of the driving force for the development of such high speed, 
high sensitivity, tightly focused laser beam systems has been MALDI-MSI, in which the 
laser beam focus, sensitivity and throughput helps determine the achievable spatial 
resolution.  
 
Figure 1-3: A schematic overview of the matrix-assisted laser desorption/ionization mechanism. 
1.2.2 Mass analyzer and ion detection   
The mass analyzer separates the ions based on their m/z ratio, after which the ions are 
detected at their m/z. In mass spectrometry two terms are often used to define the 
quality or the performance characteristics of a mass analyzer: (i) the mass accuracy 
refers to the error between the measured m/z and the calculated, true m/z of a 
compound, and (ii) the mass resolving power, or resolution, defines the ability of the 
mass analyzer to distinguish between two peaks with very similar m/z. A broad range 
of technologies are available that combine different characteristics in terms of mass 
accuracy, mass resolving power, sensitivity (ion transmission and detection 
efficiencies), m/z range, speed, tandem mass spectrometry, ease of hyphenation with 
e.g. liquid separations, ease-of-use, cost (purchase & maintenance). Such mass 
spectrometry systems include: (i) quadrupole mass analyzers, (ii) time-of-flight (TOF) 
mass analyzers, (iii) magnetic or electrostatic sector mass analyzers, (iv) quadrupole 
ion trap mass analyzers, (v) Orbitrap mass analyzers, and (vi) Fourier transform (FT) 
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ion cyclotron resonance (ICR) mass analyzers. For a detailed comparison of the 
systems the interested reader is directed toward the review by Himmelsbach 
(Himmelsbach, 2012). Here we will focus on the technologies mostly used in MALDI-
MSI. 
1.2.2.1 Quadrupole mass analyzer  
The quadrupole mass analyzer consists of a set of four parallel metal rods to which a 
combination of radio frequency (RF) and direct current (DC) voltages are applied. The 
stability of ion motion in a quadrupole is governed by the Mathieu parameters 











where U, V and f are the DC potential, RF potential and RF frequency, respectively, and 
ro is the quadrupole’s field radius (Kero et al., 2005). 
 
Figure 1-4: (A) Mathieu stability diagram for ions of m/z 28, 69, and 219. (B) Simulated mass spectra showing these 
ions as the RF and DC voltages are scanned along the dotted and solid scan lines (in A). Figure recreated from Kero et 
al. (Kero et al., 2005). 
 The quadrupole is essentially a mass filter, in which the applied RF and DC voltages 
determine which ions have a stable trajectory through the quadrupole. Figure 1.4 
shows the stability diagram for ions of m/z 28, 69 and 219. It can be seen that when 
the DC voltage (Mathieu parameter a) is set to zero, ions of a wide mass range have a 
stable motion and are passed through the quadrupole. In this mode the quadrupole 
acts as an ion guide. With increasing DC voltage, the stability region decreases in size, 
and thus the m/z range of ions with a stable trajectory decreases. By ramping the RF 
and DC voltages synchronously it is possible to perform a mass analysis, by 
sequentially only permitting the transmission of selected ions (and in which the DC 
voltage determines the mass resolution of the mass analysis). The solid and dashed 




resolution mass scan. The figure shows idealized mass spectra resulting from these two 
scans. It can be seen that the values of the RF and DC voltage can be selected to 
transmit a single ion of interest, which is used extensively in quadrupole-time-of-flight 
(Q-TOF) type instruments for selection of the precursor ion (Kero et al., 2005). 
1.2.2.2 Time-of-flight mass spectrometry  
A TOF mass analyzer (Figure 1.5A) is a pulsed system and so has been extensively 
coupled to MALDI ion sources. It is also used with ESI, in which pulsed ion gates are 
used to introduce packets of ions from the continuous ESI beam. In a MALDI-TOF 
system the ion source consists of a target plate (containing the MALDI sample) 
separated by a short distance from a series of counter electrodes. A strong electric field 
between the target plate and the first counter electrode, 20-30 kV over a distance of a 
few mm is common, means any ion formed by the MALDI process is immediately 
accelerated into the mass spectrometer. MALDI generated ions are normally singly 
charged and so the kinetic energy of the ion (in eV) is simply equal to the accelerating 
potential of the MALDI-TOF ion source. All ions then enter the time-of-flight region with 
the same kinetic energy. The time-of-flight (Tf) is defined as the time between the 
MALDI laser pulse and the moment the ion hits the detector. In its most simple form 
this can be written as: 
𝑇𝑓 =  
𝐿
𝑣
       (1) 
    𝐸𝑘 =  
𝑚𝑣2
2
 = 𝑧𝑉     
 (2) 
where L is the length of the flight tube, v is velocity, Ek is the kinetic energy, m is mass, 
z is charge, and V s the accelerating potential of the ion source. A substitution results 
in formula (3), which shows that when L and V are constant the time-of-flight is 
proportional to the square root of the m/z ratio. Higher molecular weight molecules will 
have longer flight times compared to small molecules (Cotter, 1992; Guilhaus et al., 
1997). 









      (3) 
 Such a simple TOF mass spectrometer results in a moderate mass resolving power 
(Radionova et al., 2016). Over the last decades multiple developments have further 
increased the achievable mass resolution. These include:  
 (i) pulsed extraction – otherwise known as time-lag focusing or delayed extraction, 
uses an additional pulsed electric field in the ion source to time focus the ions on to the 
detector (Brown and Lennon, 1995; Wiley and McLaren, 1955). 
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 (ii) reflectron – effectively an electrostatic mirror that reflects ions onto the 
detector. Faster ions move deeper into the mirror before being reflected, and thus 
travel a longer distance. Careful design of the reflectron field enables the ions to be 
time-focused onto the detector, thereby improving mass resolution (Mamyrin et al., 
1973). 
 (iii) longer flight tubes – as can be seen in equation (3) a long flight tube 
theoretically leads to longer flight times, and increased time between ions of different 
mass (so greater mass resolution). However, this is offset by dispersion of the ions 
during the time-of-flight. In order to increase the flight path without losing mass 
resolution, a focusing electrostatic lens was introduced in the flight tube (Vestal and 
Juhasz, 1998). 
 (iv) orthogonal acceleration – orthogonal acceleration TOF systems decouple the 
mass analysis from the ion generation event. In this manner the variability in initial 
position and energy of ion formation, which compromises the theoretical performance 
of axial TOF systems, has less effect on the performance of an orthogonal acceleration 
TOF system (Dawson and Guilhaus, 1989).  
 
Figure 1-5: A schematic overview of (A) a linear TOF mass analyzer including a reflecton and reflectron detector for 




 Modern TOF systems have many characteristics favorable to MSI, including rapid 
scan speeds, high sensitivity, good mass resolution and mass accuracy (up to several 
ppm and 50k resolving power for thin layer samples using a highly focused laser 
beam), wide mass range, and good dynamic range (102 – 103). 
1.2.2.3 Fourier Transform mass spectrometry  
While TOF-MS will provide decent performance, based on mass accuracy and resolving 
power, for some applications higher performance is required. Fourier Transform MS 
(FTMS) is capable of providing ultra-high mass resolution and accuracy, as well as a 
much higher dynamic range. It may not be necessary for every application to analyze 
samples using ultra-high resolution and accuracy, however, in some applications in 
which the samples consist of complex analyte mixtures containing many near-isobaric 
species, FTMS is essential in order to obtain accurate and confident molecular 
identifications (Scigelova et al., 2011). 
 In FTMS, the most common mass analyzers are the Fourier Transform Ion Cyclotron 
Resonance (FTICR) (Comisarow and Marshall, 1974) and the Orbitrap (Makarov, 2000). 
And, although their appearance is very different, both FTICR and Orbitrap analyzers 
use an image current detection system and the application of a mathematical Fourier 
transformation to convert the time domain transients, produced by the image current, 
into a mass spectrum (Scigelova et al., 2011). FTICR is based on the rotational 
(cyclotron) motion of an ion in a magnetic field. In FTICR-MS (Figure 1-5B), the ions 
are guided into a Penning trap placed in the center of a strong magnetic field (usually 
provided by a superconducting magnet). There, the ions are trapped by an electric field 
provided by two trapping electrodes at both ends of the trap. The ions trapped in the 
magnetic field rotate in a plane perpendicular to the magnetic field, at their cyclotron 
frequency (minus a small frequency due to the trapping field and the presence of other 
ions in the trap). At room temperature the cyclotron frequency of an ion is very small, 
e.g. in a 9.4 T field an ion of m/z 1000 has a cyclotron radius of 0.077 mm (Marshall et 
al., 1998). In order to detect the ions, their cyclotron motion is excited by the 
application of a radio-frequency (RF) electric field at the ion’s cyclotron frequency. All 
ions of the same m/z ratio are excited, coherently, within the ICR trap, increasing their 
cyclotron radius. After the excitation field is switched off, the ICR-motion-excited ions 
remain at their excited radii. The coherent motion of these ions induces an image 
charge as they move past a detector plate; using a pair of opposing detector plates 
leads to the creation of an image current oscillating between the plates, at the ion’s 
cyclotron frequency. This image current is converted to a voltage, amplified and 
digitized, and forms the free-induction-decay (FID) of the FTICR experiment. A Fourier 
transform is used to convert the ICR signal from the time domain to the frequency 
domain. In the absence of an electric field or the presence of other ions (space charge) 
an ion moving freely in a magnetic field, rotates with a characteristic cyclotron 
frequency, given by 
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𝜔 =  
𝑞
𝑚
𝐵       (4) 
in which ω is the ICR frequency, q represents charge, m is the mass of the ion and B is 
the magnetic field strength (Nikolaev et al., 2016). In the presence of space charge the 
ion moves with two distinct circular motions, the reduced cyclotron motion (at a 
frequency slightly below that of the free cyclotron frequency) and the magnetron 
motion (a slow and low frequency secular motion). A number of different equations 
have been reported for accurate calibration of FTICR datasets (Barry et al., 2013; 
Marshall, 1998). The two most common calibration equations are those reported by 



















 The advantage of the Francl equation is that the numerator is dependent only on 
the magnetic field strength, and B is essentially a correction factor for the near-
constant shift in frequency due to space charge. Accordingly, FTICR mass spectra that 
have been calibrated using the Francl equation can be recalibrated using a single 
internal lock mass to correct for differences in space charge from scan to scan (Barry et 
al., 2013; Easterling et al., 1999). 
 Ultra-high resolution and mass accuracy of FTICR mass spectrometers are highly 
dependent on the strength of the magnetic field provided by the superconductive 
magnets. For this reason, progress in FTICR-MS resolution/mass accuracy has 
benefited from developments in superconductive magnet technology (Nikolaev et al., 
2016). 
1.2.3 Tandem mass spectrometry     
The availability of a wide variety of ionization, mass analysis and detection methods 
has made mass spectrometry a powerful tool for the characterization of biomolecules. 
In order to assign definitive identities to the detected ions it is necessary to fragment 
the ions into structurally informative fragments. Structural information is obtained by 
selecting and isolating single ion species from the sample, cause them to fragment, and 
analyze the masses of the fragments (de Hoffmann, 1996). This is commonly referred 
to as tandem mass spectrometry (MS/MS), as it involves at least two stages of mass 
analysis. The first stage of mass analysis is used to select and isolate the precursor ion. 
Following the fragmentation event (discussed in more detail below) the fragment ions 




m/z, before reaching the detector. Depending on the instrumental setup MS/MS can be 
performed either in space by coupling two mass analyzers; in time by performing the 
two events in the same mass analyzer, utilizing an ion storage device; or in a 
combination of space and time, in so-called hybrid instruments (de Hoffmann, 1996).  
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Figure 1-6: Overview of the different fragment ions produced during peptide fragmentation. The top panel shows the 
fragmentation of the peptide backbone, the lower panel shows the ions formed during fragmentation. 
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 A common example of MS/MS in space is performed using a Q-TOF type 
instrument, in which the precursor ion is isolated with a quadrupole mass analyzer. The 
isolated ions are then accelerated into a collision cell (typically another multipole in a 
separate vacuum chamber held at higher pressure) where they will collide with an inert 
gas (e.g. N2). The collision converts some of the kinetic energy of the precursor ion into 
internal energy. If the increase in internal energy is sufficient it will cause the precursor 
ions to fragment in a process termed collision-induced dissociation (CID), pioneered by 
Jennings, and McLafferty in the late 1960s (Jennings, 1968; McLafferty et al., 1973). In 
a Q-TOF setup, the newly formed fragments enter a TOF section for mass analysis and 
detection. By switching the DC component of the quadrupole off/on, a Q-TOF 
instrument can be rapidly switched between MS and MS/MS. Such switching is now 
routinely performed for data dependent MS/MS, in which the most intense ions 
detected in the MS scan are selected for isolation in the quadrupole, and fragmented 
by CID before fragment ion analysis.  
 MS/MS in time is normally employed in trap-based MS platforms (e.g. ion traps and 
FTICR). The fragmentation step occurs following a chain of events: (i) all ions are 
guided to the mass analyzer, (ii) all but the selected ions are ejected from the trap, (iii) 
the ion’s flight path is excited by using an auxiliary RF field at the frequency of the ion’s 
secular motion in the trap, (iv) a collision gas is introduced into the trap, collisions 
between the excited ions and gas molecules cause fragmentation, (v) mass analysis of 
the fragments (de Hoffmann, 1996). 
 Many fragmentation methods are currently available, each with its specific set of 
fragmentation characteristics and application areas, nevertheless the basic principle of 
fragmenting selected precursor ions in order to obtain structural information remains 
the same. In the tandem MS analysis of peptides, the choice of fragmentation method 
will affect the type of fragment ions detected in the MS/MS spectrum. Roepstorff & 
Fohlman proposed the nomenclature for the different fragment ions which is still used 
to date, albeit after modifications by Johnson et al. (Johnson et al., 1987; Roepstorff & 
Fohlman, 1984) (Figure 1-6 & Table 1-1). 
1.3 Mass spectrometry imaging 
The mass spectrometric analysis of sample surfaces was made available with the 
introduction of secondary ion MS (SIMS). However, the introduction of MALDI-MS 
provided the breakthrough for the analysis of large biomolecules. Both SIMS and 
MALDI-MS are capable of acquiring mass spectra from discrete locations, which makes 
them suitable technologies for imaging applications. The first macromolecular mass 
spectrometry imaging (MSI) analysis of biological samples was performed in 1997 by 
Caprioli et al. (Caprioli et al., 1997). This first publication showed the distribution of 
several proteins and peptides in various biological tissues following analysis by spatially 
correlated MALDI-MS. While the early work in the Caprioli lab focused on the 




MS, it was quickly recognized that the MSI technology was of great value for 
biomedical and clinical research (Chaurand et al., 1999; Stoeckli et al., 1999, 2001). 
 The principle behind every MSI analysis is the acquisition of spatially correlated 
mass spectra from discrete spots on a sample surface (Figure 1-7). The single mass 
spectra, acquired following a Cartesian coordinate system, are assembled into a data 
cube in which the X- and Y-axes represent the X- and Y-coordinates of the image, the 
Z-axis represents the m/z ratio, and the values at each voxel the intensities. By 
selecting a specific m/z, representing an analyte, one can plot the intensity as a 
function of position, to display the relative abundance of the analyte throughout the 
analyzed sample (McDonnell and Heeren, 2007). 
1.3.1 MSI modalities   
Depending on the application and the analytical requirements, a variety of MSI 
modalities are available (Figure 1-8). Secondary ion mass spectrometry (SIMS, Figure 
1-8B) is available for the very high spatial resolution (~50 nm) analysis of atomic ions 
and small molecules (Slodzian et al., 1992). In SIMS, a focused (primary) ion beam is 
fired at the sample surface. Upon impact, part of the primary ions’ kinetic energy is 
transferred to the atoms and ions on sample surface. If their resulting kinetic energy 
exceeds the binding energy of the substrate, the atoms and ions are released (Delcorte 
and Garrison, 2000). The analysis of larger molecules by SIMS suffers from poor 
sensitivity, as a result of the decrease in secondary ion emission for higher m/z species 
(Touboul et al., 2004). In desorption electrospray ionization (DESI, Figure 1-8C), the 
first MSI modality capable of analysis under ambient conditions, features of both ESI 
and desorption ionization methods are combined. An electrospray needle, directed at 
the sample, is used to create a focused electrospray by applying a high electrical 
potential to the spray solution. Like in a conventional ESI source, droplet formation, 
desolvation and acceleration is assisted by a gas flow (Takáts et al., 2004). During the 
brief interaction of the charged droplets with the target surface, analytes present on 
the surface are transferred to the mass spectrometer inlet following the droplet pick-up 
model (Venter et al., 2006). DESI-MSI is very well suited for small molecule and lipid 
analysis, but similar to SIMS, has a low sensitivity analyzing large biomolecules from 
tissue samples. One of the major advantages of DESI, and other ambient ionization 
methods, is that it does not require sample preparation for the analysis of analytes 
from either solid, frozen, liquid, or gaseous samples (Takáts et al., 2004, 2005). The 
success of DESI-MSI was followed by the rapid development of many novel ambient 
ionization methods. A thorough review of a large number of ambient ionization 
methods is provided by Wu et al. (Wu et al., 2013). Here a short description of the 
more established techniques is provided. 
 In laser ablation electrospray ionization (LAESI, Figure 1-8D) mass spectrometry, a 
focused mid-infrared laser irradiates discrete spots on the sample surface exciting OH 
vibrations of water molecules in the sample, causing desorption of the analyte 
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molecules from the sample surface. The desorbed molecules are post-ionized by 
capturing them in an electrospray jet, positioned 1-3 cm above the sample surface. 
LAESI is performed under atmospheric pressure in ambient conditions, and does not 
require extensive sample preparation as it uses water in the sample as the laser-
absorption matrix. This MSI modality has been applied for the analysis of a multitude of 
analyte classes, ranging from small molecules to peptides and proteins (Nemes and 
Vertes, 2007; Wu et al., 2013). 
 Nano-DESI (Figure 1-8E) and liquid extraction surface analysis (LESA, Figure 1-8F) 
are closely related MSI modalities as they both use liquid microjunction surface-
sampling (LMJ-SSP) to transfer analytes from the sample surface to the MS. LMJ-SSP is 
based on a set of capillaries that are in close proximity of each other and to the sample 
surface. A solvent flow connects the capillaries and sample surface through a liquid 
microjunction, allowing the localized extraction of analytes from the sample surface 
(Van Berkel et al., 2002). The configuration of the capillaries is what sets apart nano-
DESI and LESA. In a typical LESA setup, a concentric capillary is placed just above the 
sample surface in a perpendicular fashion. Solvent will flow through the outer capillary, 
forming a liquid junction with the sample surface, allowing analyte extraction from the 
sample surface. The inner capillary is used to aspirate the dissolved analytes and guide 
them to an ESI source where the analytes are ionized and enter the MS, as illustrated 
in Figure 1-8F (Kertesz and Berkel, 2010). The nano-DESI setup is based on the same 
principles, but uses two separate capillaries (one solvent supplying capillary, and one 
aspirating capillary) that move over the sample in conjunction, allowing lower flow 
rates and smaller liquid bridges (resulting in better lateral resolution) (Lanekoff et al., 
2013). Both these MSI modalities operate under atmospheric pressure and ambient 
conditions and find their applications in the analysis of small molecules, 
pharmaceuticals, lipids, and (proteolytic) peptides (Van Berkel et al., 2008; Eikel et al., 
2011; Rao et al., 2013). 
 Due to its versatility, the most popular MSI modality is MALDI-MSI (Figure 1-8A); 
while most ambient MSI modalities are limited to the analysis of small molecules and 
lipids, MALDI-MSI is routinely used for the analysis of small molecules, lipids, N-linked 
glycans, (proteolytic) peptides, intact proteins, and more recently also proteoforms 
(Dilillo et al., 2017; Ellis et al., 2016; Kriegsmann et al., 2016; Liu et al., 2013a; Lou et 
al., 2016a; Powers et al., 2013). Most ambient MSI modalities have in common that, in 
order to analyze a sample, hardly any sample preparation is required. In MALDI-MSI 
the class of analytes that is eligible for analysis is determined mostly by the sample 





Figure 1-7: Schematic overview of the principle of mass spectrometry imaging (MSI). 
 
Figure 1-8: Schematic representations of various MSI modalities: (A) matrix-assisted laser desorption/ionization 
(MALDI), (B) secondary ion mass spectrometry (SIMS), (C) desorption electrospray ionization (DESI), (D) laser-
assisted electrospray ionization (LAESI), (E) nano-flow desorption electrospray ionization (nano-DESI), and (F) liquid 
extraction surface analysis (LESA). Adapted from Addie et al. (Addie et al., 2015).  
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1.4 Sample preparation for MALDI-MSI 
1.4.1 Tissue fixation and sampling     
MALDI-MSI is commonly used for the analysis of biological tissue samples. While 
MALDI-MSI analysis of insect and plant tissue have been reported (Grassl et al., 2011; 
Kaftan et al., 2014; Kaspar et al., 2011; Khalil et al., 2015; Peukert et al., 2012; 
Sturtevant et al., 2016), MALDI-MSI is more commonly used for biomedical research 
involving the analysis of human or animal model tissues (Balluff et al., 2010; Carreira et 
al., 2015; Dekker et al., 2014). MALDI-MSI is usually performed on thin tissue sections 
of thickness 4-20 µm, obtained from either fresh frozen, heat stabilized, or chemically 
fixed (most commonly using formalin) tissues (Goodwin, 2012; Thomas and Chaurand, 
2014). In order to maintain tissue integrity during the process of tissue sectioning, 
tissues are often embedded in an embedding material. For different applications, a 
great variety of embedding materials are available; paraffin, optimal cutting 
temperature (OCT), aqueous solutions of gelatin, and/or carboxymethyl cellulose (CMC) 
(Casadonte and Caprioli, 2011; Chen et al., 2009a; Schwartz et al., 2003; Stoeckli et 
al., 2007). The different tissue fixation and embedding methods each come with their 
specific set of benefits and limitations (Tables 1-2 & 1-3).  
 For MALDI analyses, performed in vacuum or intermediate pressure ion sources, the 
tissue samples are mounted on a conductive surface (the conductive surface is needed 
for the definition of the electric extraction field, which transfers ions to the mass 
analyzer). The conductive surface also helps dissipate the charge formed by 
photoelectrons after illumination with the UV laser. Ineffective dissipation of the charge 
will result in local distortions of the electric field in the sampled area, and cause mass 
shifts of the detected ions (Frankevich et al., 2003; Ibáñez et al., 2007; Knochenmuss, 
2004). Steel target plates were used in early MALDI-MSI experiments. However, 
mounting tissues on glass coated with a transparent and conductive material (e.g. 
indium tin-oxide (ITO)) is now routine as it enables the post-analysis co-registration 
with histological images (Amstalden van Hove et al., 2010; Chaurand et al., 2004; 
Chughtai et al., 2012). A common problem in histopathology is the detachment of 
tissue sections from the glass slides during staining procedures in which the samples 
are repeatedly submerged in a series of staining solutions. In order to increase the 
adherence of the tissue sections to the glass slide, the slide is coated using a strong 
polycationic polymer of L-lysine residues, poly-L-lysine. The cationic sites in the L-lysine 
polymer interact with the anionic sites in the tissues, strengthening the adherence 
between the glass and the tissue. This method, first implemented by Zavalin et al., is 
commonly implemented in the workflow for protein analysis by MALDI-MSI (Zavalin et 
al., 2012).  
1.4.2 Tissue washing     
The chemical complexity of a tissue section can lead to poor sensitivity in MALDI-MSI 




improve detection sensitivity by selectively removing interfering compounds from the 
tissue section, whilst retaining the spatial distribution of the analytes of interest. Tissue 
washing was first introduced for the MALDI-MSI analysis of intact proteins, and 
improved measurement sensitivity by removing physiological salts and a large part of 
the lipid content present in the tissue (Lemaire et al., 2006; Schwartz et al., 2003). 
Early tissue washing procedures for protein analysis usually contained several steps by  
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either rinsing or submersing the samples in a variety of organic solutions (e.g. ethanol, 
isopropanol, chloroform, acetone, or hexane). Later, also washes with water, or 
aqueous buffers were added to increase the sensitivity of the analysis of hydrophobic 
compounds (e.g. membrane proteins, specific classes of lipids), and proteins after on-
tissue proteolytic digestion (Angel et al., 2012; Enthaler et al., 2013a; Grey et al., 
2009; Groseclose et al., 2007; Nicklay et al., 2013; Thomas et al., 2013). Also, water-
based tissue washes were successful in the clean-up of tissue sections by removal of 
polymers (e.g. polyethylene glycol (PEG), and polyethylene vinyl (PEV)) originating 
from embedding media, such as OCT (Cazares et al., 2009). 
 The early tissue washing protocols were developed on (mouse or rat) brain tissue. 
The brain contains many distinct regions with profound difference in their molecular 
composition, which simplifies the assessment of molecular delocalization, or lateral 
diffusion. However, with the introduction of MALDI-MSI in clinical research, studies 
were set up with tissues of different origin (e.g. other organs, tumors) and methods 
optimized for brain tissue proved insufficient or incompatible. Several tissue treatment 
optimization studies exemplify the improvement in analysis quality that can be gained 
from the tedious effort of method optimization (Enthaler et al., 2013a; Lou et al., 
2016b; Martin-Lorenzo et al., 2015). 
 Tissue washing is usually omitted when it comes to analyzing small molecules, as 
the tissue washing procedures are commonly used to remove small molecules as 
interferants in the analysis of other molecular classes. However, Shariatgorji et al. have 
proposed a tissue cleanup procedure based on pH-controlled buffers for the targeted 
analysis of small molecule drugs by MALDI-MSI. In this particular study, tissues were 
washed in a pH-controlled, and concentration adjusted buffer in which the target 
compounds were insoluble and the interfering endogenous compounds were removed, 
improving the measurement sensitivity for various pharmaceutical compounds 
(Shariatgorji et al., 2012). 
1.4.3 On-tissue digestion       
In bottom-up proteomics, proteins are identified by analyzing and fragmenting 
proteolytic fragments, produced by an in-solution digestion with a proteolytic enzyme 
(Altelaar et al., 2012). Similar to this approach, proteolytic enzymes can be applied 
directly to tissue sections to digest the proteins in-situ. This on-tissue digestion 
approach was first explored by Shimma et al. in 2006, who applied trypsin to a fresh 
frozen mouse brain section using a chemical inktjet printer and performed on-tissue 
MALDI-MS/MS to identify proteolytic peptides directly from the tissue (Shimma et al., 
2006). In 2007, the on-tissue digestion approach was applied by Groseclose et al. to 
perform MALDI-MSI of proteolytic peptides (Groseclose et al., 2007). In this pioneering 
work the analysis of proteolytic peptides by MALDI-MS/MS was used to identify the 
proteolytic peptides in a similar fashion presented by Shimma et al.. Moreover, the 




proteolytic peptides, was used to assign identities to m/z features detected in an intact 
protein MALDI-MSI analysis. MALDI-MS/MS directly from tissue sections has, since 
then, been successfully performed by a number of groups (Groseclose et al., 2007; 
Schober et al., 2011; Shimma et al., 2008). However, the lack of chromatographic 
separation and the small amount of tissue present in each pixel make it a very 
challenging approach. Ion mobility separation (IMS) MALDI-MSI has been performed to 
compensate for the lack of chromatographic separation, and has proven itself a useful 
tool for on-tissue feature identification (McLean et al., 2007; Stauber et al., 2010; Trim 
et al., 2008). However, the greatest number of peptide identity assignments have been 
achieved through mass matching the MALDI-MSI peak list with peptide identifications 
obtained through LC-MS/MS analysis of tissue extracts (Casadonte et al., 2014; 
Schober et al., 2011). High-resolution, accurate mass (HRAM) MS is essential in order 
to obtain accurate and confident peptide identifications from the LC-MS/MS analysis 
and to resolve the complex mixture of (near) isobaric proteolytic peptides created by 
the on-tissue proteolytic digestion (Groseclose et al., 2007; Schober et al., 2012). 
Despite the challenge that the complexity of the sample imposes on the experiment, 
the analysis of proteolytic peptides does enhance the proteomic information gained 
from a single tissue section, by enabling the analysis of larger proteins that are 
otherwise difficult to analyze by MALDI-MSI (Groseclose et al., 2007). An additional 
benefit of on-tissue proteolytic digestion is that it allows the analysis of sections 
originating from FFPE tissues, and as many clinical biobanks consist of FFPE tissues, 
the ability to obtain spatially correlated proteomic information from these samples is 
invaluable. A (partial) reversal of the formalin fixation by an antigen retrieval step, 
followed by a proteolytic digestion ‘releases’ the peptides and makes them eligible for 
MALDI-MSI analysis (Djidja et al., 2009b; Groseclose et al., 2008; Lemaire et al., 2007; 
Ronci et al., 2008). 
 Trypsin is often the enzyme of choice for bottom-up proteomics and on-tissue 
digestion MALDI-MSI analyses, nevertheless other proteases, such as pepsin, elastase, 
Arg-C, Lys-C, and Lys-N, as well as combinations of proteases, such as trypsin/Lys-C, 
have also been reported and have proven to be beneficial for proteome coverage 
(Angel et al., 2012; Enthaler et al., 2013a; Grey et al., 2009; Groseclose et al., 2007; 
Nicklay et al., 2013; Thomas et al., 2013). Although the majority of reports concerning 
on-tissue digestion MALDI-MSI describes the use of proteolytic enzymes, the 
pioneering work by Groseclose et al. also demonstrated the ability of the 
endoglycosidase Peptide N-glycosidase F (PNGase F) to perform in-situ protein 
deglycosylation (Groseclose et al., 2007). Later, Powers et al. demonstrated the ability 
to perform N-linked glycan MALDI-MSI after on-tissue digestion with PNGase F on both 
fresh frozen and FFPE tissues (Powers et al., 2013, 2014). As N-linked glycans are not 
affected by the chemistry of the formalin fixation, N-glycan MALDI-MSI can be 
performed from FFPE tissues both with and without the prior treatment with an antigen 
retrieval method (Holst et al., 2016; Briggs et al., 2017; Powers et al., 2013, 2015). 
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 In bottom-up proteomics disulfide bond reduction in conjunction with alkylation is 
routinely used to help denature the proteins and thereby increase their accessibility to 
the proteases. Green-Mitchell et al. have adapted this approach for direct use on tissue 
sections, in order to improve and confirm the detection of insulin in pancreatic tissue 
sections (Green‐Mitchell et al., 2011). 
1.4.4 On-tissue derivatization      
Chemical derivatization, the alteration of the chemical properties of a molecule by 
adding a (functional) chemical group, is often applied in MS-based research to increase 
the measurement sensitivity for the analysis of compounds that suffer from poor 
ionization (Liu and Hop, 2005; Melikian et al., 1999). More recently, this strategy has 
been translated to enable the in-situ analysis of derivatized analytes by MALDI-MSI 
(Chacon et al., 2011; Franck et al., 2009). Chemical derivatization of small molecules 
for MALDI-MSI analysis is typically not only used to improve the ionization efficiency, 
but also to increase the analyte mass to prevent suppression, or masking, by MALDI 
matrix peaks that are commonly found in the same m/z range. On-tissue derivatization 
is commonly used in MALDI-MSI for the analysis of amino acids, neurotransmitters, and 
amino metabolites, and has been applied in studies on cancer and neurodegenerative 
disorde rs (Shariatgorji et al., 2014; Esteve et al., 2016; Toue et al., 2014). 
 Whilst on-tissue derivatization is mostly used for the analysis of small molecules, an 
in situ derivatization method for protein and peptide N-termini has also been reported. 
This method was reported to improve the in-situ identification of on-tissue digested 
proteins (Franck et al., 2009). Furthermore, the in-situ derivatization of sialylated N-
glycan species was reported by Holst et al., and resulted in: (i) stabilization of sialic 
acids during MALDI-MSI analysis, (ii) reduction of the ionization bias induced by the 
negative charge of the sialic acids in the positive ion analysis, and (iii) differentiation 
between α2,3- and α2,6-linked sialic acid, which are implied in tumor progression and 
resistance to chemotherapy (Holst et al., 2016). 
1.4.5 Matrix application        
A robust and homogeneous MALDI matrix deposition is key to a high quality MALDI-
MSI analysis. The choice of matrix, solvent system, and the deposition method 
determine which the analyte class may be analyzed, as well as the sensitivity and 
spatial resolution with which they may be examined (Goodwin, 2012; Thomas and 
Chaurand, 2014b). In the first MALDI-MSI analyses, described by Caprioli et al., matrix 
was applied by rinsing the tissues in a saturated matrix solution, resulting in severe 
lateral diffusion of the analyte molecules. The same publication describes matrix 
deposition using electrospray resulting in an improvement of the determination of the 
analyte location (Caprioli et al., 1997). Since these initial experiments many matrix 
deposition methods have been developed, which can be divided into three groups: (i) 




 The spotting methods are based on the droplet matrix application approach that is 
commonly used in sample preparation protocols for regular MALDI-MS. An array of 
pico-liter-sized droplets is spotted on to the tissue surface using a chemical printer, 
resulting in matrix spots with a diameter of ~200 µm. The small spotting volumes, e.g. 
~10 pL per spot per iteration, and the inter-spot spacing decreases the risk of 
molecular delocalization. Other than the lower risk of molecular delocalization, spot-
based methods are known for their superior S/N ratio, and number of detected 
analytes compared to other matrix deposition methods. One of the major limitations of 
the spot-based methods is the relatively low spatial resolution, which is limited by the 
droplet pitch and is defined during the matrix deposition (Aerni et al., 2006; Végvári et 
al., 2010). 
 Spray-based matrix application has the advantage that the matrix is deposited in a 
continuous manner, which enables the definition of the spatial resolution based on the 
size of the matrix crystals (~20 µm). Several automated sprayer systems are available, 
either based on a pneumatically-assisted spray (TM Sprayer (HTX Technologies, 
Carrboro, NIC, USA), SunCollect (SunChrom GmbH, Friedrichsdorf, Germany), iMatrix 
spray (Stoeckli and Staab, 2015)), or vibration-based nebulization (ImagePrep (Bruker 
Daltonics, Bremen, Germany) of the matrix solution (Thomas and Chaurand, 2014). 
 More recently, solvent-free matrix deposition by sublimation was introduced for the 
MALDI-MSI analysis of small molecules and lipids (Hankin et al., 2007; Puolitaival et al., 
2008). The absence of solvent results in very small matrix crystal sizes, which allows 
for extremely high spatial resolution analyses by MALDI-MSI (~5 µm) (Chaurand et al., 
2011). Initially, sublimation was only used for small molecules and lipids due to the 
limited molecular extraction capabilities of the method. However, sublimation in 
combination with a matrix recrystallization step allowed the analysis of intact proteins 
up to 30 kDa at spatial resolutions as low as 10 µm (Yang and Caprioli, 2011). 
1.5 Clinical mass spectrometry imaging 
In the two decades since its introduction, MSI has established itself as an invaluable 
tool in many scientific areas, including pharmaceutical research, forensic science, and 
clinical research (Aichler and Walch, 2015; Atkinson et al., 2007; Balluff et al., 2010; 
Groeneveld et al., 2015; Reyzer et al., 2003; Wolstenholme et al., 2009). One of the 
key characteristics of MALDI-MSI, resulting in its widespread application in clinical 
research is the non-destructive nature of the method, allowing post-MSI histological 
staining and co-registration of the histological image with the MSI data. This 
multimodal MSI-histological imaging approach allows a direct investigation of how the 
underlying molecular composition varies with the tissue’s histology.  
1.5.1 Biomarker discovery        
The discovery of disease- or phenotype-specific biomolecular markers or profiles is a 
research area in which the capabilities of MSI are commonly exploited. Especially in 
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cancer, the histological landscape is extremely complex and heterogeneous and often 
contains a multitude of different cell types, including tumor cells with variable levels of 
differentiation, surrounding normal tissue such as adipose or connective tissue, tumor 
vasculature, and infiltrating immune cells. Moreover, when comparing tissue specimens 
from multiple patients the inter-patient variation will add to the complexity, as the 
cellular composition of the tumor microenvironment and the differentiation state of the 
tumor cells will vary with each patient. The multimodal MSI-histological imaging data 
enables a retrospective, digital extraction of molecular profiles from specific regions of 
interest, a process called virtual microdissection. By carefully selecting the regions of 
interest by expert pathologists, based on the clinical question, the virtual 
microdissection reduces the histological heterogeneity, and thereby enables a 
meaningful comparison of the molecular profiles from histologically homogeneous 
regions within and between patients. Once specific molecular features have been 
identified for the relevant areas they can be compared with clinical patient data (e.g. 
disease prognosis, treatment response, metastasis) in specialized statistical tests (Addie 
et al., 2015; Aichler and Walch, 2015; Lou et al., 2016b). The described methodology 
has been used to identify that the absence of the functional mitochondrial polypeptide 
cytochrome C oxidase 7A2 (COX7A2) serves as a prognostic marker for poor survival in 
cohort of esophageal adenocarcinoma (fresh frozen, n = 39). A result that was 
confirmed through a validation study applying immunohistochemical (IHC) stainings of 
the identified protein biomarkers to an independent tissue set (FFPE, n = 102) (Elsner 
et al., 2012). Moreover, an MSI-based follow-up study revealed a positive correlation 
between the absence of functional COX7A2 and response to neo-adjuvant 
chemotherapy with cisplatin. This finding was later confirmed in work on esophageal 
cell lines treated with a COX7A2-specific siRNA, which resulted in defective 
mitochondria causing an increased sensitivity to the cisplatin therapy (Aichler et al., 
2013). These studies are excellent examples of the capabilities of MALDI-MSI in clinical 
research, although it must be noted that these studies were based on the analysis of 
intact proteins from fresh frozen tissue sections. The analysis of fresh frozen tissue 
samples often hampers the size of the analyzed cohorts as most tissue archives consist 
of FFPE tissues.  
 A tissue microarray (TMA) consists of an assembly of needle core biopsies, in which 
the selection of relevant and comparable regions from different patients is performed 
during TMA construction, and thus prior to MSI data acquisition. The advantages of 
TMA analysis by MALDI-MSI include the increased throughput and a reduced 
experimental variance. Several examples of large scale clinical studies including TMA 
analyses by MALDI-MSI are available. These include an early study by Djidja et al., in 
which peptide classifiers for various tumor grades of pancreatic adenocarcinoma were 
constructed, based on the on-tissue digestion MALDI-MSI of a TMA of FFPE biopsies 
from 30 patients (Djidja et al., 2010). More recently, Kriegsmann et al. were successful 




adenocarcinoma (ADC) and squamous cell carcinoma (SqCC), an important 
classification for treatment stratification. The classifier was built using the data from a 
training TMA that contained needle core biopsies of 110 ADC and 98 SqCC patients, 
and utilized 339 distinct m/z features. The application of the classifier to the MALDI-
MSI data from a validation TMA containing 58 ADC and 60 SqCC samples resulted in 
the correct classification of 117 cases (accuracy 99.1%). Several differential expressed 
proteins, including known proteins used in current IHC classification (CK5, CK7), as well 
as novel markers (CK15, HSP27), were identified and validated by MS/MS and IHC 
(Kriegsmann et al., 2016). 
1.5.2 Molecular histology        
It is well established that the progression of some cancers can be described as a 
process of clonal evolution that starts with a single aberrant cell that, driven by 
(epi)genetic and/or metabolic changes, ultimately evolves into a heterogeneous tumor 
containing various subclones of the initial tumor clone (Dalerba et al., 2011; Gerlinger 
et al., 2012; Greaves and Maley, 2012). Typically, most biomarker discovery studies are 
based on the molecular characterization of homogenized tissue samples, ideally after 
microdissection of tumor cell-rich regions. While some of the tumor subpopulations 
may have distinct morphological features, others cannot be discerned on the basis of 
histology alone due to similar or overlapping morphologies. As these subpopulations 
are thought to drive tumor progression and influence the patient’s prognosis, their 
elucidation is of high importance to increase our knowledge on the evolution of cancer 
(Greaves and Maley, 2012; Wu et al., 2010). MSI has been shown to be able to 
uncover the molecular intratumor heterogeneity, otherwise obscured by the lack of 
characterizing morphological features. In this case tissue annotation is not performed 
by visual inspection of the tissue’s histology, but by a statistical segmentation based on 
the similarity of the tissue’s biomolecular content (Deininger et al., 2008; Jones et al., 
2011). A more recent publication by Balluff et al. displays the capability of MALDI-MSI 
to unravel the biomolecular intra-tumor heterogeneity and define distinct tumor 
subpopulations purely on the basis of molecular information obtained in the MSI 
experiment. Correlation to clinical patient information resulted in the identification of 
clinically relevant tumor subpopulations (Balluff et al., 2015). 
1.6 Sarcoma 
Soft tissue sarcoma (STS) is a class of uncommon tumors that arise in mesenchymal 
tissues, such as bone, cartilage, and connective tissues (e.g. muscle and fat). While 
STS can occur anywhere in the human body, approximately 75% occurs in the 
extremities (commonly in the thigh), 10% in the trunk wall, and another 10% in the 
retroperitoneum. The combination of their limited occurrence, 1% of all malignant 
tumors, and a large number of histological subtypes (> 50) often with overlapping 
morphology, results in challenges regarding diagnosis and treatment (Fletcher et al., 
2013; Taylor et al., 2011). Firstly, their rarity results in a very low probability for a 
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general pathologist to encounter many of the STS subtypes. Secondly, the overlapping 
morphology, demonstrated intra-tumor heterogeneity and the only sparse availability of 
discriminating diagnostic markers complicate tumor subtyping (Willems et al., 2010a). 
 Previously, different sarcoma subtypes have been studied using MALDI-MSI. 
Caldwell et al. were the first to publish the potential of MSI in sarcoma research. 
MALDI-MSI of proteins was performed on a variety of STS tissues, including 
“fibrosarcoma”, leiomyosarcoma, liposarcoma, undifferentiated pleomorphic sarcoma, 
malignant peripheral nerve sheath tumor and synovial sarcoma, in order to establish 
biomolecular differences between low-grade STS, high-grade STS and skeletal muscle 
control tissue. Several proteins, including previously characterized markers for other 
tumor types (calgizzarin, calcyclin, macrophage inhibitory factor, and calgranulin) as 
well as multiple histones, were found to differentiate high- and low-grade STS. Other 
proteins, including several myosin light-chains, appeared completely absent in tumor 
tissues, while vimentin was exclusively detected in the STS tissues. Five of the markers 
established by MSI, were successfully validated by IHC on FFPE tissues and showed 
similar expression patterns compared to MSI results (Caldwell et al., 2005). 
Additionally, Caldwell et al. studied the capability of MSI to establish tumor margins of 
an undifferentiated pleomorphic sarcoma. Using MALDI-MSI of intact proteins they 
were able to extend the tumor margin beyond the capabilities of histological 
examination through the detection of differential, disease-like, molecular signatures in 
regions that were considered non-diseased after histological examination. IHC 
validation of the MSI markers revealed a mixture of non-diseased cells and 
transforming tumor cells, morphologically indistinguishable from the non-diseased cells, 
stretching beyond the histologically determined tumor margins (Caldwell et al., 2006). 
Willems et al. studied the lipid and protein content of myxofibrosarcoma (MFS) and 
myxoid liposarcoma (MLS) using MALDI-MSI. Lipid MSI analysis revealed that the 
presence of various triglycerides (TG) was associated with low grade MLS, and the 
presence of different phosphatidylcholines (PC) was indicative of high grade MLS. 
These findings confirmed previous NMR-based findings that demonstrated the ability of 
histology-specific lipid analysis to classify different liposarcoma subtypes (Willems et al., 
2010a). Additionally, biomolecular intratumor heterogeneity of intermediate-grade MFS 
was demonstrated and confirmed the multinodular tumor pattern, based on clonal 
selection previously observed on the genetic level in low-grade MFS (Jones et al., 2011; 
Willems et al., 2010a). These methods for the investigation of molecular intratumor 
heterogeneity were applied in a biomarker discovery study on chondrosarcoma, and 
demonstrated that different histological variants of central and peripheral 
chondrosarcoma were distinguishable by specific sets of proteins, including Vimentin, a 
well-established generic marker of sarcomas (Jones et al., 2013). Lou et al. published a 
study in which the ability of MALDI-MSI to distinguish between four types of high-grade 
sarcoma (osteosarcoma (OS), undifferentiated pleopmorphic sarcoma (UPS), 




twenty proteins were found as diagnostic markers for the different tumor types, an 
additional nine proteins showed prognostic value as they were associated with overall 
patient survival (Lou et al., 2016a). A similar study was performed investigating a 
metabolic marker for STS. Inositol cyclic phosphate and carnitine were established as 
potential generic prognostic markers for STS patients (Lou et al., 2017). 
1.6.1 Myxoid liposarcoma        
MLS is a malignant myxoid STS, which accounts for 5% of all adult cases of STS. 
Representing a third of the cases, it is the second most common type of liposarcoma 
(LPS) (Fletcher, 2014). MLS is often found in the extremities of young adults, and is 
treated by surgical resection (Antonescu et al., 2001; Fletcher, 2014). The histology of 
MLS consists of a mixture of cells, including uniform round mesenchymal cells, oval 
shaped primitive, nonlipogenic mesenchymal cells and small signet-ring lipoblasts in a 
myxoid ECM with a characteristic capillary vasculature (Fletcher et al., 2013). Specific, 
highly dense regions containing undifferentiated round cells with little cytoplasm and 
no ECM, termed ‘round cell’ regions are associated with high metastatic potential and a 
general poor prognosis. Other indicators for poor prognosis are the presence of 
necrotic tissue, the male gender, high age, and multifocal disease (Antonescu et al., 
2001; Nishida et al., 2010; de Vreeze et al., 2010; Hoffman, et al., 2012; Fletcher et 
al., 2013). The myxoid ECM, clearly visible in conventional light microscopy, consists of 
a variety of secreted proteins and polysaccharides, and determines the physical 
properties of the tissue (Graadt van Roggen et al., 1999). The myxoid ECM is 
characteristic for various types of epithelial and mesenchymal tumors. In epithelial 
tumors a myxoid ECM is often a secondary phenomenon, while in mesenchymal tumors 
it is often considered an intrinsic part of the tumor (Willems et al., 2010a). Albeit that 
the myxoid ECM is an intrinsic part of the tumor entity it is not considered directional in 
diagnosis. Myxoid STSs contains a variety of morphologically similar tumors with 
varying clinical behavior, ranging from truly benign to highly malignant (Graadt van 
Roggen et al., 1999; Willems et al., 2010b).  
 The chimeric transcription factor oncogene, FUS-DDIT3 is characteristic to MLS 
(>95% of all cases), and is the result of a reciprocal translocation t(12;16)(q13;p11). 
In this translocation, the 5’ half of the FUS gene is fused with the complete reading 
frame of the DDIT3 gene. The remaining 5% of the cases harbor a similar 
translocation, t(12;22)(q13;p12), which fuses the EWSR1 gene to the DDIT3 gene. The 
exact mechanism of oncogenesis remains unknown, although it is hypothesized that 
the chimeric fusion gene acts as an aberrant transcriptional factor, stimulating cell 
proliferation whilst inhibiting adipogenic differentiation (de Graaff et al., 2016; Powers 
et al., 2010). 
36 Chapter 1 
 
1.7 Aims of the thesis 
MSI is a useful tool for the investigation of pathologies in which established 
histopathological methods may not always be conclusive. In this thesis, the aim was to 
develop novel enzyme-based on-tissue chemistry methods for an improved 
characterization of the biomolecular landscape of tissues. These methods were 
developed to further implement MSI in clinical research in general, and were applied to 
aid the biomolecular characterization of tumor progression in MLS.  
 While MSI has been proven to be a valuable tool in clinical research, questions 
remain about the technical reproducibility and applicability of this technology in routine 
clinical research. Furthermore, the use of proteolytic enzymes has raised questions in 
the field of in-solution bottom-up proteomics, regarding the influence of the enzyme 
incubation time on the repeatability of the analysis. However, enzyme incubation time 
and repeatability had not been addressed for on-tissue digestion MALDI-MSI. Chapter 
2 of this thesis addresses the question: What is the influence of the enzyme incubation 
time on the repeatability and spatiotemporal dynamics of on-tissue digestion? 
 The use of on-tissue proteolytic digestion can improve proteome coverage in a 
MALDI-MSI analysis, compared to the analysis of intact proteins. Nevertheless, the 
information obtained from a single tissue section is still limited. Chapters 3 and 5 of 
this thesis address the question whether the use of multiple enzymes can increase the 
molecular information obtained using on-tissue digestion MALDI-MSI on both fresh 
frozen and FFPE tissues.  
 The field of MSI is currently moving toward high-resolution analyses, both in mass 
resolution and image resolution. The application of high resolution MSI in clinical 
research is compromised by the long data acquisition times and the large data load 
which characterize the high-resolution measurements. The virtual microdissection 
normally performed to focus the data analysis on specific/comparable cell types means 
that, in many instances, only a fraction of the MSI data is used in the subsequent 
statistical evaluation. Thus, throughput may be increased, measurement time 
decreased, and dataload reduced, if the MSI data acquisition could be focused on these 
histological regions of interest. Chapter 4 of this thesis describes an automated 
histology-guided MSI platform, to facilitate high-resolution MSI analysis in clinical 
research. The functionality and performance of the histology-guided MSI platform are 
described using a histologically well-characterized selection of FFPE MLS tissues. 
 Chapter 6 describes a clinical biomarker discovery study to establish a molecular 
marker for MLS tumor progression based on the application of the multimodal MSI 
approach described in Chapter 5 on a previously constructed TMA containing FFPE 
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 In MSI, on-tissue proteolytic digestion is performed to access larger protein species 
and to assign protein identities through matching the detected peaks with those 
obtained by LC-MS/MS analyses of tissue extracts. The on-tissue proteolytic digestion 
also allows the analysis of proteins from FFPE tissues. For these reasons on-tissue 
digestion-based MSI is frequently used in clinical investigations, e.g. to determine 
changes in protein content and distribution associated with disease. In this work we 
sought to investigate the completeness and uniformity of the digestion in on-tissue 
digestion MSI. Based on an extensive experiment investigating three groups with 
varying incubation times: (i) 1.5 hours, (ii) 3 hours, and (iii) 18 hours, we have found 
that longer incubation times improve the repeatability of the analyses. Furthermore, we 
discovered morphology-associated differences in the completeness of the proteolysis 
for short incubation times. These results support the notion that a more complete 
proteolysis allows better quantitation. 
2.1 Introduction 
Since its introduction in 1997 by Caprioli et al. (Caprioli et al., 1997) matrix-assisted 
laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) has become a 
valuable tool in clinical research. MALDI-MSI has the ability of simultaneously recording 
hundreds of untargeted biomolecular analytes in a spatially correlated manner to 
provide the analyst with cell type-specific molecular signatures. Different sample 
preparation strategies can be applied to investigate the abundance and spatial 
distribution of various molecular classes, ranging from endogenous small molecules and 
pharmaceuticals, to lipids, peptides, and proteins, directly from a tissue section 
(McDonnell and Heeren, 2007). The aforementioned characteristics make MALDI-MSI a 
well-suited tool for biomarker discovery or for the investigation of the molecular 
mechanisms underlying disease (Balluff et al., 2011; Carreira et al., 2015; Cole et al., 
2011; Djidja et al., 2010; Poté et al., 2013). 
 In order to identify proteins, increase proteome coverage and enable the analysis of 
proteins from formalin-fixed paraffin embedded tissue sections, the enzymatic digestion 
performed in classic bottom-up proteomics has been adapted to MALDI-MSI and is also 
mostly performed using the endopeptidase trypsin (Groseclose et al., 2008; Heijs et al., 
2015; Lemaire et al., 2006; Shimma et al., 2006). 
 As discussed by Brownridge et al. (Brownridge and Beynon, 2011), for in solution 
bottom-up proteomics, the digestion of a protein to its ‘limit peptides’ can follow many 
pathways, resulting in a large number of intermediate digestion products. In this 
context, ‘limit peptides’ are proteolytic peptides that lack missed proteolytic cleavage 
sites, meaning that all peptide bonds that could be cleaved were cleaved. It can be 
argued that the repeatability of an enzymatic digestion is solely achieved and only 
guaranteed if all proteins are converted to their limit peptides. In the same study it was 
shown that not all amino acid sequences have the same digestion efficiency, and it was 
42 Chapter 2 
 
concluded that enzyme incubation time is key to achieving repeatable digestion results 
(Brownridge and Beynon, 2011). 
 A tissue section can be very heterogeneous and constitutes a chemically complex 
environment. Accordingly, there are questions pertaining to the efficiency of the 
proteolysis and whether there may be region-specific differences in reaction rate, both 
of which would affect the repeatability of on-tissue proteolytic digestion MSI 
experiments. Surprisingly, in literature there is little consensus on the incubation times 
that have to be used for such digestions (Casadonte and Caprioli, 2011; Groseclose et 
al., 2007; Heijs et al., 2015; Sio et al., 2015). A workshop organized by the large 
European MSI network COST Action BM1104 that focused on comparing on-tissue 
digestion methods and data found little consensus and significant variation. 
 For example, in brain tissue white and grey matter are known to have distinct 
molecular compositions with different chemical characteristics, e.g. white matter is 
richer in lipid content making it more hydrophobic (Kaufman and Bard, 1999; Watson, 
2012). However, it is unknown whether these differences have an effect on the on-
tissue enzymatic digestion. Here we have investigated the brain region-specific 
efficiency of on-tissue digestion using MALDI-MSI. Using three groups of mouse brain 
tissue sections (N = 9) we varied the length of the incubation time: (i) 1.5 hours, (ii) 3 
hours, and (iii) 18 hours. To get more quantitative insight into the success of the 
digestion, three previously identified proteolytic fragments originating from myelin basic 
protein (MBP, MBP_MOUSE, UniProt: P04370), were synthesized as isotopically-labeled 
reference standards (ILRS). Following the digestion incubation, the ILRS peptides were 
homogeneously sprayed on the tissue sections to enable intensity normalization of the 
endogenous MBP fragments. In this manner ionization bias could be traced throughout 
the tissue (Hamm et al., 2012; Källback et al., 2012; Porta et al., 2015) and throughout 
the evolution of the on-tissue digestion experiment. 
 Although the on-tissue digestion method is very effective and its application more 
commonly used, little has been reported about the repeatability, dynamics and spatial 
uniformity of on-tissue digestion in histologically heterogeneous tissue sections. One of 
the most comprehensive studies regarding on-tissue digestion, recently reported by 
Diehl et al. (Diehl et al., 2015), compared many parameters such as incubation time, 
type of MALDI matrix, and protease, but the main focus was to improve spatial 
resolution and image quality. The dynamics of the digestion, its repeatability and 
region-specific differences were not addressed. To the best of the author’s knowledge, 
this is the first in depth investigation into the dynamics and mechanics of on-tissue 
digestion MALDI-MSI in a region-specific manner. 
2.2 Methodology 
2.2.1 Chemicals and reagents  
All chemicals were purchased from Sigma-Aldrich (Steinheim, Germany) except ethanol 
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(Merck, Darmstadt, Germany). Trypsin was purchased from Promega (Madison, USA). 
The isotopically-labeled peptide standards were produced by the Peptide Synthesis 
facility at Leiden University Medical Center (Leiden, Netherlands). 
2.2.2 Isotopically labelled peptide standards  
Isotopically labeled variants containing L-Threonine-13C4,15N, (+5 Da, designated T*) of 
the following, previously identified (Heijs et al., 2015), tryptic peptides of myelin basic 
protein (MBP_MOUSE, UniProt P04370) were synthesized: (i) T*THYGSLPQK – m/z 
1,136.5 Da, (ii) T*QDENPFFHFFK – m/z 1,465.71 Da, and (iii) 
T*QDENPFFHFFK^NIVTPR – m/z 2146.1 Da (missed cleavage, ^). The isotopically 
labeled peptides were dissolved in 0.1% trifluoroacetic acid (TFA) and mixed to get an 
equal response for each peptide from the mass spectrometer: (i) m/z 1,136.5 Da – 500 
nM, (ii) m/z 1,465.71 Da – 100 nM, and (iii) m/z 2,146.1 Da – 75 nM. 
2.2.3 Sample collection  
A three-month-old, male, C57BL/6J mouse was sacrificed by cervical dislocation. The 
brain was excised, flash-frozen on dry ice and stored at -80°C until analysis. Twelve-µm 
thick coronal tissue sections (-1.06 – 0.74 mm bregma) were obtained using a cryostat 
microtome (Leica Microsystems, Wetzlar, Germany) at -12°C. Three adjacent sections 
were thaw-mounted per poly-L-lysine coated indium-tin-oxide (ITO) glass slide (Bruker 
Daltonics, Bremen, Germany) and stored at -80°C. For every incubation time a group of 
three slides was prepared, resulting in 9 replicates for each incubation time (Figure 2-
1A). All experiments were approved by the Animal Experiment Ethics Committee of 
Leiden University Medical Center. 
2.2.4 Sample preparation  
Tissue sections were brought to room temperature in a freeze-drier for 30 minutes. 
The tissue sections were then washed for 30 s in 70% ethanol, 30 s in 96% ethanol, 10 
dips in deionized water, 30 s in 70% ethanol, and 30 s in 96% ethanol. Trypsin (20 
ng/µL in deionized water) was then applied using a SunCollect automatic sprayer 
(SunChrom, Friedrichsdorf, Germany) as previously described (Heijs et al., 2015). In 
order to investigate the digestion dynamics different incubation times (1.5 h, 3 h & 18 
h) were used. The digestion was incubated at 37°C in an airtight saturated chamber 
(50% methanol in deionized water). Proteolysis was terminated by covering the tissue 
sections with the mixture of isotopically labeled peptides (in 0.1% trifluoroacetic acid 
(TFA)) using the SunChrom SunCollect sprayer. A total of 2 layers was sprayed at 5 
µL/min using the same sprayer settings as the trypsin application (Heijs et al., 2015). 
Finally, MALDI matrix (25 mg/mL 2,5-dihydroxybenzoic acid (DHB) in 50% acetonitrile 
(ACN) and 0.1% TFA) was applied using the SunCollect sprayer as described (Heijs et 
al., 2015). 
2.2.5 MALDI-FTICR imaging  
MALDI-FTICR-MSI was performed using a 9.4 T SolariX XR mass spectrometer (Bruker 
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Daltonics) in positive-ion mode, using 150 laser shots per spot and 100 x 100 µm pixel 
size. Data was acquired for each tissue section and additional areas adjacent to the 
tissues to function as a matrix control. Spectra were recorded in the m/z range 600–
3,500 Da with a 512k data point transient (1.1 s duration), corresponding to an 
estimated resolution of 200,000 at m/z 400 Da. The average detected mass resolution 
over the analyzed mass range was 54,000, and the mass resolution in the center of the 
mass range, at m/z 1,500, was 65,000. Data acquisition was performed using 
ftmsControl (Bruker Daltonics) and peptides visualized with flexImaging 4.0 (Bruker 
Daltonics). After MSI data acquisition the MALDI matrix was removed by washing the 
glass slides in 70% ethanol (2x 2 min), then Nissl stained and digitally scanned using a 
digital slide scanner (IntelliSite Pathology Ultra-Fast Scanner, Philips, Eindhoven, The 
Netherlands). The scanned histology images were co-registered to the MSI datasets in 
flexImaging. 
2.2.6 Data analysis  
The digestion dynamics were determined globally for the full tissue sections, and locally 
for specific histological features present in the mouse brain sections. 
2.2.6.1 Global analysis – total average spectra  
For the global analysis, the average spectra for each of the analyzed sections and their 
respective matrix controls, obtained from flexImaging, were exported as comma-
separated values (CSV) and read into the freely available software tool mMass 
(http://www.mmass.org) (Strohalm et al., 2008). Mass spectral processing was 
performed using the following settings: (i) baseline subtraction – precision 15, relative 
offset 25, (ii) smoothing – Savitzky-Golay, width 0.05 m/z, 1 cycle, (iii) peak picking – 
S/N ≥ 5, relative intensity ≥ 0.6%, (iv) deisotoping – max. charge 2+, isotope mass 
tolerance 0.02 m/z, isotope intensity tolerance 50%, remove isotopes and unknowns, 
and (v) recalibration to a reference list containing the masses of the isotopically labeled 
peptide standards. Using mMass’ peak list comparison tool, the peaks present in the 
matrix control were removed from the tissue peak list leaving only tissue specific peaks. 
The tissues specific peaks were exported to Excel 2010 (Microsoft). In Excel the total 
number of tissue specific peaks were grouped per digestion time point, and statistical 
comparison of the time-associated changes performed. A Kolmogorov-Smirnov test was 
applied to test the groups for normal distributions. Differences in distribution between 
the three groups were investigated using a Kruskal-Wallis test. If it was found that a 
group was distributed differently with statistical significance (p ≤ 0.05), a Mann-
Whitney test was used instead. 
2.2.6.2 Global analysis – myelin basic protein 
To investigate the digestion of MBP, the intensities of the three selected MBP peptides 
and their isotopically labeled variants were extracted from the average spectra of the 
tissues. In Excel, the intensities of the endogenous peptides were normalized using the 
intensities of the ILRS using (1). 
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𝐼𝑛𝑜𝑟𝑚 =  
𝐼𝑒𝑛𝑑𝑜𝑔𝑒𝑛𝑜𝑢𝑠
𝐼𝐼𝐿𝑅𝑆
      (1) 
 Statistical comparisons of the time-associated changes were performed similar to 
the analysis of the full spectra (detailed description above). 
2.2.6.3 Local analysis – MBP digestion in white and grey matter  
The alignment of the histology images to the MSI datasets facilitated the extraction of 
mass spectral data from specific histological regions. Two specific regions, equal in size 
(i.e. number of pixels) were selected from each tissue section: (i) white matter, a part 
of the lateral forebrain bundle system and, (ii) grey matter, a part of the cerebral 
cortex. The resulting XML files listed all spectra contained within these regions of 
interest (ROIs).  
 The MALDI-MSI datasets and corresponding XMLs were read into Data Analysis 4.2 
(Bruker Daltonics), average spectra were calculated for all ROIs and peak picking was 
performed using the FTMS peak picking algorithm (S/N ≥ 5, Rel. Int. ≥ 0.6%). The 
intensities of the three MBP fragments and their respective isotopically labeled 
standards were exported to Excel 2010. In Excel the intensities of the endogenous 
proteolytic peptides were normalized to their respective ILRS, using (1). Statistical 
analysis of the histology-associated differences was performed as described above for 
the full average mass spectra. 
2.3 Results and discussion 
The on-tissue enzymatic digestion of proteins is used in MALDI-MSI to increase 
proteome coverage and assign protein identities to the peaks detected by MALDI-MSI. 
It is known from efforts to perform absolute protein quantification using LC-MS/MS that 
enzyme incubation time determines the completeness of the protein digestion and also 
the repeatability of the analysis (Brownridge and Beynon, 2011). Accordingly, we 
investigated the completeness of the digestion and the repeatability of on-tissue 
digestion by varying the incubation time and analyzing the resulting peptides using 
MALDI-MSI. A series of mouse brain tissue sections was analyzed: three groups of 9 
tissue sections were digested for (i) 1.5 hours, (ii) 3 hours, or (iii) 18 hours and 
analyzed using a 9.4 T MALDI-FTICR instrument (Figure 2-1A). 
2.3.1 Global analysis – total average spectra  
The average mass spectrum from each complete tissue section was extracted, 
processed (background subtraction, smoothing), peak-picked and then recalibrated 
using the ILRS peptides as internal calibrants (Figure S2-1, Supplementary 
information). To obtain the number of tissue specific ions per tissue section, each 
tissue section’s peak list was corrected by subtracting all peaks detected in the matrix 
control area adjacent to the tissue section. This correction removed all m/z features 
originating from the MALDI matrix, protease, and isotopically labeled reference 
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standard, leaving only tissue-specific m/z features. The resulting peak lists were 
deisotoped, grouped according to incubation time and then averaged (Figure 2-1B). A 
Mann-Whitney test was performed to calculate the statistical significance of the 
differences observed between the number of tissue-specific peptide ions per incubation 
time. It was found that after a 1.5-hour incubation the number of peptide ions was 
significantly lower, compared to the 3-hour and 18-hour incubations. No significant 
difference was observed between the number of tissue specific peptide ions from the 
3-hour and 18-hour incubations. Although the number of peaks did not differ 
significantly between the 3-hour and 18-hour incubations, the variability was 
considerably larger in the 3-hour group compared to the 18-hour group. Great care 
should be employed when interpreting such peak lists of MSI data because the 
continuous production of new proteolytic fragments results in an increasingly complex 
chemical environment, which is known to cause ion suppression in MALDI mass 
spectrometry (Stauber et al., 2010).  
2.3.2 Global analysis – myelin basic protein   
To acquire more clarity into the dynamics of on-tissue digestion, a single protein was 
selected and isotopically labeled variants of the tryptic peptides were synthesized for 
use as internal reference standards. In this manner the ion suppression could be traced 
throughout the tissue and during the evolution of the digestion. Myelin basic protein 
(MBP, MBP_MOUSE, UniProt: P04370) was selected owing to its ready detection by 
MALDI-MSI (Clemis et al., 2012; Diehl et al., 2015; Heijs et al., 2015) and its distinct 
localization in the brain. MBP is an abundant protein in the central nervous system and 
has a crucial role in maintaining the multi-layered myelin membrane that builds up the 
myelin sheaths covering the nerve cells axons (Siegel et al., 1999). MBP is known to 
interact with the lipids in the myelin membrane and has a strong expression in regions 
consisting largely of white matter (Figure 2-2A-B) (Min et al., 2009; Siegel et al., 1999). 
Three of the MBP proteolytic fragments frequently reported by on-tissue digestion 
MALDI-MSI were selected: (i) TTHYGSLPQK (196-205, 1,131.5793 Da), (ii) 
TQDENPFFHFFK (211-222, 1,460.7168 Da), and (iii) TQDENPVVHFFKNIVTPR (211-228, 
2,141.1138 Da). Fragment 211-228 is a missed-cleavage peptide that indicates 
incomplete digestion. Fragment 211-222 is the ‘limit peptide’ produced by the complete 
digestion of fragment 211-228, so any differences in their relative intensities may be 
interpreted as differences in the relative completion of the digestion. The isotopically 
labeled reference standards for the three MBP peptides were synthesized using a N15 
and C13 labeled threonine residue (Δ[M+H+] = +5 Da) incorporated on the N-terminal 
side of the three MBP fragments. A mixture of these peptides was prepared such that 
their intensities were similar to those of endogenous MBP fragments. From the 
respective concentrations for each of the three isotopically-labeled MBP peptides in the 
ILRS peptides mixture ((i) m/z 1,136.5 Da – 500 nM, (ii) m/z 1,465.71 Da – 100 nM, 
(iii) m/z 2,146,1 Da – 75 nM) it appears that the analysis of missed-cleavage peptides 
by MALDI mass spectrometry does not exhibit a similar bias in analysis sensitivity as  




Figure 2-1: (A) Overview of the experiments. For each of the incubation times nine tissue sections were analysed. 
Three sections were mounted on one glass slide, the three slides were analysed on different days. (B) The number of 
tissue specific peaks (median) for each of the incubation times. The error bars represent the first and third quartile 
values. The asterisks represent p ≤ 0.05.  
 
Figure 2-2: (A) Immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) data for myelin basic 
protein from the Allen Mouse Brain Atlas (©2015 Allen Institute for Brain Science. Available from: http://mouse.brain-
map.org). (B) A scanned image of the histology (Nissl staining) of the MSI analyzed tissue section. (C) The effect of 
normalization to ILRS peptides on the distributions of MBP determined by on-tissue digestion MALDI-MSI. The top row 
contains the non-normalized images of the proteolytic fragments. The middle row shows the intensity distribution of 
the ILRS peptides, and the lower row shows the normalized images. 
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Figure 2-3: ILRS normalized visualizations of the MBP ‘limit peptide’ at m/z 1,460.7 Da (TQDENPFFHFFK) and missed-
cleavage peptide m/z 2,141.1 Da (TQDENPFFHFFKNIVTPR) for each of the three incubation times. The bar plot shows 
the normalized intensities (median) for both the ‘limit peptide’ (white) and the missed-missed cleavage peptide (black) 
for each of the incubation times. The error bars represent the first and third quartile values and the asterisks p ≤ 0.05. 
 
Figure 2-4: Comparison of MBP on-tissue digestion in mouse brain white and grey matter. (A) Selection of regions 
consisting largely of white and of grey matter that contain identical numbers of pixels. (B) The normalized intensities 
of ‘limit peptide’ m/z 1,460.5 Da and missed-cleavage peptide m/z 2,141.1 Da in regions with white and grey matter 
plotted versus incubation time. The error bars represent the 1st and 3rd quartile values. (C) Box plots showing the 
ratio of the intensity of the missed-cleavage peptide to the ‘limit peptide’ in white and grey matter over time. The 
insets show magnifications of the boxplots for 3 h and 18 h. The asterisks represent p ≤ 0.05. 
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during the analysis by electrospray ionization (ESI)-based mass spectrometry 
(Brownridge and Beynon, 2011). The equal sensitivity for the analysis of both ‘limit 
peptides’ and missed-cleavage peptides in MALDI-MSI emphasizes the need to drive 
the on-tissue digestion to completion, as the detection of missed-cleavage peptides will 
affect the reproducibility of the analysis. 
 Following the MALDI-MSI analysis the intensities of the endogenous peptides were 
normalized to the intensity of their ILRS peptides. Figure 2-2C shows the effect ILRS 
normalization has on the visualization of the peptide distributions. Visualization of the 
homogeneously applied ILRS peptides on the mouse brain tissue sections clearly shows 
that there is more suppression within the lateral forebrain bundle system, which is a 
part of the brain’s white matter, as compared to the rest of the tissue section. The 
impact of ILRS normalization has been previously described for small molecules, such 
as pharmaceuticals and endogenous metabolites, and for proteolytic peptides in 
MALDI-TOF-MSI and MALDI-MRM-TOF-MSI (Clemis et al., 2012; Hamm et al., 2012; 
Prideaux and Stoeckli, 2012; Shariatgorji et al., 2014). 
 Following the normalization of the endogenous MBP peptides to their ILRS 
analogues the experiments with different incubation times, and the different regions 
could be quantitatively compared. The average (normalized) intensity was calculated 
for each incubation time and for each ROI to find whether the incubation time had a 
significant effect on the on-tissue digestion of MBP (Figure 2-3, Figure S2-2, 
Supplementary information). The presented data indicates significant differences 
between the intensity distributions of all three MBP fragments between 1.5 h and 3 h 
incubations. Additionally, the 211-222 (m/z 1,460.7 Da) and 211-228 (m/z 2,141.1 Da) 
fragments also show significant differences between the 3 h and 18 h incubations. As 
expected, the intensity distributions of both ‘limit peptide’ and missed-cleavage peptide 
have an inverse correlation, indicating that between the 3 h and 18 h time points MBP 
digestion is still ongoing. 
2.3.2 Local analysis – MBP digestion in white and grey matter  
It is known that the varying chemical composition of different organs/regions-of-tissue 
can have different mass spectral responses, leading to biased MSI representations of 
the true peptide distribution (Hamm et al., 2012; McDonnell and Heeren, 2007). Figure 
2-2C shows such difference in ionization response for all three MBP peptides between 
regions in the mouse brain that contain white or grey matter. In this study we have 
investigated whether the different physical-chemical properties of the different 
morphological regions also affect the proteolytic digestion. Two regions, equal in size, 
from both grey and white matter were selected in each of the analyzed tissue sections 
and the spectra were extracted (Figure 2-4A). The ILRS normalized intensities of the 
MBP fragments 211-222 (m/z 1,460.7 Da) and 211-228 (m/z 2,141.1 Da) were 
determined for the two regions, and plotted versus time (Figure 2-4B). These results 
indicate a greater abundance of MBP in the region with white matter as compared to 
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the region with grey matter, which is in line with mRNA expression and 
immunohistochemistry results obtained from the Allen Brain Atlas (Figure 2-2A). 
Furthermore, it appears that MBP digestion is performed faster in white matter 
compared to grey matter as the equilibrium intensity between the ‘limit peptide’ and 
the missed-cleavage peptide lies close to 1.5 h in white matter and close to 12 h in 
grey matter. Furthermore, statistical analysis of the ratio between the missed-cleavage 
peptide and the ‘limit peptide’ (ratio = I2141/I1460) showed a significant difference 
between white and grey matter after only 1.5 h of incubation (Figure 2-4C). However, 
the results also indicated that these morphology-induced differences did not persist 
after 3-h and 18-h incubations, providing further evidence that a longer incubation 
provides more repeatable and reliable data. 
 In the current work we have demonstrated that in order to improve on-tissue 
digestion MALDI-MSI data longer incubation times are required. By performing an 18-h 
incubation, we were able to decrease the variability of the data sets regarding the 
number of tissue specific peaks. Furthermore, we were able to show differences in the 
digestion of MBP: (i) the missed-cleavage fragment 211-228 (m/z 2,141.1 Da) was 
significantly less abundant after 18 h compared to 3 h incubation time, (ii) the ‘limit 
peptide’ (fragment 211-222, m/z 1,460.5 Da) resulting from the digestion of the 
missed-cleavage peptide significantly increased after 18 h compared to 3 h. More 
importantly, for short digestions we were able to show differences in MBP digestion 
induced by the tissue morphology. These results urge caution owing to the numerous 
sources of technical bias in the MALDI-MSI data after short on-tissue digestion 
incubation times; as repeatability was improved, digestion more complete and 
morphology associated bias absent at longer incubation times, longer incubation times 
are advised. 
2.4 Conclusions 
Here we present the first in-depth investigation into the mechanics and spatio-temporal 
dynamics of on-tissue enzymatic digestion. To improve the repeatability and 
comparability of the MALDI-MSI data, normalization of targeted proteolytic fragments 
of MBP using isotopically-labeled reference standards was applied. The results indicate 
that a longer incubation of the enzymatic proteolysis reaction improves the quality of 
on-tissue digestion MALDI-MSI datasets by making the datasets more repeatable and 
remove morphology-induced measurement bias. This work is another step towards 
more trustworthy data obtained from on-tissue digestion MALDI-MSI analyses and 
towards the further implementation of the technique to clinical research. 
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2.6.1 Supplementary figures 
 
Figure S2-1: Examples of pre-processed average spectra for (top) 1.5 hour digestion, (middle) 3 hour digestion, and 
(bottom) 18 hour digestion. 
 
Figure S2-2: Visualizations of ILRS normalized ‘limit peptide’ at m/z 1,131.5 Da (TTHYGSLPQK) for each of the three 
incubation times. The plot shows the normalized intensities (median) for the ‘limit peptide’. The error bars represent 






Comprehensive analysis of the 
mouse brain proteome sampled 















Bram Heijs; Ricardo J. Carreira; Else A. Tolner; Arnoud H. de Ru; Arn M.J.M. van den 
Maagdenberg; Peter A. van Veelen; Liam A. McDonnell, “Comprehensive analysis of the 
mouse brain proteome sampled in mass spectrometry imaging,” Analytical Chemistry 
87(3), pp. 1867-1875, 2015.




Comprehensive analysis of the mouse brain proteome sampled in MSI 55 
 
 
 On-tissue enzymatic digestion is performed in MSI experiments to access larger 
proteins and to assign protein identities. Most on-tissue digestion MSI studies have 
focused on method development rather than identifying the molecular features 
observed. Herein, we report a comprehensive study of the mouse brain proteome 
sampled by MSI. Using complementary proteases, we were able to identify 5,337 
peptides in the MALDI matrix, corresponding to 1,198 proteins. 630 of these peptides, 
corresponding to 280 proteins, could be assigned to peaks in MSI data sets. Gene 
ontology and pathway analyses revealed that many of the proteins are involved in 
neurodegenerative disorders, such as Alzheimer’s, Parkinson’s and Huntington’s 
disease. 
3.1 Introduction 
Matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) is 
an analytical technique in which the distributions of hundreds of biomolecular ions can 
be recorded directly from tissue sections (Caprioli et al., 1997). It allows the 
simultaneous and untargeted investigation of many molecular classes, including 
pharmaceuticals, metabolites, lipids, peptides, and proteins (McDonnell and Heeren, 
2007). One of the principal application areas of MALDI-MSI is the investigation of the 
molecular content of pathological tissue samples in order to find biomarkers or provide 
insights into the molecular mechanisms underlying a disorder. The discovery of putative 
biomarkers has often focused on proteins since the results can then be independently 
validated using immunohistochemistry (Balluff et al., 2010; Cazares et al., 2011; 
Meding et al., 2012). 
 To increase proteome coverage, aid protein identification, and enable the analysis 
of formalin-fixed paraffin embedded (FFPE) tissues, the enzymatic protein digestion 
performed in classic bottom-up proteomics has been adapted for MALDI-MSI 
(Groseclose et al., 2008; Lemaire et al., 2006; Shimma et al., 2006). Protein 
identification directly from the tissue section can be performed by MS/MS analysis of 
the proteolytic peptides but remains challenging due to the very high complexity of the 
peptide mixture generated after digestion (Houel et al., 2010). Instead the peptide 
identities are commonly assigned to those previously identified via extraction of 
proteolytic peptides followed by LC-MS/MS analysis (Maier et al., 2013; Schober et al., 
2011). 
 As in bottom-up LC-MS/MS based proteomics, on-tissue digestion is most often 
performed using trypsin; its cleavage specificity, C-terminal of arginine and lysine, 
results in proteolytic peptides that have an intrinsic positive charge on the C-terminus, 
thus enhancing their detection by positive-ion MS (Brownridge and Beynon, 2011; 
Vandermarliere et al., 2013). A crucial difference is that MALDI-MS is biased towards 
the detection of Arg-terminated peptides (Krause et al.,1999). The suppression of Lys 
C-terminated tryptic peptides in MALDI-MS results in an undesired loss of sequence 
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information and proteome coverage. This is likely to be exacerbated in MALDI-MSI 
because of the absence of any explicit peptide separation. 
 The use of multiple proteases has been shown to have a beneficial effect on 
proteome and sequence coverage in both LC-ESI-MS and LC-MALDI-MS based studies 
(Choudhary et al., 2003; Gatlin et al., 2000; Hohmann et al., 2009; Wa et al., 2006). A 
recent study indicated that similar complementarities might be obtained in on-tissue 
digestion MALDI-MSI experiments: a combination of trypsin, pepsin and elastase was 
shown to have a positive effect on protein sequence coverage (Enthaler et al., 2013b). 
However since pepsin and elastase do not cleave basic amino acids many of the 
proteolytic peptides will not be detected with high sensitivity. To maintain high 
detection sensitivity it is essential that the proteases cleave the most basic amino acids, 
i.e. Lys and Arg. While these are the same residues cleaved by trypsin, previous LC-
MS/MS results have already demonstrated that the different sequence and 
conformation specificities of Lys-C, Arg-C and Lys-N can improve proteome and 
sequence coverage by reducing the number of missed cleavages (Brownridge and 
Beynon, 2011). 
 Here we have investigated the degree of increased proteome coverage that may be 
obtained in MALDI-MSI by using a similar complementary cohort of enzymes, 
specifically (i) trypsin, (ii) Lys-C, (iii) recombinant Lys-N (r-Lys-N), (iv) Arg-C, and (v) a 
mixture of trypsin and Lys-C (trypsin/Lys-C). 
3.2 Methodology 
3.2.1 Chemicals and reagents  
All chemicals were purchased from Sigma-Aldrich (Steinheim, Germany) except ethanol 
(Merck, Darmstadt, Germany). All proteases were purchased from Promega (Madison, 
USA) except r-Lys-N (U-Protein Express BV, Utrecht, The Netherlands). 
3.2.2 Sample collection  
Three-month-old, male, C57BL/6J mice were sacrificed by cervical dislocation. The 
brains were excised, flash-frozen on dry-ice and stored at -80°C until analysis. Twelve-
µm thick coronal tissue sections were obtained using a cryostat microtome (Leica 
Microsystems, Wetzlar, Germany) at -12°C. The sections were thaw-mounted onto 
poly-L-lysine coated indium-tin-oxide (ITO) glass slides (Bruker Daltonics, Bremen, 
Germany) and stored at -80°C. All experiments were approved by the Animal 
Experiment Ethics Committee of Leiden University Medical Center. 
3.2.3 Tissue preparation  
The tissue sections mounted on indium tin oxide (ITO) coated slides were collected 
from -80°C storage and equilibrated to room temperature in a freeze dryer for 30 
minutes. Thereafter, all tissues were washed as follows: (i) submerge in 70% ethanol 
for 30 s; (ii) submerge in 96% ethanol for 30 s; (iii) 10 short dips in deionized water; 
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(iv) submerge in 70% ethanol for 30 s; (v) submerge in 96% ethanol for 30 s (Enthaler 
et al., 2013a). Finally, the sections were dried in a vacuum desiccator for 15 min. 
3.2.4 On-tissue disulphide bond reduction  
Tissue sections were covered with 4 layers of 2 mM tris(2-carboxyethyl)phosphine 
(TCEP) (in deionized water) using the SunCollect automatic sprayer (SunChrom, 
Friedrichsdorf, Germany). The flow rate for the TCEP application was set to 10 µL/min, 
which resulted in the application of 360 nmol TCEP/cm2. Detailed information on the 
SunCollect settings can be found in Table S3-1 (Supplementary information). The total 
incubation time at 23°C (room temperature) was 30 min (including ca. 10 min spraying 
time). 
3.2.5 On-tissue enzymatic digestion   
All proteases were dissolved in deionized water to a final concentration of 0.02 µg/µL. 
4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) containing enzyme buffers 
for Lys-C and r-Lys-N were exchanged with deionized water using a 10 kDa molecular 
weight cut off (MWCO) spin filter (Merck Millipore, Billerica, MA, USA). Arg-C was 
dissolved in 2 mM dithiothreitol (DTT) to activate the enzyme. Five layers of proteolytic 
enzymes were applied using the SunCollect automatic sprayer at a flow rate of 5 
µL/min. This resulted in the application of 7.5 µg enzyme/cm2 (Table S3-1, 
Supplementary information). The tissues were incubated for 18 hours at 37°C in a 
saturated air chamber (50% methanol in deionized water). Finally, MALDI matrix was 
applied using the SunCollect sprayer. For the MALDI-TOF-MSI analyses 5 mg/mL α-
cyano-4-hydroxycinnamic acid (CHCA) in 50% acetonitrile (ACN) and 0.3% 
trifluoroacetic acid (TFA) was applied. For MALDI-MSI experiments performed with the 
MALDI-FTICR mass spectrometer it was found that the CHCA matrix produced 
excessive matrix clusters. Accordingly for MALDI-FTICR-MSI analyses, 50 mg/mL 2,5-
dihydroxybenzoic acid (DHB) in 50% ACN and 0.1% TFA was used as matrix. 
3.2.6 MALDI-TOF imaging    
MALDI-TOF-MSI was performed on an UltrafleXtreme MALDI-TOF/TOF (Bruker 
Daltonics) in positive-ion reflectron mode, using 500 laser shots per spot and 100 x 100 
µm pixel size. Data was acquired in a m/z range from 800-3,000 Da. Data acquisition, 
pre-processing and visualization were performed using the flex software package by 
Bruker Daltonics (flexControl 3.4; flexAnalysis 3.4; flexImaging 3.0). 
3.2.7 MALDI-FTICR imaging    
MALDI-FTICR-MSI was performed on a 9.4 T SolariX XR mass spectrometer (Bruker 
Daltonics) in positive-ion mode, using 250 laser shots per spot and 150 x 150 µm pixel 
size. Data was acquired in a m/z range from 600-3,500 Da with a 512k datapoint 
transient (1.1 s duration) and an estimated resolution of 200,000 at m/z 400 Da. Data 
acquisition was performed using ftmsControl (Bruker Daltonics) and visualizations were 
obtained from flexImaging 4.0 (Bruker Daltonics). 
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3.2.8 Data analysis MALDI-TOF-MSI    
Regions of interest (ROIs) containing the full area of the coronal section were selected 
in flexImaging and 500 random spectra from within each ROI extracted into 
ClinProTools 3.0 (build 22, Bruker Daltonics). The spectra underwent smoothing and 
baseline subtraction (Top Hat algorithm), total-ion-count normalization, and peak 
picking at different signal-to-noise ratios. The peak lists were exported to Excel 2010 
for further calculations. 
3.2.9 Peptide extraction     
Consecutive tissue sections were prepared for MALDI-MSI using the same sample 
preparation protocol. Instead of MALDI-MSI analysis, the proteolytic peptides were 
extracted from the matrix coating using a series of solvents with increasing organic 
content: (i) 10 µL of 0.1% TFA (repeat 4 times); (ii) 10 µL of 50% ACN / 0.1%TFA 
(repeat 4 times); (iii) 90% ACN / 0.1% TFA (repeat 4 times) (Enthaler et al., 2013a). 
Extracts were combined, dried and resuspended in 0.1% TFA, and then cleaned with 
Omix C18 tips (Agilent). The purified extracts were dried and stored at -20°C until LC-
MS/MS analysis. 
3.2.10 LC-MS/MS analysis  
Peptide extracts were analyzed using an Easy nLC1000 (Thermo, Bremen, Germany) 
coupled to a Q-Exactive mass spectrometer (Thermo). Fractions were injected onto a 
homemade pre-column (100 μm × 15 mm; Reprosil-Pur C18-AQ 3 μm, Dr. Maisch, 
Ammerbuch, Germany) and eluted via a homemade analytical column (15 cm × 50 μm; 
Reprosil-Pur C18-AQ 3 µm). The gradient was 0% to 30% solvent B (90% ACN / 0.1% 
formic acid (FA)) in 120 min. The analytical column was drawn to a tip of ∼5 μm and 
acted as the electrospray needle of the MS source. The Q-Exactive mass spectrometer 
was operated in top10-mode. Parameters were: Full scan - resolution 17,500; AGC 
target 3,000,000; max fill time 20 ms; MS/MS - resolution 35,000; AGC target 
1,000,000; max fill time 60 ms; intensity threshold 17,400; Apex trigger was set to 1-5 
seconds, and allowed charges were 1-5.  
 
3.2.11 LC-ESI-MS/MS database search  
Peptide and protein identifications were extracted from the SwissProt database using 
the Mascot server. Up to two missed cleavages were allowed and methionine oxidation 
was set as a variable modification. Peptide assignments were made with a tolerance of 
10 ppm. MS/MS fragment tolerance was 20 mmu. Protein identifications were assigned 
based on a minimum of one confident peptide at 1% false discovery rate (FDR). Only 
peptides and proteins with red bold notification were included in the final lists of non-
redundant peptides. For trypsin and trypsin/Lys-C, peptides and proteins with a Mascot 
significance score ≥ 30 were included, for Lys-C, r-Lys-N and Arg-C the threshold score 
was ≥ 25. 
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3.2.12 Gene ontology and pathway analysis  
A list containing the Uniprot accession numbers of the identified proteins was uploaded 
into the STRAP software tool (v1.1.0.0, Boston University School of Medicine) (Bhatia 
et al., 2009). The KEGG pathway analysis (PA) was performed by uploading the list in 
the online STRING 9.1 tool (Jensen et al., 2009). As p-value correction, the “FDR 
correction” option was applied. 
 
3.2.13 Data analysis MALDI-FTICR-MSI  
Average spectra from the MALDI-FTICR-MSI datasets were exported into CSV format 
and loaded into mMass (http://www.mmass.org) (Strohalm et al., 2008). Peak picking 
was performed on peaks with S/N ≥ 5 and intensity ≥ 1,500 A.U.. The peak lists were 
then deisotoped with a maximum charge of 3+ and an isotope mass tolerance of 0.05 
Da. 
 
3.2.14 MALDI-FTICR-MSI peptide identity assignment  
MALDI-FTICR-MSI peak lists and Mascot database search results from the LC-MS/MS 
analyses were exported to Excel 2010. The MSI peaks were assigned to identified 
peptides based on a mass tolerance of 20 ppm. 
3.3 Results 
On-tissue digestion is used to increase proteome coverage and to assign identities to 
the peaks detected by MALDI-MSI. In this study we investigated whether additional 
arginine and lysine proteolytic enzymes, with different cleavage specificities, could 
further improve on-tissue digestion MALDI-MSI by increasing sequence and proteome 
coverage. MALDI-MSI was combined with LC-MS/MS of on-tissue digestion matrix 
extracts to compare the accessible proteolytic peptides produced by the enzymes 
trypsin, Lys-C, trypsin/Lys-C, r-Lys-N and Arg-C, and to determine which proteolytic 
peptides were detected by MALDI-MSI. 
 
3.3.1 MALDI-TOF-MSI: image comparison  
To assess the effects of sample preparation (online Supplementary information) for the 
different enzymes, ion distributions for proteolytic peptides from the same protein were 
compared with both each other and the gene expression data from the Allen Mouse 
Brain Atlas (http://www.brain-map.org). Figure 3-1 shows example mass spectra and 
MSI images obtained from coronal sections of a C57BL/6J mouse brain subject to on-
tissue digestion with the different proteases. The images are of proteolytic peptides 
originating from myelin basic protein (MBP), assigned to confidently identified peptides 
from the LC-MS/MS analysis of matrix extracts. The mass resolution of the 
UltrafleXtreme MALDI-TOF/TOF platform used for these MSI experiments is insufficient 
to resolve the isobaric ions produced by on-tissue digestion, and so the images may 
include contributions from unresolved isobaric ions. The distributions of the MBP 
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proteolytic peptides were consistent with the MBP gene expression images contained in 
the Allen Brain Atlas, Figure 3-1F, indicating that any isobaric ions were minor 
contributors and that no artifacts resulted from the on-tissue digestion procedure. 
It is important to note that the quality of the MSI images was poor when the enzymes 
were applied using the buffer system recommended by the manufacturers (e.g. 
ammonium bicarbonate; HEPES; Tris-HCl), with no visualization of clear anatomical 
structures for different m/z values (Figure S3-1, Supplementary information). For this 
reason, all enzymes, except Arg-C, were dissolved in milliQ water (pH 6.5 – 7). 
 
3.3.2 MALDI-TOF-MSI: comparison of average spectra  
The average mass spectra obtained by MALDI-MSI analysis for both trypsin (Figure 3-
1A) and trypsin/Lys-C (Figure 3-1B) digestions presented a curved mass spectral profile 
that has already been described in several publications (Groseclose et al., 2008; 
Lemaire et al., 2006; Shimma et al., 2006). The profile reflects the very high 
complexity of the resulting proteolytic peptide mixtures as well as the inability of the 
reflectron-TOF mass analyzer to fully resolve all peaks. Proteolytic digestions using 
proteases with cleavage specificity for single amino acids, such as Lys-C, r-Lys-N or 
Arg-C, yielded a smaller number of peptides. As can be seen in Figure 3-1C-E, when 
Lys-C, r-Lys-N or Arg-C were used, the spectra exhibited a flatter baseline and peaks 
with higher absolute intensity. Figure 3-1G shows that digestion with trypsin yielded a 
higher total number of m/z features than digestions using proteases with single-site 
cleavage specificity. However, on-tissue digestion with Arg-C presented the largest 
number of high intensity m/z features, S/N > 20, consistent with the previously 
reported bias of MALDI towards Arg-terminated tryptic peptides. Note: the number of 
m/z features reported in Figure 3-1G should be considered a low estimate because of 
the inability of the reflectron-TOF mass analyzer to resolve isobaric ions (Schober et al., 
2012). 
 
3.3.3 Peptide and protein identification  
To further investigate the dependence of the on-tissue digestion MALDI-MSI 
experiment on the protease, the proteolytic peptides extracted from the tissue section, 
following deposition and crystallization of the matrix, were analyzed by LC-MS/MS 
(using consecutive tissue sections that had undergone identical sample preparation). 
The analysis of the matrix extracts of the five protease preparations resulted in a total 
of 5,050 non-redundant peptides (online Supplementary information), over 2.8 times 
the number obtained from the matrix extract of the trypsin digested tissue. When 
including redundant peptides, the total number increased to 5,339 (online 
Supplementary information), which was also 2.8 times the number of peptides 
identified with trypsin alone (Figure 3-2A). The relatively low number of peptides 
identified after digestion with Lys-C and r-Lys-N was unexpected, but confirmed by 
repeat experiments. This observation is due to the enzyme buffer exchange performed  




Figure 3-1: Overview of the on-tissue-digestion MALDI-MSI data. Myelin basic protein peptide ion distributions and 
average mass spectra for the digested tissue sections; (A) m/z = 1,131.6 (TTHYGSLPQK); (B) m/z = 1,081.6 
(FFSGDRGAPK); (C) m/z = 2,026.0 (SQHGRTQDENPVVHFFK); (D) m/z = 2,026.0 (KSQHGRTQDENPVVHFF); (E) m/z 
= 2,141.1 (TQDENPVVHFFKNIVTPR); (F) mouse brain Nissl histologic staining and MBP gene expression data from the 
Allen Brain Atlas; (G) average number (n = 4) of extracted m/z features with different signal to noise ratios. 
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for both enzymes. To achieve optimal digestion conditions proteases are usually 
dissolved in specific buffer systems containing additives, such as chelating agents, salts 
and sugars. The buffers for both Lys-C and r-Lys-N contained HEPES, a compound 
known to cause signal suppression in MALDI-MS above a certain concentration 
threshold (Amini et al., 2000; Signor and Erba, 2013). This effect is demonstrated in 
Figure S3-1 (Supplementary information), which compares the average spectra 
obtained after on-tissue digestion MALDI-MSI with Lys-C dissolved in the 
manufacturer’s recommended buffer (50 mM HEPES (pH 8.0), 10 mM 
ethylenediaminetetraacetic acid (EDTA) and 5 mg/mL raffinose), and the average 
spectra obtained after digestion with the same enzyme dissolved in MQ-water after 
buffer exchange. The latter spectrum shows an increase of more than 2-fold in 
absolute intensity but the number of peptides is significantly less than would be 
expected on the basis of previous LC-MS/MS experiments. 
 
 Similar results were achieved at the protein level (Figure 3-2B). The combined data 
of all on-tissue digestion experiments resulted in a total of 1,194 confidently identified 
non-redundant proteins. When redundant proteins where included, a total of 1,198 
proteins was identified of which 52.2% had not been previously identified in the matrix 
extract of the trypsin-digested tissue section. Thirty-seven proteins, including 
redundant proteins, were identified exclusively in the tryptic digests, corresponding to 
3.1% of the total number of identified proteins. The largest gain in proteome coverage 
was achieved using Arg-C: 22.7% of the total number of identified proteins originated 
exclusively from this extract. A subset of only 96 proteins was identified in all matrix 
extracts, which corresponds to 8.0% of the total number of identified proteins. 
 
 Besides the increase in proteome coverage, individual protein sequence coverage 
also gained from combining the data obtained with multiple proteases (Figure 3-2C). 
For instance, analysis of spectrin-1 (SPTN1; 2,472 amino acid residues; MW = 284 
kDa; Uniprot entry: P16546), a highly abundant protein in mouse brain that is involved 
cytoskeletal structure (Zagon et al., 1986), resulted in a sequence coverage of 26.3% 
from the matrix extract of the trypsin digested tissue section. By combining the data 
from all enzymes the sequence coverage for SPTN1 increased to 44%. Similar trends 
were observed for other proteins as shown in Figure 3-2C. 
 
 To test whether the proteome coverage could be improved by reducing protein 
disulfide bonds before enzymatic digestion, a series of experiments were performed in 
which on-tissue enzymatic digestion was preceded by on-tissue disulfide bond 
reduction using 2 mM TCEP (in milliQ water), a compound that was previously shown 
to be compatible with MALDI-MS (Fischer et al., 1993; Kulak et al., 2014). The ion 
distributions from the reduced tissues were of similar quality as the ones obtained from 
non-reduced tissues, indicating that the TCEP reduction did not affect the localization of 
the peptides in the tissue (data not shown). The gain in proteome coverage for each  




Figure 3-2: Analysis of the on-tissue digested matrix proteome. (A) Number of peptides identified for each protease 
above the significant threshold. Confident non-redundant peptides required a red bold notation in Mascot and a 1% 
FDR. Mascot score thresholds were ≥30 for trypsin and trypsin/Lys-C, and ≥25 for Lys-C, r-Lys-N and Arg-C. Addition 
of redundant peptides was achieved by removing the red bold requirement. (B) Number of proteins identified for each 
protease. Confident non-redundant (NR) protein identifications were assigned based on 1 or more significant peptides, 
a red bold notation in Mascot and 1% FDR. Mascot score thresholds were ≥30 for trypsin and trypsin/Lys-C, and ≥25 
for Lys-C, r-Lys-N and Arg-C. Addition of redundant proteins (IR) was achieved by removing the red bold requirement. 
(C) A comparison of sequence coverage for microtubule associated protein 6 (MAP6), myelin basic protein (MBP) and 




Figure 3-3: Comparison of confident unique protein identifications obtained from matrix extracts taken from tissue 
sections treated with on-tissue digestion (red) and tissue sections treated with on-tissue disulfide bond reduction 
followed by on-tissue digestion (green). Proteins occurring in both experiments were designated as overlap (grey). 
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protease was determined by comparing protein identifications from both non-reduced 
and reduced datasets (Figure 3-3). For r-Lys-N the TCEP-reduced protein extract 
resulted in the identification of an additional 142 proteins, which were not previously 
identified in the non-reduced sample. A small gain in proteome coverage was also 
observed in the extract of trypsin (32 additional identified proteins) and trypsin/Lys-C 
(35 additional identified proteins).  
3.3.4 Gene ontology analysis of the matrix proteome   
The combined data from the digested matrix proteomes was submitted to a gene 
ontology analysis. The results show that the matrix proteome contained mostly 
cytoplasmic proteins (48.7%), followed by nuclear proteins (14.9%) and membrane 
proteins (16.3%) (online Supplementary information). These results are in accordance 
with previous data by Maier et al. (Maier et al., 2013), which focused on the intact 
proteins sampled by MALDI-MSI.  
 A KEGG pathway analysis (online Supplementary information), revealed that many 
of the proteins in the digested matrix proteome play a role in metabolism: amongst the 
most significant pathways are oxidative phosphorylation, the Krebs cycle, glycolysis and 
pyruvate metabolism. Protein pathways involved in neurodegenerative disorders (e.g. 
Alzheimer’s disease, Parkinson’s disease and Huntington’s disease) as well as in long-
term depression were identified amongst the most significant hits. 
3.3.5 MALDI-FTICR-MSI: linking MSI to LC-MS/MS  
To resolve isobaric peptide ions and assign identities the on-tissue digestion 
experiments were repeated with a 9.4T MALDI-FTICR-MS. For trypsin digestion 156 
peptides, corresponding to 100 proteins (Table 3.1) and 8.2% of the peptides identified 
by LC-MS/MS, could be assigned to peaks in the MSI dataset. For the other proteases 
the numbers were: (i) trypsin/Lys-C 9.8%; (ii) Lys-C 17.4%; (iii) r-Lys-N 12.6%; (iv) 
Arg-C 9.2%. The combined list of assigned peptides for the five proteases 
corresponded to 280 proteins (an increase of 180 proteins if compared to just trypsin 
alone).  
Table 3.1: Results of the peptide identity assignment on the MALDI-FTICR-MSI data. 
Protease 
Assigned peptides incl. 
redundant peptides total (#) 
Corresponding proteins total  
(#) 
Trypsin 156 100 
Trypsin/Lys-C 242 133 
Lys-C 67 40 
r-Lys-N 135 86 
Arg-C 152 115 
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 For several proteins, more than one peptide was assigned, which allowed for 
comparison of the peptide distribution within one tissue section or between tissue 
sections that were digested with different proteases. Figure 3-4 shows several 
examples of MBP proteolytic fragments that were assigned based on the described 
methodology. The peptide distributions were verified using the gene expression profile 
for the Mbp gene obtained from the Allen Brain Atlas (Figure 3-1F). More examples are 
presented in the online Supplementary information. 
3.4 Discussion 
One of the most comprehensive studies regarding the proteome sampled by MALDI-
MSI identified 1,400 proteins from diverse human tissues (Maier et al., 2013). It was 
based on the extraction of intact proteins from tissues coated with MALDI matrix, the 
matrix proteome, followed by separation by gel electrophoresis and in-gel trypsin 
digestion. Despite the valuable information collected, in terms of the proteins ultimately 
accessible by MSI, the published data does not allow a direct comparison with MALDI-
MSI because most identified proteins are substantially larger than those usually 
detected by MALDI-MSI (McDonnell et al., 2014; Schober et al., 2012). Instead, the 
identification of the proteins analyzed by MALDI-MSI is often performed using on-tissue 
enzymatic digestion, in which the MALDI-MSI data is assigned, on the basis of accurate 
mass, to LC-MS/MS data from tissue extracts (Maier et al., 2013; Groseclose et al., 
2007; Gustafsson et al., 2013). Digestion with different enzymes has been shown to 
increase proteome coverage in bottom-up proteomics (Choudhary et al., 2003; Gatlin 
et al., 2000; Hohmann et al., 2009; Wa et al., 2006). Similarly, Enthaler et al. (Enthaler 
et al., 2013b) demonstrated that the combination of trypsin, pepsin and elastase 
increased protein sequence coverage in MALDI-MSI. The increased sequence coverage 
follows from the high number of cleavage sites – elastase cleaves at the C-terminus of 
small hydrophobic amino acids, G, S, I, L, A, V (Rietschel et al., 2008) and pepsin at 
the C-terminus of amino acids, P, Y, W, L (Mótyán et al., 2013) – but at the expense of 
very complex MSI datasets containing many isobaric ions.  
 Instead we investigated whether the different activities of additional enzymes that 
cleave at the basic amino acids (to maintain MS detection sensitivity) can also aid 
MALDI-MSI. The enzymes trypsin, Lys-C, trypsin/Lys-C, Lys-N and Arg-C were 
investigated. A standard digestion protocol was first established using trypsin. Once 
similar results were reproducibly obtained, including from different animals, the method 
was adapted for the other proteases by changing the solution conditions (minimal 
changes to the spraying and incubation conditions). The success of the different 
proteases further demonstrates the robustness of the method (see Table S3-1 
(Supplementary information) for spray method). In this paper we have focused on the 
improvement in proteome coverage that may be obtained in on-tissue digestion 
MALDI-MSI by combining the results from different proteases; to ensure comparability 
the data presented are obtained from a single animal.  
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Figure 3-4: Ion distributions representing MBP peptides obtained from MALDI-FT-ICR-MSI were assigned to peptides 
identified by LC-ESI-MS/MS. The images were obtained from the MALDI-FT-ICR-MSI datasets of (i) trypsin (green 
box), (ii) trypsin/Lys-C (blue box), (iii) Arg-C (purple box), (iv) Lys-C (orange box), (v) r-Lys-N (red box). For each of 
the single ion images (represented by the jet intensity scale) the corresponding sequence and measurement error are 
presented 
 All enzymes were diluted to the same concentration and sprayed over the tissue 
with the same method. The presence of salts and buffers in the protease solutions of 
Lys-C and r-Lys-N led to poor matrix crystallization, low signal intensity and noisy MSI 
images (Figure S3-1, Supplementary information). A buffer exchange with milliQ water 
(pH 6.5 – 7) improved the quality of the MS images but the low number of peptide and 
protein identifications indicated that the lack of salts and buffers adversely affected 
enzymatic activity (Figure 3-2). Still, the combination of proteases greatly increased the 
number of detected peptides and proteins; the 5,337 peptides and 1,198 proteins 
represent an increase of 179% and 110%, respectively, as compared to trypsin alone 
(1,913 peptides; 570 proteins). 
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 Unlike LC-MS/MS based protein identification, MSI of proteolytic peptides does not 
differentiate unique peptides from non-unique peptides and all peptides are detected in 
the same mass spectrum. Consequently, the datasets will contain non-unique peptides 
as well as many isobaric ions. Both of these characteristics frustrate efforts to identify 
proteolytic peptides directly from tissue using MS/MS (Houel et al., 2010). The use of 
multiple enzymes for on-tissue digestion has the advantage of producing different 
peptides from the same protein that can be used to confirm its distribution in the tissue 
sample (Figures 3-1 and 3-4). 
 To connect the confidently identified peptides and proteins from the matrix extracts 
to the on-tissue digestion MALDI-MSI experiments high mass resolution MALDI-MSI 
data was acquired on a 9.4T MALDI-FTICR instrument. Between 8.2 - 17.4% of the 
peptides identified by LC-MS/MS could be assigned to peaks in the high mass resolution 
MALDI-MSI datasets (Table 3.1). The combined total number of 633 peptides 
originated from 280 proteins (online Supplementary information). A previous 
publication by Schober et al. (Schober et al., 2012) reports a similar approach where 
over 1,100 peptides were first identified from a mouse brain tissue homogenate, of 
which 13% were assigned to m/z features in a high mass resolution MALDI-MSI 
dataset, and corresponded to 101 proteins. The Schober paper used extensive peptide 
fractionation to increase protein identification rates and analyzed the entire tissue’s 
proteome. In contrast the results reported here utilized no fractionation and only 
analyzed the matrix proteome. Without the fractionation step 140 peptides were 
identified in the LC-MS/MS analysis of which 60 could be assigned to m/z features in 
the MALDI-MSI dataset, corresponding to 38 proteins (Schober et al., 2012). Here, 
using complementary enzymes for on-tissue digestion and LC-MS/MS of the matrix 
peptides (without any fractionation step) we could assign more than 600 peptides, 
corresponding to 280 proteins. 
 The peptide assignments were based on a mass error tolerance of ±20 ppm. The 
cyclotron frequency of an ion inside an ICR cell, and therefore the accurate calibration 
of an FTICR instrument, is dependent on the magnetic field strength as well as the 
local electric field. Accordingly, the calibration is dependent on the number of ions in 
the cell, which in MALDI-MS varies from shot-to-shot, and in MALDI-MSI from pixel to 
pixel. Consequently, there are slight mass deviations in all pixels, resulting in broader 
peaks in the average mass spectrum. Peak picking and peptide identity assignment 
were based on the average, non-aligned mass spectrum and therefore a higher mass 
tolerance was applied. However, the consensus between the images obtained for 
different peptides, utilizing different proteases provides additional corroboration. 
 The LC-MS/MS data reported here of MALDI matrix extracts also acts as a guide to 
the proteins/peptides that may be analyzed via MALDI-MSI. It has previously been 
shown that MSI detected only a fraction of those detected by LC-MS/MS analysis of 
tissue extracts (Schober et al., 2011). A single 100 x 100 µm pixel analyses the 
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equivalent of ≈12 cells (assuming average cell size of 20 µm and tissue thickness of 10 
µm), and which is analyzed without any explicit purification and separation step. To be 
detected by MALDI-MSI the peptides are required to be present in the MALDI matrix 
and present at sufficiently high levels. While we have demonstrated an increase in 
proteome coverage the number remains a fraction of the tissue’s total proteome, 
because of the sample-volume-limited nature of the analysis and the need for matrix 
incorporation of the peptides. The FTICR-MS used here, and the Orbitrap used 
previously (Schober et al., 2012), are characteristically very high dynamic range mass 
analyzers. To significantly increase the number of peptides detected by MSI will require 
significant increases in the charge capacity of these ion trap mass analyzers (while 
maintaining performance) in order for the lower level peptides to be above the 
detection threshold. 
 Amongst the 280 assigned proteins detected here were several histones. Histones 
are highly implicated in cancer progression through their role in determining chromatin 
structure and gene accessibility. Proteolytic fragments of histones have been previously 
reported in cancerous tissues analyzed by on-tissue-digestion MALDI-MSI (Djidja et al., 
2009a, 2009b). Several peptides were assigned to subunits of mitochondrial ATPases 
(AT1A1, -2, -3, AT2B1, -2, ATPA, ATP5H & ATP5J). These trans-membrane proteins are 
known to be involved in a multitude of neurological disorders, e.g. familial hemiplegic 
migraine (Morth et al., 2009; Poulsen et al., 2010) and Alzheimer’s disease 
(Markesbery, 1997; Zlokovic, 2011). These results were confirmed by the GO analysis 
and KEGG pathway analysis which show that proteins involved in several metabolic 
pathways and neurological disorders are well represented in the digested matrix 
proteome (online Supplementary information). 
3.5 Conclusions 
This work reports the peptides identified from the on-tissue-digestion matrix proteome 
as well as the peptides detected by ultra-high mass resolution MALDI-MSI, for multiple 
enzymes; both valuable sources of information for researchers applying on-tissue 
digestion MSI. The results demonstrate the ability to increase proteome coverage by 
using different enzymes and indicate that on-tissue digestion MALDI-MSI analysis of 
the mouse brain can be applied in a wide range of disease related, biomarker discovery 
or other neuro-scientific research applications. 
 It should be noted that we have been deliberately conservative with the thresholds 
used in the assignments (>0.6% base peak). It is known that FTICR and Orbitrap mass 
spectrometry can span a very wide dynamic range, and more peptides could have been 
assigned if a lower threshold was used. However, at lower thresholds many peaks were 
associated with noisy images and the greatly increased number of peaks is 
accompanied by an increased risk of mis-assignment. It is expected that with additional 
improvements in dynamic range, sensitivity and on-tissue MS/MS based verification of 
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peptide identities that even more peptides will be assignable and the application 
potential of MALDI-MSI increased further. 
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3.7 Supplementary information 
The full supplementary information, files and tables are available on the internet via 
http://pubs.acs.org/doi/suppl/10.1021/ac503952q. 
3.7.1 Supplementary tables 
Table S3-1: Overview of the settings used on the SunChrom SunCollect sprayer during TCEP-, protease and matrix 
application. 
Setting TCEP Protease Matrix 
Vial X (mm) 0.5 0.3 0.5 
Vial Y (mm) 2.0 0.3 2.0 
Z (mm) 25.0 45.5 25.0 
Z-offset (mm) 0.0 0.0 0.0 
Layers (#) 4 5 3 
Flowrate Layer 1 (µL/min) 10 5 10 
Flowrate Layer 2 (µL/min) 10 5 35 
Flowrate Layer 3 (µL/min) 10 5 35 
Flowrate Layer 4> (µL/min) 10 5 - 
Speed X Low (3) Low (4) Low (3) 
Speed Y Medium (1) Medium (1) Medium (1) 
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3.7.2 Supplementary figures 
 
Figure S3-1: The effect of the enzyme buffer exchange procedure required to remove ion suppressing compounds 
(e.g. HEPES) from the enzyme buffer. The top panel contain an image and an average spectrum taken from a lys-C 
on-tissue digestion MALDI-MSI analysis, without performing enzyme buffer exchange. The bottom image and 
spectrum were taken from a lys-C on-tissue digestion MALDI-MSI analysis, subsequent to the enzyme buffer exchange 
procedure. Ion intensities in the MALDI-MSI data are represented by the jet intensity color scale. 
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 Mass spectrometry imaging (MSI) is widely used for clinical research because when 
combined with histopathological analysis the molecular signatures of specific 
cells/regions can be extracted from the often-complex histologies of pathological 
tissues. The ability of MSI to stratify patients according to disease, prognosis and 
response is directly attributable to this cellular specificity. MSI developments are 
increasingly focused on further improving specificity, through higher spatial resolution 
to better localize the signals or higher mass resolution to better resolve molecular ions. 
Higher spatial/mass resolution leads to increased data size and longer data acquisition 
times. For clinical applications, which analyze large series of patient tissues, this poses 
a challenge to keep data load and, acquisition time manageable. Here we report a new 
tool to perform histology guided MSI; instead of analyzing large parts of each tissue 
section the histology from adjacent tissue sections is used to focus the analysis on the 
areas of interest, e.g. comparable cell types in different patient tissues, thereby 
minimizing data acquisition time and data load. The histology tissue section is 
annotated and then automatically registered to the MSI-prepared tissue section; the 
registration transformation is then applied to the annotations, enabling them to be 
used to define the MSI measurement regions. Using series of formalin-fixed, paraffin-
embedded human myxoid liposarcoma tissues we demonstrate an 80% reduction of 
data load and acquisition time, thereby enabling high resolution (mass or spatial) to be 
more readily applied to clinical research. The software is freely available for download. 
4.1 Introduction 
Histological analysis is arguably the most common tool in diagnostic pathology and 
clinical research. The use of molecular assays further aids in understanding, 
determining, and differentiating diseases (Aichler and Walch, 2015; Altelaar et al., 
2012; Bovée and Hogendoorn, 2010). A technique that recently emerged is matrix-
assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI), which 
is an analytical technique that combines conventional microscopy with spatially 
resolved and label-free detection of hundreds of biomolecules directly from a tissue 
section (Caprioli et al., 1997). MALDI-MSI has proven itself a valuable tool in molecular 
pathology as it is capable of revealing the molecular histology of a tissue section and 
finding distinct molecular profiles that can predict the nature of the underlying tissue 
(Willems et al., 2010b; Balluff et al., 2015; Casadonte et al., 2014; Gustafsson et al., 
2011; Meding et al., 2012).  
 
 The impact of MSI in clinical research is directly attributable to the cellular 
specificity of the analysis; signatures of specific cells/regions can be extracted from the 
often-complex histologies of pathological tissues. MSI developments are increasingly 
focused on further improving specificity, through higher spatial resolution to better 
localize the signals or higher mass resolution to better resolve ions with identical 
nominal masses. 
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 MSI analysis of proteins via on-tissue enzymatic digestion, metabolites, lipids and 
recently even intact proteins, all benefit from higher mass resolution by better resolving 
the many molecular species with the same nominal mass, so-called isobaric ions (Buck 
et al., 2015; Heijs et al., 2015; Muller et al., 2015; Spraggins et al., 2015). When 
analyzing large tissue series, a compromise must be sought between resolution and 
throughput, to keep the data load, acquisition time and computational challenges 
manageable. This is primarily because the established approach is to first record MSI 
data, and then use histopathological analysis of the same tissue section to define via a 
virtual microdissection which MSI data will be used in the statistical analysis. However 
only a fraction of the MSI data is typically used in the statistical analysis, as the cellular 
content of the compared regions must be well matched within the same tissue as well 
as within tissues from different patients. Accordingly, the data acquisition throughput 
and data load could be better optimized by adapting the histology-defined protein-
profiling approach (Cornett et al., 2006) to high resolution MSI, namely limiting MSI 
data acquisition to those regions whose data will be used in the statistical analysis. 
 
 In the current work we have developed an automated image registration pipeline to 
register an annotated, histological image of an adjacent tissue section to a lower 
resolution image of the MSI-prepared tissue section. Subsequently, the annotation 
borders are propagated to the low resolution image, enabling the exclusive analysis of 
the annotated regions by MSI. This histology-guided MSI approach ensures that the 
MSI data is acquired solely from tissue regions with similar morphological makeup.  
Using series of formalin-fixed, paraffin-embedded human myxoid liposarcoma tissue we 
demonstrate an 80% reduction of data load and acquisition time, thereby enabling high 
resolution (mass or spatial) to be more readily applied in clinical research. 
4.2 Methodology 
4.2.1 Chemicals and reagents  
All chemicals were purchased from Sigma-Aldrich (Steinheim, Germany) except ethanol 
and xylene (Merck, Darmstadt, Germany). Trypsin was purchased from Promega 
(Madison, USA).  
4.2.2 Tissues & sample collection  
Myxoid liposarcoma (MLS) tissues were fixed in formalin and embedded in paraffin 
following standard histopathological procedures. All tissue samples were handled in a 
coded fashion according to Dutch national ethical guidelines (Code for proper 
secondary use of human tissue, Dutch Federation of Medical Scientific Societies). 
Adjacent tissue sections, 6 µm, were cut from the formalin-fixed, paraffin-embedded 
(FFPE) tissue blocks using a microtome. Tissue sections designated for MALDI-MSI 
analyses were mounted on poly-L-lysine coated indium-tin-oxide (ITO) glass slides 
(Bruker Daltonics, Bremen, Germany), dried overnight at 37°C and stored at 4°C until 
the analysis. Tissues designated for histological analysis were mounted on Starfrost 
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adhesive microscope slides (Light Labs, Dallas (TX), USA), stained with haematoxylin & 
eosin (H&E) and scanned using a digital slide scanner (IntelliSite Pathology Ultra-Fast 
Scanner, Philips, Eindhoven, The Netherlands). This tissue section is referred to as the 
histological-tissue-section in the subsequent text. 
 
4.2.3 On-tissue digestion MALDI-MSI  
FFPE tissue sections designated for MSI analysis were first put on a 60°C heating block 
to improve adherence of the tissue section to the slide. Deparaffination was performed 
by washing the slides twice in 100% xylene (I - 5 min, II - 10 min). Prior to heat-
induced antigen retrieval (HIAR) in 10 mM citric acid pH6, the slides were washed twice 
in 100% ethanol (2 min each) and twice in milliQ water (5 min each). After HIAR two 
more washes in milliQ water (1 min each) were performed. The tissues were dried in a 
vacuum desiccator for 15 minutes. Fiducial markers were placed using water-based 
Tipp-Ex and a lower resolution (2400 dpi) optical image recorded using a flatbed 
scanner. This image is referred to as the pre-MSI-optical-image. Immediately thereafter 
trypsin (20 ng/µL in deionized water) was sprayed on the tissue using the SunCollect 
automatic sprayer (SunChrom, Friedrichsdorf, Germany) (5 layers at 5 µL/min). 
Following an 18 h incubation in a saturated (50% methanol) environment at 37°C, 
three layers (at 10, 35, and 35 µL/min) of MALDI matrix (20 mg/mL 2,5-
dihydroxybenzoic acid in 50% acetonitrile and 0.1% trifluoroacetic acid) were sprayed 
on the tissue using the SunCollect automatic sprayer (Heijs et al., 2015). 
 
 MALDI-FTICR-MSI was performed on a 9.4 T SolariX XR mass spectrometer (Bruker 
Daltonics) in positive-ion mode, using 150 laser shots per spot and 100 x 100 μm pixel 
size, calibrated using Peptide Calibration Standard (Bruker Daltonics). Spectra were 
recorded in the m/z range 600–3,500 Da with a 512k data point transient (1.1 s 
duration), corresponding to an estimated resolution of 200,000 at m/z 400 Da. The 
average detected mass resolution over the analyzed mass range was 54,000, and the 
mass resolution in the center of the mass range, at m/z 1,500, was 65,000. Data 
acquisition was performed using ftmsControl (Bruker Daltonics), and visualizations were 
obtained from flexImaging 4.0 (Bruker Daltonics). Following the MALDI-MSI data 
acquisition, excess matrix was removed by washing in 70% ethanol (2x 2 min) and this 
MSI-analyzed-tissue-section also stained with H&E. The stained tissues were scanned 
using a digital slide scanner and used to assess the accuracy of the registration 
between this MSI-analyzed-tissue section and the histological tissue section. This image 
is referred to as the post-MSI-histological-image. 
 
4.2.4 Image registration software tool  
4.2.4.1 Pre-processing 
Background noise was first removed from both the histological-tissue-section image 
and pre-MSI-optical-image. The pre-processing retains the tissue foreground 
information while setting the background pixels to zero. The intensity distribution of the 
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optical image follows a bimodal histogram that represent background and foreground 
pixel distribution, hence their separation is readily achieved by setting a global 
threshold using Otsu’s method16. Morphological operations then followed to fill-in any 
gaps introduced by setting the image intensity threshold. The region with the maximum 
area of connected components was selected to form a mask that separates the tissue 
from the background. The high-resolution histology images were pre-processed using 
the pre-processing-pipeline presented by Abdelmoula et al. (Abdelmoula et al., 2014). 
 
4.2.4.2 Image Registration  
The registration process is performed between a fixed image (If), in this case the pre-
MSI-optical-image, and a moving image (Im), the histological-tissue-section image. The 
moving image is warped to be spatially aligned with the fixed image according to the 
standard registration optimization problem given in equation (1).  
 
?̂? = arg min
𝜇
𝐶[𝐼𝑓 , 𝑇(𝐼𝑚)]     (1) 
 The optimized transformation parameters are captured in the vector μ in such a 
way the cost function C is minimized with respect to the transformation model T using 
the adaptive stochastic gradient descent optimizer (Klein et al., 2011). First, Im was 
linearly transformed, using affine transformation, to capture the global deformation 
parameters (i.e. translation, rotation, scaling, and shearing), followed by a non-linear 
transformation model of B-Spline to correct for local deformations. The registration was 
performed in a multi-resolution scheme (4 levels) using a Gaussian pyramid model and 
the mutual information was used as a cost function to assess the registration quality. 
The multi-resolution registration has proven faster and more robust than single-scale 
techniques with a convergence that is less likely to be trapped in a local optimum 
(Unser et al., 1993). The mutual information has been introduced for multi-modality 
image registration, as it measures the statistical dependence between two images with 
the same geometrical information but different intensity distributions and maximizing 
their statistical measure implies they are geometrically aligned (Maes et al., 1997; 
Pluim et al., 2003). The Elastix software package was used to implement the reported 
registration algorithms (Klein et al., 2010). 
 
4.2.4.3 Evaluation  
The accuracy of the image registration was assessed by comparing expert pathological 
annotations of the post-MSI-histological-image (JVMGB) with those provided by 
registering the annotations of the histological-tissue-section to the pre-MSI-histological-
image. The accuracy was quantified by using the Dice similarity coefficient (DSC), 
which is a measure for the similarity between two samples (Dice, 1945). 
 




Figure 4-1: (A) Scanned image of an H&E stained myxofibrosarcoma tissue with annotated regions of clinical 
interest. Pixels present in the ROIs were selected for data analysis. Various tumour grades were selected based on 
their cellular differentiation, green, yellow and blue annotations represent well differentiated, moderately differentiated 
and undifferentiated tissue regions respectively. (B) The (relative) surface of the differently diagnosed tissue regions 
compared to the total surface of the full tissue section. (C) The average percentage of pixels used for data analysis 
per tumour subtype for a total of 55 soft tissue sarcoma samples. 
4.3 Results and discussion 
An established approach in clinical MALDI-MSI is to analyze large areas of a series of 
tissue sections at a predefined spatial resolution. Subsequently, excess matrix is 
removed and a histological staining of the analyzed section allows to perform virtual 
microdissection, and to export the pixels from regions with similar cellular makeup for 
further data analysis (Figure 4-1A).  
 A previous analysis to study intact proteins from a patient series of high grade 
sarcomas (n = 55) revealed that, after virtual microdissection, an average of just 22% 
(±11%) of the MALDI-MSI data was used in the subsequent data analysis (Figure 4-
1B-C). This dataset was acquired at a 100 µm spatial resolution on a relatively low 
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mass resolution MALDI-TOF/TOF platform (UltrafleXtreme, Bruker Daltonics) but 
already resulted in a total dataset size of 232 GB for the 55 analyzed tissue sections. 
This post-MSI virtual microdissection approach is sub optimal for high resolution 
studies, because of the greatly increased data load and data acquisition times 
associated with higher mass/spatial resolution. 
 We recognized that we could increase the measurement throughput and, decrease 
data load if MSI data acquisition was limited to histologically comparable regions, in an 
MSI analogue of the histology defined protein profiling approach (Cornett et al., 2006). 
Therefore, we have developed histology-guided MSI (HG-MSI) software that makes use 
of automated image registration to limit data acquisition to specific histologically pre-





Figure 4-2: A schematic overview of the most important steps in the HG-MSI workflow. The workflow enables the 
selection of MALDI-MSI measurement regions to be guided by the tissue’s histology. 
 The Histology_Guided_MS software performs an automatic registration of images of 
adjacent tissue sections: (i) the moving image (Im), which is represented by an 
annotated high resolution image of an H&E stained tissue section, here referred to as 
the histological-tissue section (Figure 4-3A), and (ii) the fixed image (If), a lower 
resolution optical image required for the MALDI-MSI analysis, here referred to as the 
pre-MSI-optical-image (Figure 4-3B-top). In this manner the histological annotations 
are mapped onto the pre-MSI-optical-image and can be used to define the 
measurement regions (Figure 4-3B-bottom). 
 The adjacent tissue sections were manually mounted onto different glass slides and 
scanned at different resolutions; and so the registration encompasses a linear, affine 
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registration to correct for global deformations (e.g. translation, scaling, rotation, and 
shearing) as well as a non-linear, B-spline transform to compensate for local 
deformations (e.g. differences in sizes of regions, stretches introduced during 
mounting) (Abdelmoula et al., 2014). 
 
Figure 4-3: (A) Histological-tissue-section image of a myxoid liposarcoma tissue, including annotations marking the 
clinically relevant regions. (B-top) Pre-MSI-optical-image of the tissue prior to the MALDI-MSI analysis. The section 
was adjacent to the section shown in (A). (B-bottom) The output image of the Histology_guided_MS registration 
algorithm. The image shows the aligned, annotated regions from (A) propagated to the pre-MSI-optical-image (B-top). 
(C) Post-MSI-optical-image; the H&E stained tissue after MALDI-MSI data acquisition (B), including the aligned 
annotated regions from (A). (D) Example MSI image of m/z 944,51 Da corresponding to Histone H2A peptide 
AGLQFPVGR represented by the Jet intensity scale. (E-F) Comparison between conventional MSI and histology-guided 
MSI. Shown are the average (E) and total (F) data size and acquisition times for the MLS tissue series (n = 7). 
 As the MSI measurement regions are determined by the histological annotations 
from an adjacent section, an investigation of the image registration accuracy is 
necessary. After MSI data acquisition excess MALDI matrix was removed and the tissue 
sections were H&E stained and, digitally scanned, this is the post-MSI-optical-image. 
The automatically registered annotations from the histological-tissue-section were 
mapped on to this image (Figure 4-3C & 4-4A), and then compared with the results of 
an expert manual histopathological annotation of the post-MSI-optical-image (Figure 4-
4B). Visually it can be seen that there is a good agreement between the annotations. 
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 The HG-MSI software was tested by analyzing the proteolytic peptides from an on-
tissue digestion investigation of a patient series of FFPE MLS tissues (n = 7) using a 9.4 
T MALDI-FTICR instrument (Figure S4-1, Supplementary information). MLS was chosen 
as these tumors have a very heterogeneous histology (Willems et al., 2010b) that 
allowed the selection of ROIs with different tumour grades and/or additional 
histological features (e.g. fat differentiation, and mucine pools).  
 
Figure 4-4: An evaluation of the image registration through the measure of annotation overlap using the Dice 
coefficient. (A) Automatically aligned annotations propagated to the post-MSI-optical-image. (B) Manually annotated 
post-MSI-optical-image. (C) + (D) Binary masks of the annotated regions in (A) and (B). (E) Fusion of the two binary 
mask showing the degree of overlap. In white, truly overlapping regions. In green and pink the non-overlapping 
regions. (F) An overview of the Dice coefficients for the analyzed tissues. 
 Analyzing the tissue series, utilizing the HG-MSI software, resulted in a total data 
load of 192 GB, which was just 18% of the 1,049 GB that would be generated by 
analyzing each tissue section of the series completely (Figure S4-2, Supplementary 
information). Similarly, the data acquisition time was also reduced by 82% from 112 
hours to 20 hours (Figure 4-3E-F). Ultimately, throughput and data load are 
determined by the total area of the selected ROIs. For these tissues only regions with 
clear histologic grades (e.g. low, moderate and high grade) based on distinct 
histological features were selected, resulting in annotated areas varying between 12 - 
29% of the total tissue surface.  
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 The effectiveness of the HG-MSI software to focus on specific histological regions 
was then quantified using the Dice similarity coefficient (DSC) (Figure 4-4A-E), to 
provide a metric for the spatial overlap of the annotated regions in the automatically 
and manually annotated post-MSI-optical image. No overlap would result in a DSC of 0, 
perfect overlap in DSC of 1. For this tissue series the average DSC was 0.8458 (± 
0.0012), confirming that the HG-MSI approach does indeed allow the analyst to target 
the specific regions (Figure 4-4F).  
 There are several causes that may contribute to the 15% reduction of the DSC. The 
first is that adjacent sections are not identical and so small differences are expected. 
Second, it was found that some of the histological regions were harder to define in the 
post-MSI-optical-image, and which may have led to slight differences in the annotation 
areas. Third, artifacts from the tissue sectioning and mounting such as stretches, tears 
and folds can cause large differences even between adjacent sections. For example, 
tissue L2235 and L4175 (Figure S4-1, Supplementary information) represent the 
experiments with the highest and lowest DSCs respectively (Figure 4-4F). Whereas the 
images of L2235 exhibit no clear sectioning/mounting artifacts and very distinct 
histological features, the histological-tissue-section of L4175 was folded and the 
histological features less distinct. To limit the impact of sectioning/mounting artifacts 
on the registration a manual, free-hand cropping function was added to the registration 
tool to exclude such regions from the registration process. 
 We have demonstrated this HG-MSI software for the analysis of proteolytic peptides 
from specific histopathological regions in tumor tissues using a Bruker Daltonics MALDI-
FTICR-MSI. However, the tool is vendor neutral and is applicable to all MSI 
methodologies (e.g. DESI, SIMS, etc.), the only requirement is that an optical image of 
the tissue section is used to define the measurement regions. Similarly, the HG-MSI 
software may be used to better focus high spatial resolution as well as high mass 
resolution analysis, for all analyte classes and, all tissue types. The software is freely 
available for download (http://www.maldi-msi.org/download/SW_HG_MSI.rar). A 
detailed overview of the histology-guided MSI workflow and software manual is 
available as online Supplementary information. The only prerequisite to run the 
Histology_guided_MS executable is the installation of the Matlab Compiler Runtime 
(R2012a (7.17)) which is free to download from the Mathworks website 
(www.mathworks.com/product/compiler/mcr).  
 The compromise associated with specifying data acquisition from distinct 
histological regions is that retrospective data analysis possibilities are more limited than 
if each tissue section was analyzed in its entirety. For example, for the 
myxofibrosarcoma sample shown in Figure 4-1 if only the well-differentiated tumor 
regions (3.6% of the example tissue section) were selected for MSI data acquisition 
then it would no longer be possible to compare its mass spectral signature with those 
from the moderately differentiated tumor (9.3%) and undifferentiated tumor regions 
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(4.2%), or the tumor stroma and healthy tissue. It is thus crucial to specify, at the 
outset, which histological comparisons will/may be made. Accordingly, the tool is better 
suited to those analyses in which the slow scan speed (high mass resolution) or large 
number of pixels (high spatial resolution) makes it impractical to apply to a large 
patient series of complete tissue sections. 
4.4 Conclusions 
In this work we report a new freely available tool for histology-guided MALDI-MSI and 
provide the software required to perform automated image registration so that the 
annotations from an adjacent histological image can be transferred to the tissue section 
that will be analyzed by MSI. The results demonstrate the strength of the approach, 
particularly for high resolution MSI, in which the high resolution leads to longer 
acquisition times. The ease of use and general applicability of the tool in any MSI 
workflow will ultimately result in a higher throughput, a smaller data load, and more 
comparable data.  
4.5 Acknowledgements 
This work was supported by the ZonMW Zenith project “Imaging Mass Spectrometry-
Based Molecular Histology: Differentiation and Characterization of Clinically Challenging 
Soft Tissue Sarcomas” (No. 93512002; B.H.), the ICT consortium COMMIT project “e-
biobanking with Imaging” and the Cyttron II project “Imaging Mass Spectrometry”. 
4.6 Supplementary information 
The full supplementary information, files and tables are available on the internet via 
http://pubs.acs.org/doi/abs/10.1021/acs.analchem.5b03610. 
  
Histology-guided high resolution MALDI mass spectrometry imaging 85 
 
 
4.6.1 Supplementary figures 
 
 
Figure S4-1: An overview of the H&E stained MLS tissues. (left) Tissue numbers; (middle) histology image prior to 
annotation; (right) MSI tissue after quality control staining. 
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Figure S4-2: An example showing the differences in analysis surface between the HG-MSI platform and conventional 
MSI analysis. In yellow, the histology-guided analysis regions, and in red, the full surface area of the tissue analyzed in 
a conventional MSI experiment. The number of pixels is based on a spatial resolution of 100 µm. The datasize of the 
conventional MALDI-MSI dataset was calculated using (1). 
𝑆𝑖𝑧𝑒𝑁𝑜𝑟𝑚𝑎𝑙 =  𝑃𝑖𝑥𝑒𝑙𝑠𝑁𝑜𝑟𝑚𝑎𝑙 (
𝑆𝑖𝑧𝑒𝐻𝐺
𝑃𝑖𝑥𝑒𝑙𝑠𝐻𝐺
)   (1) 
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 On-tissue digestion matrix-assisted laser desorption/ionization mass spectrometry 
imaging (MALDI-MSI) is able to record spatially correlated molecular information from 
formalin-fixed, paraffin-embedded (FFPE) tissue sections. In this work we present the 
in-situ multimodal analysis of N-linked glycans and proteins from the same FFPE tissue 
section. The robustness and applicability of the method are demonstrated for several 
tumors, including epithelial and mesenchymal tumor types. Major analytical aspects, 
such as lateral diffusion of the analyte molecules and differences in measurement 
sensitivity due to the additional sample preparation methods have been investigated for 
both N-glycans and proteolytic peptides. By combining the MSI approach with extract 
analysis we were also able to assess which mass spectral peaks generated by MALDI-
MSI could be assigned to unique N-glycan and peptide identities. 
5.1 Introduction 
Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) is 
an analytical technique for the spatially resolved biomolecular investigation of tissue 
sections (Caprioli et al., 1997; McDonnell and Heeren, 2007). A major advantage of 
MSI is that it can be combined with histology so that cell-type specific mass spectral 
profiles can be extracted from the MSI datasets. Such cell-type specific molecular 
signatures have been used to identify diagnostic and prognostic biomarkers (Balluff et 
al., 2011, 2015; Dekker et al., 2014; Meding et al., 2012). 
 MALDI-MSI is also able to analyze different molecular classes, using essentially the 
same technology but different sample preparation strategies. MALDI-MSI has been 
used to assess how protein, lipid, metabolite, and glycan profiles change in cancerous 
tissues. To readily exploit the potential insights and improved diagnostic performance 
that may be obtained by combining the molecular information from different molecular 
classes, the multimodal molecular profiles from identical histological features can be 
compared. Multimodal MSI is a widely-used term and covers different strategies. For 
example, one could combine MSI with a complementary imaging modality, or apply 
repeated MSI analyses to the same tissue: (i) utilizing different ionization modalities 
(Eberlin et al., 2011; Amstalden van Hove et al., 2010), (ii) analyzing multiple polarities 
using the same ionization source (Ellis et al., 2016), or (iii) analyze multiple analyte 
classes using the same ionization source. Previous work by Steven et al., in which the 
separate analysis of lipids and proteins from the same fresh frozen mouse brain section 
was presented, shows the potential of the latter multimodal MSI approach (Steven and 
Bunch, 2013). However, to better exploit the tissue banks available in most clinical 
centers, as well as the improved histological clarity, the multimodal analysis should be 
applicable to formalin-fixed, paraffin-embedded (FFPE) tissues. 
 FFPE tissue sections can be analyzed using on-tissue digestion, in which enzymes 
are directly applied to the tissue and MALDI-MSI used to analyze the released species 
(Shimma et al., 2006). On-tissue digestion MALDI-MSI of proteins has been performed 
using a variety of different proteolytic enzymes, including trypsin, pepsin, elastase, Arg-
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C, Lys-C, and recombinant Lys-N (Enthaler et al., 2013b; Heijs et al., 2015). A recent 
extension to the on-tissue digestion approach is the use of peptide N-glycosidase F 
(PNGase F), which releases N-linked glycans, or N-glycans, from glycoproteins (Powers 
et al., 2013). 
 N-glycans are one of the most common post-translational modifications (Figure 5-
1A+B), play a fundamental role in many molecular and cellular processes, and are 
established biomarkers in clinical research (Adamczyk et al., 2012; Pinho and Reis, 
2015; Varki et al., 2015). Serum biomarkers, such as the glycoproteins CA19-9 and 
carcinoembryonic antigen are currently used for the prediction of pancreatic cancer and 
follow-up in colorectal cancer (CRC) (Drake et al., 2010; Thirunavukarasu et al., 2011). 
In MALDI-MSI, despite only being recently introduced, PNGase F-based on-tissue 
digestion has been successfully applied for the analysis of N-glycans in normal tissues 
(Miyoshi and Nakano, 2008; Muinelo-Romay et al., 2008; Pinho and Reis, 2015), in 
human hepatocellular carcinomas (Powers et al., 2015), and in tissue microarrays 
(Powers et al., 2014).  
Figure 5-1: (A) An overview showing the structural formulas of the most prevalent monosaccharide building blocks of 
N-linked glycans, and their symbol in the schematic representation. (B) Schematic representations of the three N-
glycan classes with common core structure. The asparagine (Asn) residue represents the first amino acid of the 
consensus sequence “Asn-X-Thr/Ser”. (C) An overview of the sequential on-tissue digestion MALDI-MSI workflow, 
showing the order of the various sample preparation steps. 
 Combining the information on the protein and glycan levels in a given tissue has 
been demonstrated to increase their potential utility as diagnostic biomarkers: α-1,6-
core-fucosylated haptoglobin is explored as a biomarker in various malignancies such 
as pancreatic and colorectal cancer, and the U.S. Food and Drug Administration (FDA) 
approved α-1,6-core-fucosylated alpha-fetoprotein was demonstrated as biomarker for 
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hepatocellular carcinomas. (Miyoshi and Nakano, 2008; Muinelo-Romay et al., 2008; 
Park et al., 2011)  
 Here, we report a multimodal MALDI-MSI analysis of both N-linked glycans and 
proteolytic peptides from a single tissue section using sequential on-tissue digestion 
MALDI-MSI. Importantly, the tissue section remains almost un-damaged by the analysis 
and so can be histologically stained, annotated and registered to the MSI datasets. In 
this manner, N-glycans and proteins from exactly the same cells or histological features 
can be extracted, and used for further analysis. 
5.2 Methodology 
5.2.1 Chemicals and reagents   
All chemicals were purchased from Sigma-Aldrich (Steinheim, Germany) except ethanol 
and xylene (Merck, Darmstadt, Germany). Trypsin was purchased from Promega 
(Madison, USA). Recombinant Peptide N-Glycosidase F (PNGase F) from Flavobacterium 
meningosepticum was expressed and purified as previously described (Powers et al., 
2013). 
5.2.2 Tissues & sample collection    
Leiomyosarcoma (LMS, L1091-3), myxoid liposarcoma (MLS, L2039), and colorectal 
carcinoma (CRC, C67) tissues were formalin-fixed and paraffin-embedded following 
established histopathological methods (Figure S5-1, Supplementary information). 
Following Dutch national ethical guidelines (Code for proper secondary use of human 
tissue, Dutch Federation of Medical Scientific Societies), all tissue samples were 
handled in a coded fashion. Using a microtome, 6 µm thick sections were cut from the 
FFPE tissue blocks. The tissue sections were mounted on poly-L-lysine coated indium-
tin-oxide (ITO) glass slides (Bruker Daltonics, Bremen, Germany), dried overnight at 
37°C and stored at 4°C protected from light until further treatment. Slides dedicated 
for MALDI-MSI analysis contained two consecutive tissue sections, one used for the 
enzymatic digestions, the other used for a negative, no-enzyme control. Single sections 
for histology staining and molecular extractions were placed on Starfrost adhesive 
microscope slides (Light Laboratories, Dallas, TX).  
5.2.3 Sequential on-tissue digestion MALDI-MSI    
A buffer exchange, using a 10 kDa molecular weight cut-off (MWCO) spin filter (Merck 
Millipore, Billerica, MA), was performed on the recombinant PNGase F enzyme to 
ensure uniform purity and enzyme concentration over all performed experiments. The 
buffer exchange was performed according to the manufacturers’ protocol. Prior to the 
sample preparation, the ITO slides containing FFPE tissue sections were placed on a 
hot plate (60°C) for 60 minutes to increase the adherence of the tissues to the ITO 
slides. Paraffin was removed by submerging the slides in xylene (wash 1 - 5 min; wash 
2 - 10 min). The tissues were washed with ethanol (100%, 2x 2 min) and deionized 
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water (2x 5 min), dried in a vacuum desiccator (~10 min) before homogeneously 
applying PNGase F (100 ng/µL in deionized water) using a SunCollect pneumatic 
sprayer (SunChrom, Friedrichsdorf, Germany; 15 layers at 10 µL/min). Following 
overnight incubation, MALDI matrix (5 mg/mL α-2,4-hydroxycinammic acid in 50% ACN 
and 0.1% TFA) was homogeneously deposited on the tissue sections using the 
SunCollect sprayer (6 layers: (1) 10 µL/min, (2) 20 µL/min, (3) 30 µL/min, and (4+) 40 
µL/min). MSI analysis of the N-linked glycan species was performed on a Bruker 
UltrafleXtreme MALDI-TOF/TOF instrument (Bruker Daltonics). Data was recorded in 
reflectron positive ion mode covering the mass range between m/z 900 to m/z 4,000, 
using 500 laser shots per spot and a 100 x 100 µm pixel size. More in-depth 
information on the MALDI-TOF-MS method is provided in Table S5-1A (Supplementary 
information). 
 Following the N-glycan data acquisition, excess MALDI matrix was removed from 
the tissues using ethanol washes (70%, 2x 1 min) and the tissue was conditioned for 
heat-induced antigen retrieval (HIAR) by washing with deionized water (2x 5 min). 
HIAR was performed in a 10 mM citric acid buffer adjusted to pH6 with 1 M NaOH. 
After HIAR, the tissues were carefully washed with deionized water (2x 2 min) and 
trypsin (20 ng/µL in deionized water) was deposited homogeneously using a SunCollect 
pneumatic sprayer (15 layers at 10 µL/min). Following overnight incubation at 37°C, in 
a saturated environment (50% methanol in deionized water), MALDI matrix was 
applied using the SunCollect system and a solution of 20 mg/mL 2,5-dihydroxybenzoic 
acid (DHB) in 50% ACN and 0.1% TFA. MSI analysis of the proteolytic peptides was 
performed on a 9.4 T Bruker SolariX XR MALDI-FTICR instrument equipped with a 
dynamically harmonized ParaCell™. Data was acquired in positive ion mode in the mass 
range m/z 600 to m/z 3,500 with an average resolving power of 54,000 over the 
analyzed mass range, using 150 laser shots per spot and a 100 x 100 µm pixel size. 
More in-depth information on the MALDI-FTICR-MS method is provided in Table S5-1B 
(Supplementary information).  
 For both N-glycan, and proteolytic peptide analysis, control experiments were 
performed on consecutive tissue sections on the same glass slides. The control samples 
were treated following the same protocols described above but without application of 
enzymes, and MALDI-MSI data acquisition was performed at a 250 x 250 µm pixel size. 
Also, to show repeatability of the method on the same tissue, the sequential on-tissue 
digestion MALDI-MSI analysis of the LMS (L1091-3) was performed in duplicate. The 
two analyses are indicated as LMS-1 and LMS-2. 
5.2.4 N-glycan extraction and identification     
For MS/MS identification of the N-glycans present in the tissue sections, separate tissue 
sections on Starfrost adhesive microscope slides were treated following the protocols 
described in the previous section, although matrix application was omitted. Released N-
glycans were extracted by carefully distributing 100 µL deionized water on top of the 
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tissue, 15 min incubation at 37°C, and collected by micropipette. Extracts were dried in 
a vacuum centrifuge and resuspended in 20 µL deionized water. For purification, 10 µL 
of the sample was brought to 85% ACN, followed by cotton hydrophilic interaction 
liquid chromatography (HILIC) micro-solid phase extraction (SPE) using 200 µL pipette 
tips (Selman et al., 2011). N-glycans were eluted in 15 µL deionized water from which 
5 µL were spotted in duplicate onto a Bruker AnchorChip plate. Dried samples were co-
crystallized with 0.5 µL super DHB matrix (5 mg/mL in 50% ACN) supplemented with 1 
mM NaOH. MS1 and MS2 spectra were recorded using an UltrafleXtreme MALDI-
TOF/TOF-MS for the identification of the N-glycans. Furthermore, overall average 
spectra from the MALDI-MSI analyses were exported from flexImaging 4.1 (Bruker 
Daltonics) to CSV format. The CSV-formatted spectra were imported in mMass (v5.5.0, 
http://www.mmass.org) (Strohalm et al., 2008), where baseline correction, smoothing, 
peak picking (S/N ≥ 6), de-isotoping and internal re-calibration was performed. The 
mMass peak lists were exported to both Excel 2010 (Microsoft) and the Glyco-
Peakfinder tool (http://www.eurocarbdb.org/ms-tools/) in GlycoWorkbench (2.1 stable 
build 146, http://www.eurocarbdb.org/), which was used for generating a preliminary 
glycan composition list. The suggested compositions were then compared to the results 
of the MS/MS analyses for confirmation. 
5.2.5 Proteolytic peptide extraction and identification   
Consecutive tissue sections were prepared for extracts using the same sample 
preparation protocol as for MALDI-MSI. The matrix application and MALDI-MSI analysis 
were omitted, and instead, the proteolytic peptides were extracted from the matrix 
using a series of solvents: (i) 50 µL of 0.1% TFA, and (ii) 50 µL of 50% ACN in 0.1% 
TFA. The extracts were combined, dried, resuspended in 0.1% TFA, and cleaned using 
Omix C18 tips (Agilent, Santa Clara, California). Peptide extracts were analyzed using 
an Easy nLC1000 (Thermo, Bremen, Germany) coupled to a Q-Exactive mass 
spectrometer (Thermo). Fractions were injected onto an in-house prepared pre-column 
(100 μm × 15 mm; Reprosil-Pur C18-AQ 3 μm, Dr. Maisch, Ammerbuch, Germany) and 
eluted via a homemade analytical column (15 cm × 50 μm; Reprosil-Pur C18-AQ 3 µm). 
The gradient was 0% to 30% solvent B (90% ACN / 0.1% FA) in 120 min. The 
analytical column was drawn to a tip of ∼5 μm and acted as the electrospray needle of 
the MS source. The Q-Exactive mass spectrometer was operated in top10-mode. 
Parameters were as follows: full scan, resolution 17,500, AGC target 3,000,000, max fill 
time 20 ms; MS/MS, resolution 35,000, AGC target 1,000,000, max fill time 60 ms, 
intensity threshold 17,400. Apex trigger was set to 1−5 s, and allowed charges were 
1−5. The Thermo.RAW files were converted to MGF files using the MSconvert software 
(64-bit for Windows, http://proteowizard.sourceforge.net). Peptide and protein 
identifications were extracted from the SwissProt database using the Mascot server. A 
maximum of two missed cleavages was allowed and methionine oxidation, deamidation 
(NQ), and N-terminal acetylation were set as variable modifications. Peptide 
assignments were made with a tolerance of 10 ppm. MS/MS fragment tolerance was 
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set to 20 mmu. Results were searched against a decoy database. Protein identifications 
were assigned based on a minimum of one confident peptide at 1% false discovery 
rate (FDR). Only peptides and proteins with red bold notification and a Mascot 
significance score ≥ 38 were included in the final lists of unique peptides. 
5.2.6 Peptide identity assignment    
Average spectra from the MALDI-FTICR-MSI datasets were exported into CSV format 
and loaded in mMass. Peak picking was performed on peaks with S/N ≥ 5 and a 
relative intensity ≥ 2.5%. The peak lists were treated with a deisotoping algorithm set 
to remove isotope peaks with a maximum charge of 2+ and an isotope mass tolerance 
of 0.02 Da. MALDI-FTICR-MSI peak lists and Mascot database search results from the 
LC-ESI-MS/MS analyses were exported to Excel 2010 (Microsoft). The m/z features 
originating from the MSI data were aligned to the m/z values of the identified peptides 
from the Mascot search results. Peptide identity assignments were based on a mass 
tolerance of ±10 ppm.  
5.2.7 Fold change calculations     
Regions of interest (ROIs) for (non-)tumor regions were selected in both N-glycan and 
peptide MSI datasets. The MSI data was loaded in Data Analysis 4.2 (Bruker Daltonics) 
to obtain average spectra and extract intensities for N-glycans and peptides from the 
ROIs. Intensities from (non-)tumor ROIs were averaged in Excel 2010 to obtain a 
single intensity value for the (non-)tumor areas. The fold change was calculated as the 
ratio Itumor / Inon-tumor. 
5.3 Results and discussion 
On-tissue digestion MALDI-MSI, utilizing proteases and endoglycosidases, enables the 
analysis of proteins and glycans from FFPE tissues (Casadonte and Caprioli, 2011; 
Gustafsson et al., 2013; Heijs et al., 2015; Powers et al., 2013, 2014). In this work we 
have merged both on-tissue digestion protocols to create a new multimodal method 
that enables the analysis of both N-glycans and proteolytic peptides from the same 
FFPE tissue section (Figure 5-1C). By combining the workflows, we increased the 
comparability between the MSI datasets of two intimately related analyte classes.  
5.3.1 Antigen retrieval      
When analyzing proteins in FFPE tissues an antigen retrieval step is necessary to 
remove the cross-links between the proteins established by formalin fixation (Shi et al., 
2013, 1991). However, it was found that heat-induced antigen retrieval (HIAR) prior to 
PNGase F digestion (and subsequently followed by proteolytic digestion) caused de-
sialylation of the N-glycans and severe delocalization of the proteins (data not shown). 
These artefacts were circumvented by performing the HIAR-based antigen retrieval 
after analysis of the N-glycans and removal of the excess MALDI-matrix (Figure 5-1C). 
For N-glycan MSI analysis, protocols both including (Gustafsson et al., 2015; Powers et 
Multimodal MSI of N-glycans and proteins from the same tissue section 97 
 
 
al., 2014) and excluding (Powers et al., 2013) HIAR have been described. The chemical 
reactions involved in formalin fixation (Tanca et al., 2012) and the chemical 
composition of the N-linked glycans (Figure 5-1A+B) make it unlikely that the N-
glycans will become part of the formalin-cross-linked network and so remain accessible 
to PNGase F. This was confirmed by our N-glycan MALDI-MSI analyses prior to HIAR, 
as a large number of N-glycan species were detected (Table 5-1 & Figure 5-2A). The N-
glycan MSI analyses of the different tumor tissues yielded a total of 59 unique N-glycan 
species, of which we were able to confirm 25 by MALDI-MS/MS on glycan extracts 
(Table 5-1 & online Supplementary information).  
5.3.2 N-glycan MALDI-TOF-MSI       
Visualizing the distributions of several specific N-glycan species revealed that their 
abundance in the CRC, LMS, and MLS tissues was restricted to specific morphological 
structures in the tissue (Figure 5-2 & Figures S5-2 and S5-3, Supplementary 
information). For example, the complex-type N-glycan Hex5HexNAc4dHex1 (Hexose = 
Hex, N-acetylhexosamine = HexNAc, fucose = dHex) detected at m/z 1,809.6 
[M+Na]+ co-localized exclusively with healthy striated muscle cells and collagen-rich 
areas in both analyses of the LMS tissue, while other N-glycans, such as 
Hex4HexNAc4dHex1 at m/z 1,647.6 [M+Na]+, and Hex4HexNAc4 at m/z 1,501.5 
[M+Na]+ were almost exclusively localized in the tumor area of the same LMS tissues 
(Figure 5-2B+C & Figure S5-1A and S5-2, Supplementary information). In the CRC and 
MLS tissues similar patterns were observed, e.g. the high-mannose type N-glycans 
(Hex6HexNAc2 at m/z 1,419.5 [M+Na]+, Hex7HexNAc2 at m/z 1,581.5 [M+Na]+, and 
Hex9HexNAc2 at m/z 1,905.6 [M+Na]+) were detected in the tumor areas. These N-
glycans have previously been associated with tumor cells in pancreatic, prostate, and 
hepatocellular carcinoma tissues (Powers et al., 2014, 2015). Hex5HexNAc2 at m/z 
1,257.4 [M+Na]+, was highly abundant in several non-calcified necrotic regions 
present within the tumor area of the CRC tissue (Figure S5-3B+C, Supplementary 
information). The high mannose-type glycans are the precursors of the intracellular N-
glycan biosynthesis pathway (Freeze, 2006; Varki et al., 2015). The high abundance of 
this specific glycan in the necrotic regions is likely the result of increased cell lysis, a 
common phenomenon in necrotic tissue, causing an uncontrolled release of intercellular 
molecules (Proskuryakov et al., 2003). 
Table 5-1: Overview of the N-glycans detected in the MALDI-MSI and MS/MS datasets. Structural confirmation by 
MS/MS is within ± 1 monosaccharide. 
m/z Composition Neutral Exchange LMS CRC MLS 
[M+Na]+ 
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Figure 5-2: (A) The overall average mass spectrum after the N-glycan MALDI-MSI analysis of the LMS-1 tissue 
(L1091-3). The annotated glycan compositions were either confirmed by MS/MS identification or were known from 
literature. (B) Scanned image of the H&E stained LMS-1 (L1091-3) tissue. (C) Visualizations of the distribution of 
various N-glycans throughout the tissue. The shown glycan species were confirmed by MS/MS or confirmed by 
literature. The images were obtained from a TIC normalized dataset. 
5.3.3 MALDI-FTICR-MSI of proteolytic peptides  
The performance of the trypsin digestion after N-glycan release, referred to as 
sequential digestion, was compared to a regular on-tissue trypsin digestion experiment, 
referred to as the control digestion. The MALDI-FTICR-MSI data obtained from 
sequential digestions and control digestions were very similar for all analyzed tumor 
types (Figure 5-4A & Figures S5-4 and S5-5A+D, Supplementary information). On 
average, the spectra from the sequential digestions yielded 806(±148) isotope clusters 
and the spectra from the control digestions contained 844(±207) isotope clusters, with 
a peak overlap of 79(±14)%. The MSI images of specific peptide ions were also highly 
comparable between both control and sequential digestions and duplicate analyses 
(Figure 5-4B & Figures S5-4 and S5-5C+F, Supplementary information). For example, 
for sequential and control digestions of the LMS and CRC tissues the Histone H2A type 
1 peptide AGLQFPVGR (m/z 944.5312 [M+H]+) was highly specific to the tumor areas; 
the proteolytic fragment NSLESYAFNMK (m/z 1,303.5986 [M+H]+) originating from 
heat shock cognate 71 kDa protein (HSP7C_HUMAN) was found to be very abundant in 
the tumor regions in both control and sequential digestion of the MLS tissue. Heat 
shock cognate 71 kDa protein is an established marker to distinguish myxoid 
liposarcoma from myxofibrosarcoma (Wang et al., 2014).  
 It was then investigated whether the additional sample preparation procedures for 
the multimodal on-tissue digestion MALDI-MSI, based on sequential analysis of glycans 
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and proteins, induced lateral diffusion of proteins. Figures 5-3 and 5-4 provide 
examples of proteolytic peptides highly localized to specific morphological features, 
indicating that any lateral diffusion was insignificant on the length-scale of the 
experiments. 
5.3.4 Multimodal accessible proteins and glycoproteins  
To determine if multimodal on-tissue digestion influenced which proteins are accessible 
by on-tissue digestion, and to determine if it included glycosylated peptides the matrix 
proteomes of both control digestion and sequential digestion of the LMS and CRC tissue 
sections were investigated by LC-MS/MS (Table 5-2 & online Supplementary 
information). The results show that the number of unique peptides identified from LMS 
increased from 795 (corresponding to 325 proteins) for the control digestion to 940 
(corresponding to 351 proteins) for the sequential digestion. Similarly, for CRC the 
number of unique peptides were 948 (corresponding to 236 proteins) for the control 
digestion and 1,334 (corresponding to 509 proteins) for the sequential digestion. The 
number of proteins unique to the sequential digestion was notably greater compared to 
the control digestion (Figure S5-6A, Supplementary information). These numbers 
indicate increased proteome coverage as a result of the sequential digestion. 
Furthermore, the sequential digestion also increased protein sequence coverage, as the 
number of identified peptides per protein systematically increased (Figure S5-6B, 
Supplementary information).  
 N-glycans are attached via Asn residues present in the consensus sequence “Asn-X-
Ser/Thr” (“X” can be any amino acid except proline). N-glycan release by PNGase F 
induces a deamidation of the Asn, but Asn deamidation is also a common protein 
modification. To identify which peptides may have been deglycosylated by PNGase F 
digestion the deamidated peptides, with the consensus sequence, obtained after 
PNGase F treatment were determined. The number of candidate deamidated peptides 
identified from LMS increased from 2 for the control digestion to 8 for the sequential 
digestion; for CRC no deamidated peptides were detected from the control digestion 
and 20 from the sequential digestion (Table 5-2). 
Table 5-2: Overview of the peptide identifications obtained after LC-MS/MS analysis of tissue extracts.  
Tumor Control Trypsin Sequential Trypsin 
Type Unique peptides Deglycosylated* Assigned to MSI Unique peptides Deglycosylated* 
Assigned 
to MSI 
LMS 795 2 94 940 8 88 
CRC 948 0 132 1334 20 134 
* Deamidation of asparagine occurred in glycosylation consensus sequence (N-x-T/S) 




Figure 5-3: Visualizations of the distributions of several N-glycan structures and proteolytic peptides corresponding to 
specific morphological features (red box: healthy striated muscle tissue and connective tissue (green), blue box: 













Figure 5-4: (A) A comparison of the profiles of MALDI-FTICR-MSI overall average spectra obtained after both 
sequential trypsin digestion (top, black) and control trypsin digestion (bottom, grey) of the LMS-1 tissue (L1091-3). 
(B) Comparison of the visualizations of specific peptide distributions. The peptides were confirmed to be present in the 
MALDI-matrix by LC-MS/MS of extracts and were assigned to the MALDI-FTICR-MSI datasets with an error < 10 ppm. 
The images were obtained from RMS normalized datasets.  
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5.3.5 On-tissue deglycosylation increases accessibility of proteins 
to proteolysis   
The increase in the number of peptides identified after N-glycan release was 
significantly greater than the number of deamidated peptides. It was found that the 
sequential digestion affected the protein sequence coverage of both glycoproteins, and 
proteins without N-linked glycan modification. Three additional tryptic peptides of the 
glycoprotein galectin-3 binding protein (LG3BH_HUMAN) were detected in the 
sequential digestion of CRC tissue (online Supplementary information), and all three 
peptides were deamidated, indicating that the trypsin cleavage sites were hindered by 
the N-glycans in the control digestion. Five additional tryptic peptides of vimentin 
(VIME_HUMAN) were detected in the sequential digestion of the LMS tissue (online 
Supplementary information). Vimentin does not contain N-glycans (only O-glycans, 
which are not released by PNGase F), but is known to interact with other glycoproteins 
(Keuschnigg et al., 2009; Wang et al., 2010). This indicates that, within the tissue 
environment, deglycosylation of the proteome can reduce the steric hindrance caused 
by the N-glycans, making proteins more accessible to proteolytic digestion. The 
increased detection of non-glycosylated peptides has been previously observed in LC-
MS/MS, and is even exploited as a biomarker assay (Lee et al., 2011). 
 The peptides detected by MALDI-FTICR-MSI were assigned to the peptide 
identifications obtained from LC-MS/MS extract analysis (Table 5-2 & online 
Supplementary information). The number of assigned peptides (matching criteria < 10 
ppm, S/N > 5, intensity > 2.5% of basepeak) in the LMS control digestion experiment 
was 69 (66 unique peptides, corresponding to 49 proteins), and was similar in the 
sequential digestion (65 peptides, 54 of which were unique, corresponding to 47 
proteins). Similarly, the number of assigned peptides in the CRC control digestion 
experiment was 110 (101 unique peptides, corresponding to 72 proteins), and was 
similar in the sequential digestion (112 peptides, 96 of which were unique, 
corresponding to 74 proteins). These numbers are greater than those reported in 
recent MALDI-MSI investigations of FFPE tissues (Casadonte et al., 2014; Meding et al., 
2013), and included a deamidated peptide, which was detected only in the sequential 
digestion of both LMS and CRC and contains a known glycosylation site. The 
deamidated peptide detected at m/z 1,669.8431, could be assigned to 
TVIRPFYLTN*SSGVD ([M+H]+), and is the C-terminal end of the glycoprotein Galectin-
3 binding protein (LG3BP_HUMAN), whose hyperglycosylated form is associated with 
tumor cell aggregation (Chen et al., 2009b; Lin et al., 2015). 
5.3.6 Differentially expressed glycans and proteins   
The results described above indicate that multimodal on-tissue digestion MALDI-MSI is 
robust and able to deliver high quality MALDI-MSI data for N-glycans and (an increased 
number of) proteolytic peptides from the same FFPE tissue section. By way of example 
Figure 5-5A shows the LMS tissue section reported in Figures 5-2, 5-3, and 5-4, with 
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annotations for tumor and non-tumor regions. Figure 5-5B shows the detected (area 
normalized) fold changes of 18 N-glycans, confirming the previous observation from 
visual inspection of the images that most glycans were detected at lower levels in the 
tumor. Figure 5-5C shows the fold changes from all peptides from the proteins reported 
in Figure 5-4. It can be seen that there is a good agreement between peptides from 
the same proteins, and even from the same peptide if it is detected as both protonated 
(red bars) and sodiated (blue bars) pseudomolecular ions.  
 These results, together with the results from other tumors presented in the 
Supporting Information, indicate how such multimodal imaging could prove valuable in 
future clinical studies, as many of the assigned peptides originate from proteins  
Figure 5-5: (A) Histology image of LMS-1 (L1091-3) with annotated non-tumor (green) and tumor (red) regions. 
Spectra acquired from holes in the tissue (black) were excluded from data analysis. (B) Area normalized fold changes 
of 18 N-glycans detected by MALDI-MSI. The green bars represent higher abundance in non-tumor regions. The red 
bars indicate a higher abundance in tumor regions. (C) Area normalized fold changes of protonated (red) and sodiated 
(blue) peptide ions originating from FIBB_HUMAN, GDIR1_HUMAN, H2A1B_HUMAN and HSP7C_HUMAN as detected 
by MALDI-MSI. 
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previously associated with disease. For example, multiple peptides from different 
histone variants (H1.2, H2A, and H4) were detected and it is well established that 
histones are heavily involved in tumor biology (online Supplementary information) 
(Singh et al., 2015; Wang et al., 2015a). Amongst the assigned peptides were 
fragments originating from vimentin, and glucose regulated protein 78kDa, proteins 
that have been associated with ovarian cancer and pancreatic adenocarcinoma in 
previous MALDI-MSI based studies (online Supplementary information) (Djidja et al., 
2009b; El Ayed et al., 2010). In the CRC tissue we were able to detect proteolytic 
fragments from Carcinoembryonic antigen-related cell adhesion molecule 5 
(CEAM5_HUMAN), a member of the carcinoembryonic antigen (CEA) family of proteins. 
The CEA proteins have been in use as diagnostic markers for CRC (online 
Supplementary information) (Zhang et al., 2015). 
5.4 Conclusions 
In this work we have presented multimodal analysis of both N-glycans and proteolytic 
peptides from the same tissue section. We have been able to: (i) image 59 unique N-
glycan species from the N-glycan MALDI-TOF-MSI datasets, and (ii) assign a total of 89 
unique peptide identifications to high-mass resolution MALDI-FTICR-MSI datasets from 
LMS tissue sections and 154 from CRC tissue sections, including a deglycosylated (N-
linked glycan) peptide. Considering these results, the sequential on-tissue digestion 
MALDI-MSI method shows great promise for application to any FFPE tissues of clinical 
relevance.  
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Figure S5-1: Annotated histology images of (A) Leiomyosarcoma (LMS-1&2, L1091-3), (B) Colorectal carcinoma 
(CRC, C67), (C) Myxoid liposarcoma (MLS, L2039). 
 
Figure S5-2: (A) A comparison of the overall average spectra obtained from the LMS-1 (L1091-3, black) and, the 
duplicate, LMS-2 (L1091-3, grey) tissue sections during N-glycan MALDI-MSI. (B) Visualizations of the distribution of 
various N-glycans throughout the LMS-1 and LMS-2 tissues. The annotated glycan structures represent compositions 
which were either confirmed by MS/MS identification or were known from literature, but structural isomers cannot be 
excluded. The images were obtained from TIC normalized datasets. 




Figure S5-3: (A) The overall average mass spectrum after the N-glycan MALDI-MSI analysis of the CRC (C67) tissue. 
(B) Scanned image of the H&E stained CRC (C67) tissue. (C) Visualizations of the distribution of various N-glycans 
throughout the tissue. The images were obtained from a TIC normalized dataset. (D) The overall average mass 
spectrum after the N-glycan MALDI-MSI analysis of the MLS tissue (L2039). (E) Scanned image of the H&E stained 
MLS (L2039) tissue. (F) Visualizations of the distribution of various N-glycans throughout the tissue. The annotated 
glycan structures represent compositions which were either confirmed by MS/MS identification or were known from 
literature, but structural isomers cannot be excluded. The images were obtained from a TIC normalized dataset. 
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Figure S5-4: (A) A comparison of the overall average spectra obtained from the LMS-1 (L1091-3, black) and, the 
duplicate, LMS-2 (L1091-3, grey) tissue sections during MALDI-MSI analysis of proteolytic peptides. (B) Comparison of 
the visualizations of specific peptide distributions in both duplicate LMS analyses. The peptides were confirmed to be 
present in the MALDI-matrix by LC-MS/MS of extracts and were assigned to the MALDI-FTICR-MSI datasets with an 
error < 10 ppm. The images were obtained from a RMS normalized datasets. 
  




Figure S5-5: (A) A comparison of the profiles of MALDI-FTICR-MSI overall average spectra obtained after both 
sequential trypsin digestion (top, black) and control trypsin digestion (bottom, grey) of the CRC (C67) tissue. (B) 
Scanned image of the H&E stained CRC (C67) tissue. (C) Comparison of the visualizations of specific peptide 
distributions. (D) A comparison of the profiles of MALDI-FTICR-MSI overall average spectra obtained after both 
sequential trypsin digestion (top, black) and control trypsin digestion (bottom, grey) of the MLS (L2039) tissue. (E) 
Scanned image of the H&E stained MLS (L2039) tissue. (F) Comparison of the visualizations of specific peptide 
distributions. Unless indicated otherwise, the peptides were confirmed to be present in the MALDI-matrix by LC-MS/MS 
of extracts and were assigned to the MALDI-FTICR-MSI datasets with an error < 10 ppm. The images were obtained 
from a RMS normalized datasets. 
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Figure S5-6: Venn diagrams showing the differences and overlap between (A) the number of protein identifications 
in both control and sequential digestions, and (B) the differences in the number of identified peptides per protein. The 
numbers in (B) represent the number of proteins. In blue, the number of proteins for which the number of peptides in 
the control digestion was larger than in the sequential digestion. In red, the number of proteins for which the number 
of peptides was higher in the sequential digestion than in the control digestion. The overlapping part represents the 
proteins where the number of peptides was equal between control and sequential digestions. 
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5.6.2 Supplementary tables  
Table S5-1: (A) An overview of important parameters in the MALDI-TOF-MS method used to obtain N-glycan MALDI-
MSI data. (B) An overview of important parameters in the MALDI-FTICR-MS method used to obtain MALDI-MSI data 
on proteolytic peptides. 
A - Bruker UltrafleXtreme 
Parameter Value 
Laser power 70% 
Laser shots per pixel 500 
Laser focus setting 3_medium 
Laser frequency 2000 Hz 
Ion Source 1 voltage 25.0 kV 
Ion Source 2 voltage 22.5 kV 
Lens voltage 8.5 kV 
Reflector 1 voltage 26.46 kV 
Reflector 2 voltage 13.45 kV (50.8% refl) 
Matrix suppression Deflection up to 890 Da 
 
B - Bruker SolariX XR (9.4T) 
Parameter Value 
Laser power 35% 
Laser shots per pixel 150 
Laser focus setting Minimum 
Laser frequency 2000 Hz 
Source optics – plate offset voltage 100.0 V 
Source optics – deflector plate voltage 200.0 V 
Source optics – capillary exit voltage 150.0 V 
Source optics – funnel 1 voltage 150.0 V 
Source optics – skimmer 1 voltage 18.0 V 
Source optics – funnel RF amplitude 150.0 Vpp 
Octopole – frequency 5 MHz 
Octopole – RF amplitude 350.0 Vpp 
Quadrupole – Q1 mass 1000 m/z 
Collision cell – collision voltage -2.0 V 
Collision cell – DC Extract bias 0.5 V 
Collision cell – RF frequency 2 MHz 
Collision cell – collision RF amplitude 1500.0 Vpp 
Transfer optics – time of flight 1.7 ms 
Transfer optics – frequency 2 MHz 
Transfer optics – RF amplitude 300.0 Vpp 
Para Cell – transfer exit lens voltage -20.0 V 
Para Cell – analyzer entrance voltage -10.0 V 
Para Cell – side kick voltage 0.0 V 
Para Cell – side kick offset voltage 0.0 V 
Para Cell – front trap plate voltage 1.5 V 
Para Cell – back trap plate voltage 1.5 V 
Para Cell – back trap plate quench voltage -30.0 V 
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 Myxoid liposarcoma (MLS) is the second most common subtype of liposarcoma, 
accounting for approximately 6% of all sarcoma cases. MLS is characterized by a 
myxoid extracellular matrix and, in 95% of the cases, by the chromosomal 
translocation t(12;16)(q13;p11), which results in the FUS-DDIT3 chimeric gene. The 
presence of >5% round cells in MLS is associated with a poorer prognosis for the 
patient, along with other risk factors like the presence of necrosis, increased tumor 
size, increased age, and the male gender. While activation of PI3K/Akt signaling and 
overexpression of microRNA miR-135b have been associated with tumor progression in 
MLS, the molecular mechanisms underlying the disease progression are largely 
unknown. Here we have applied matrix-assisted laser desorption/ionization mass 
spectrometry imaging (MALDI-MSI), an analytical technique capable of simultaneously 
recording the spatial distributions of hundreds of biomolecules directly from a tissue 
section, to analyze N-linked glycans from a MLS tissue microarray in order to identify 
molecular markers for MLS tumor progression. Comparison of the N-glycan profiles 
revealed that several high-mannose type glycans, and a monofucosylated, triantennary 
complex-type glycan were associated with tumor progression, and which mirror recent 
observations in colorectal cancer, breast cancer, and ovarian cancer. 
6.1 Introduction 
Liposarcomas (LPS) are mesenchymal neoplasms displaying variable levels of 
adipogenic differentiation. Liposarcoma has a yearly incidence of approximately 30 
cases per million, and represents 17-25% of all sarcoma cases (Fletcher et al., 2013; 
Lemeur et al., 2015). The World Health Organization (WHO) classification describes 
four different LPS subtypes: (i) well-differentiated, (ii) dedifferentiated, (iii) 
pleomorphic, and (iv) myxoid (Fletcher et al., 2013). Myxoid liposarcoma (MLS) is the 
second most common subtype of LPS, accounting for approximately 30% of all LPS 
cases and 6% of all sarcoma cases (Nishida et al., 2010). MLS is characterized by a 
myxoid extracellular matrix (ECM) and, in over 95% of cases, by the chromosomal 
translocation t(12;16)(q13;p11), which results in the chimeric FUS-DDIT3 gene. MLS 
commonly occurs in the extremities of patients that are typically of a younger age 
compared to other LPS subtypes (Fletcher et al., 2013). The presence of >5% round 
cells in MLS is associated with a poorer prognosis, as are the presence of necrosis, 
increased tumor size (>10 cm), increased age (> 45 years), and the male gender. The 
treatment of MLS is fairly effective; nonetheless 35-50% will develop either recurrence 
or metastasis. Treatment includes surgical excision, or a combination of chemo- and/or 
radiotherapy with surgical excision. Grading of MLS is done by histological examination 
of the MLS tissue, and depends on the extent of the round cell component in the 
tissue: <5% round cell component equals a low grade MLS, and ≥5% round cell 
component defines high grade MLS cases (previously designated as round cell 
liposarcoma) (Fletcher et al., 2013; de Graaff et al., 2016; Lemeur et al., 2015; Nishida 
et al., 2010). High intra-tumor heterogeneity may complicate the determination of 
histological grade, especially when the tumor mass is poorly represented by a small 
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biopsy (Fritchie et al., 2012). While it is widely accepted that the presence of the round 
cells is associated with a poor prognosis and higher risk of metastasis, the underlying 
molecular mechanisms of tumor progression are largely unknown. In a previous 
immunohistochemistry (IHC) –based study by Demicco et al. the progression of MLS 
was shown to be accompanied by activation of the PI3K/Akt pathway caused by 
overexpression of insulin-like growth factor 1 receptor (IGF1R), a loss of phosphatase 
and tensin homolog (PTEN), and activating mutations in phosphatidylinositol 4,5-
bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) (Demicco et al., 2011). 
A more recent report by Nezu et al. shows that the overexpression of microRNA miR-
135b in MLS results in down regulation of the THBS2 gene, coding for the glycoprotein 
thrombospondin-2 (TSP2), which in its turn increases expression of matrix 
metalloproteinase 2 (MMP2), responsible for enhanced degradation of the ECM and 
ultimately results in increased MLS aggressiveness (Nezu et al., 2016). 
 Conventional omics-analyses (e.g. genomics, transcriptomics, proteomics) have had 
limited success in MLS due to its high degree of intra-tumor heterogeneity. Nezu et al. 
used laser-capture microdissection to separate the contributions from the different cell-
types present in MLS (Nezu et al., 2016). This result strongly indicates the need for 
histopathological specification for any investigation of the molecular changes associated 
with MLS.  
 Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) 
is an analytical technique that allows the spatially-correlated molecular analysis of 
various molecular classes directly from tissue (Caprioli et al., 1997; McDonnell and 
Heeren, 2007). By combining the molecular analysis of modern biomolecular mass 
spectrometry with the imaging capabilities of microscopy MALDI-MSI enables the 
spatial distributions of 100’s to 1000’s of biomolecules to be simultaneously recorded 
without labeling and is untargeted in nature. Furthermore, MALDI-MSI does not 
adversely affect the tissue’s underlying histology; consequently, the tissue may be 
histologically stained after the MSI experiment and the histological image aligned with 
the MSI dataset. This multimodal data, MSI and histology, allows the tissue’s molecular 
content to be examined in its correct histopathological context, and thus, for instance, 
to compare low and high grade areas within a single tissue section. In a process 
termed virtual microdissection cell-type specific molecular signatures can be extracted, 
and then used to identify biomarkers (Balluff et al., 2015; Elsner et al., 2012; Lou et 
al., 2016; Meding et al., 2012).  
 MALDI-MSI can be used to analyze different molecular classes, using essentially the 
same technology but different tissue preparation procedures. On-tissue digestion 
MALDI-MSI using proteolytic enzymes is used to increase the range of proteins 
amenable to MALDI-MSI analysis, aid their identification and allows the analysis of 
formalin-fixed, paraffin-embedded (FFPE) tissues (Gustafsson et al., 2013; Heijs et al., 
2015; Kriegsmann et al., 2016; Schober et al., 2011). On-tissue digestion MALDI-MSI 
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using the endoglycosidase PNGase F enables the analysis of N-linked glycans, also from 
both fresh frozen and FFPE tissue sections (Powers et al., 2013, 2015). Proteins, 
previously associated with MLS tumor progression, such as TSP2, IGF1R, and other 
receptor tyrosine kinases, involved in the activation of the PIK3/Akt pathway, are 
known glycoproteins (Carlson et al., 2005; Itkonen and Mills, 2015; Negri et al., 2010). 
While these proteins have a known role in MLS progression, the role of the N-glycans is 
unknown. Therefore, we have analyzed the N-glycans by on-tissue digestion MALDI-
MSI, to investigate the molecular alterations underlying tumor progression, and aid the 
accurate diagnosis and grading of MLS tumors. 
6.2 Methodology 
6.2.1 Chemicals and reagents   
All chemicals were purchased from Sigma-Aldrich (Steinheim, Germany) except ethanol 
and xylene (Merck, Darmstadt, Germany). Recombinant Peptide N-Glycosidase F 
(PNGase F) from Flavobacterium meningosepticum was expressed and purified as 
previously described (Powers et al., 2013). 
Table 6-1: Overview of tissue specimens present on the MLS TMA. 
TMA 
 
Total MYX INT RC 
No. samples 
 
37 23 20 9 
No. of patients 
 
32 23 20 9 
Gender Male vs. Female 18 vs. 14 14 vs. 9 11 vs. 9 5 vs. 4 
Age Median [years] 43 42 43 46 
Recurrence 
 
5 3 3 0 
Metastasis 
 
4 0 1 1 
 
6.2.2 Tissues, TMA construction and patient grouping   
A tissue microarray (TMA) was previously constructed from formalin-fixed, paraffin-
embedded (FFPE) MLS tissues from 32 patients diagnosed in the Leiden University 
Medical Center (Endo et al., 2015; de Graaff et al., 2017). The array consists of 141 
needle core biopsies with a 1.5 mm diameter, divided in two paraffin blocks, here 
referred to as MLS-1 and MLS-2. Both blocks contain an additional six control cores, 
originating from human placenta, colon, spleen, neuronal, lung, and tonsil tissues. 
Cores were obtained from three distinct morphological regions in the tumor, myxoid 
(MYX) areas, intermediate (INT) areas, and round cell (RC) areas. If a patient 
presented only a single morphology three needle cores were included in the TMA; if 
more than one morphology was present (MYX+INT, MYX+RC, or INT+RC) two cores 
per morphology were included. An overview of the TMA is reported in Table 6-1. All 
samples were handled following the ethical guidelines described in the “Code for Proper 
Secondary Use of Human Tissue in the Netherlands” of the Dutch Federation of Medical 
Scientific Societies. 
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6.2.3 N-glycan MALDI-MSI  
Both TMA blocks were sectioned using a microtome. 6 µm thick sections were mounted 
on indium tin-oxide (ITO) coated glass slides (Bruker Daltonics, Bremen, Germany), 
additionally coated with poly-L-lysine for better adhesion of the needle cores. 
Importantly, TMA sections were not transferred to the glass slide using a tape transfer 
system due to the risk of polymer contamination. Slides were dried overnight at 37°C, 
and stored at 4°C in the dark until further processing. Sample preparation for the on-
tissue digestion with PNGase F was performed as previously described (Heijs et al., 
2016). N-glycan MALDI-MSI analysis was performed using a Bruker RapifleX MALDI-
TOF/TOF instrument (Bruker Daltonics). Data was recorded in reflectron, positive-ion 
mode covering the mass range between m/z 900-3,200, using 500 laser shots per spot 
and a 50 x 50 µm pixel size. 
6.2.4 Histology staining and annotation   
Following MALDI-MSI analysis, excess MALDI matrix was removed with two ethanol 
washes (70%, 2x 1min), and the TMA’s stained with haematoxylin and eosin (H&E) 
following routine pathology procedures. The H&E stained TMA’s were then scanned 
using a digital slide scanner (IntelliSite Pathology Ultra-Fast Scanner, Philips, 
Eindhoven, The Netherlands). The scanned histology images were co-registered to the 
MALDI-MSI data in flexImaging 5.0 (Bruker Daltonics). In order to obtain a more 
accurate cellular specificity, the individual TMA cores were annotated by an expert 
pathologist (JVMGB). The annotations account for intra-core heterogeneity and 
differentiate between myxoid (MYX), intermediate (INT), and round cell (RC) areas 
(Figure 6-1). Intermediate areas were more cellular than low grade myxoid areas, but 
contained too much myxoid matrix to be considered as round cell areas (JVMGB). A 
total of 157 regions of interest (ROIs) were annotated from the 141 MLS cores. 
Figure 6-1: Example H&E images of the myxoid, intermediate and round cell areas. 
6.2.5 Data pre-processing – N-glycans    
A TIC normalized average spectrum for each of the 157 annotated ROIs was exported 
in CSV file format using flexImaging 5.0. Spectral processing, analyte extraction and 
analyte curation was performed using MassyTools (version 0.1.8.1) (Jansen et al., 
MSI of N-glycans identifies biomarkers of tumor progression in MLS 119 
 
 
2015). In MassyTools a recalibration of all ROI spectra was performed on the basis of a 
predefined list of calibrants. Spectra with at least four calibrants (Table S6-1, 
Supplementary information) with a signal-to-noise (S/N) ratio over nine were 
considered for further analysis, this resulted in the exclusion of one spectrum. Feature 
extraction of 115 previously identified N-glycans (Heijs et al., 2016; Holst et al., 2016) 
was performed through integration of the areas of 95% of the theoretical isotopic 
envelope. A feature specific baseline correction was performed by subtracting the 
baseline detected within a window of 20 m/z. MassyTools additionally included 
information on the fraction of the analyte area above S/N 9, highest isotope S/N, the 
mass error per analyte in ppm (averaged for all spectra), as well as a value 
representing the similarities between the analyzed and theoretical isotope patterns for 
each analyte (QC, averaged for all spectra). Two spectra were excluded as the “fraction 
of the analyte area above S/N 9” was below three standard deviations of the mean. 
The relative areas of a total of 34 N-glycans with an average mass error below 30 ppm, 
and a QC value below 0.4 were rescaled to 100% and considered for the subsequent 
statistical analysis. 
6.2.6 Data analysis     
A statistical comparison of the different morphological MLS subtypes (MYX, INT, RC) 
was performed in MatLab (R2017a, Mathworks, Natick, MA, USA), to find molecular 
features correlated with tumor progression. The average baseline corrected, relative 
area for each of the 34 N-glycans was calculated for each subtype and for all patients. 
An Anderson-Darling normality test (adtest) was performed to test the distribution for 
each of the 34 variables. Variables that did not follow a normal distribution were log-
transformed (LOG10) in Microsoft Excel 2010, and retested for normality. A one-way 
ANOVA analysis (anova1) was used to compare the means of each morphological 
subtype (p-value < 0.05) for the normally distributed variables. The remaining, non-
normally distributed variables were tested using a non-parametric ANOVA (Kruskal-
Wallis, kruskalwallis) (p-value < 0.05). Paired tests (Wilcoxon signed rank, signrank) 
were applied for the comparisons between individual morphological classes (Myx vs. 
Int, Myx vs. RC, and Int vs. RC). All reported p-values were corrected for multiple 
testing using the Benjamini-Hochberg test for multiple testing (q-value < 0.05). 
6.3 Results & discussion 
Grading of MLS patients involves the determination of the round cell component of the 
tumor. If the round cell component is larger than 5% the patient is considered high 
grade, as an increased round cell component is associated with poor prognosis 
(Fletcher et al., 2013; de Graaff et al., 2016; Lemeur et al., 2015; Nishida et al., 2010).  
In this study we investigated whether MALDI-MSI of N-glycans could elucidate 
diagnostic molecular markers associated with the progression of MLS. 
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Figure 6-2: Schematic overview of the applied workflow. (1) TMA construction was performed as described in the 
methodology section, (2) MALDI-MSI of N-glycans, (3) histological examination and annotation, and (4) data analysis 
consisted of processing, grouping of average ROI spectra, and statistical testing. 
6.3.1 N-glycan MALDI-MSI      
The TMA was analyzed by on-tissue digestion MALDI-MSI to characterize the N-glycan 
composition of MLS. 34 N-glycans were detected and identified from the MALDI-TOF-
MSI dataset. Their respective relative areas were submitted to an ANOVA test to find 
morphology-associated differences (Figure 6-2&3), Table 6-2). After applying a multiple 
testing correction five N-glycans were significantly associated with morphological 
changes in MLS (Table 6-2, Figure 6-4), four of which were high-mannose type (H6N2, 
m/z 1419.48 [M+Na]+; H7N2, m/z 1581.53 [M+Na]+; H8N2, m/z 1743.58 [M+Na]+; 
H9N2, m/z 1905.63 [M+Na]+, where H = Hexose, and N = N-acetylhexosamine). 
Although the sample numbers are small (Table 6-1, MYX vs. INT, n = 14; MYX vs. RC, 
n = 4; and INT vs. RC, n = 5) hampering paired statistical comparisons and linear 
regression analysis, there is a clear trend showing elevated levels of high-mannose  
Figure 6-3: Visual representation of the MLS TMA N-glycan MSI basepeak spectrum compiled from all MLS cores 
present on the TMA. The spectrum represents the TMA’s total N-glycan content and includes the 34 annotated N-
glycans and their assigned compositions. 
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glycans with MLS tumor progression (Table 6-2 & S6-2, Supplementary information) 
(Figure 6-4A,B,C,D). Similarly, the association between high-mannose type glycans and 
tumor progression was previously described for breast cancer, ovarian cancer, and 
colorectal cancers (Anugraham et al., 2014; Kaprio et al., 2015; Leoz et al., 2011; Liu 
et al., 2013). The exact role of high-mannose glycans in cancer is still unknown. 
However, their higher abundance has been hypothesized to be an effect of reduced or 
incomplete maturation during the protein glycosylation pathway (Holst et al., 2015; 
Zhao et al., 2008). High-mannose type glycans can occur both intracellular and on the 
cell surface. During N-glycan biosynthesis on the surface of the cytoplasmic side of the 
endoplasmatic reticulum (ER), lipid-linked oligosaccharide precursors (LLO) are 
produced, containing up to five mannose residues. Once the LLO contains five 
mannose residues it moves to the ER lumen where an additional 4 mannose and 3 
glucose residues are added. Upon completion, the glycan is transferred to its protein 
carrier and the glucose and mannose residues are trimmed resulting in the production 
of protein-bound high-mannose type glycans. The high-mannose glycosylated proteins 
will either be transferred to the cell- surface or to the Golgi apparatus for further 
processing in to complex- or hybrid-type N-glycans (Freeze, 2006). In normal cells, 
high-mannose type glycans play a crucial role in both protein folding and the protection 
of proteins against degradation during intracellular relocalization. The hypothesis of an 
increased abundance of high-mannose glycans caused by a disruption of the 
biosynthesis pathway or through reduced expression of mannosidases is very plausible. 
The MALDI-MSI experiments were not performed with the spatial resolution needed to 
distinguish between intra- or extracellular N-glycans; microscopic analysis of tissues 
immuno-stained with high-mannose-binding antibodies, like Concanavalin A, could be 
performed to provide additional information on the subcellular location of the high-
mannose glycans, although it is not solely specific for high-mannose type glycans and 
was beyond the scope of this study.  
 The other N-glycan that displayed significant differences between the three 
morphological groups was a monofucosylated, monosialylated tri-antennary complex-
type glycan (H6N5F1S1, m/z 2487.85 [M+Na]+, where F = fucose, and S = N-
acetylneuraminic acid) (Figure 6-4E). It should be noted that the N-glycans, and more 
specifically the sialic acids, were not derivatized prior to the MALDI-MSI analysis. Sialic 
acids are highly labile groups, frequently lost during the MALDI-MS analysis, and so 
represents a detection bias against sialylated N-glycan species (Holst et al., 2016). Like 
the high-mannose type glycans, the abundance of the triantennary complex type 
glycan shows a positive correlation with tumor progression. The increased β1,3- and 
β1,6-linked GlcNAc branching of N-glycans, caused by an overexpression of the MGAT4 
and MGAT5 genes which are coding for N-acetylglucosaminyltransferase IV (GnT-IV) 
and N-acetylglucosaminyltransferase V (GnT-V), has been previously associated with 
invasion and metastasis in breast and colorectal cancer (D’Arrigo et al., 2005; Dennis et 
al., 1987, 1999; Fernandes et al., 1991). Overexpression of GnT-V and the resulting 
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Figure 6-4: (A-E) Boxplots displaying the relative area distributions of the five N-glycans with significant variance 
between the three morphological classes. (F) Boxplot displaying the relative area distributions of a monofucosylated bi-
antennary complex type N-glycan. 
increase in N-glycans with extended β1,6-linked GlcNAc branching, resulted in an 
increased cell motility, a loss of contact inhibition, and caused morphological 
transformation of normal human epithelial cells (Demetriou et al., 1995; Holst et al., 
2015). Additionally, mice with a MGAT5 deficiency showed a suppression of mammary 
tumor cell growth and metastasis (Granovsky et al., 2000; Holst et al., 2015). The 
increased activity of GnT-V is also believed to result in a complementary decrease in 
biantennary complex type N-glycans (Dennis et al., 1987). Although not statistically 
significant, the presented results show a similar trend (Figure 6-4F, Table 6-2). While 
little is known about glycosylation changes in MLS, these previous findings would 
support a role for N-glycans in tumor progression in MLS. The biosynthesis of complex-
type N-glycans is dependent on the activity of a large number of different 
glycosyltransferases, changes in the expression of these enzymes result in changed 
glycosylation profiles. The increased abundance of complex-type glycans indicates that 
the maturation of glycans is not completely disrupted, as this would primarily result in 
an increased abundance of high-mannose-type glycans and truncated glycans. 
Expression analysis of the genes coding for the various glycosyltransferases, or a 
quantitative (micro)proteomics approach, could help identify which enzymes cause the 
altered glycosylation profiles in the different MLS grades. While the presented results 
clearly display a positive correlation between the abundance of several N-glycans and 
the progression of MLS (Figure 6-4A-E), a potential complicating factor is that MLS 
tumor progression is associated with an increase in cellularity (Fletcher et al., 2013). 
The majority of the glycoproteins are either secreted or membrane-bound. The N-
glycans analyzed by MALDI-MSI are no longer attached to their carrier proteins, which 
makes it impossible to establish whether a glycan was bound to a membrane protein or 
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a secreted, extracellular protein. Correcting for cell density may correct for contribution 
from membrane-bound proteins, but would introduce a bias for secreted proteins. 
Importantly the changed glycan profile reported here for MLS shows a clear correlation 
with previously published work performed on cell lines in which the number of cells 
were monitored and the results normalized (Demetriou et al., 1995) indicating that the 
changed glycan profile represents a biological effect, such as the overexpression of 
GnT-V causing the increase in β1,6-linked GlcNAc branching, or the reduced expression 
of mannosidases causing the increase in high-mannose-type glycans, rather than an 
artifact due to differences in cell density. 
6.4 Conclusions 
The presented results indicate an association between the increase of high-mannose-
type N-glycans and a triantennary complex-type glycan with progression of MLS. 
Additional protein and lipid MSI studies, as well as an in-depth analysis of the proteome 
should shed light on the nature of these molecular alterations. 
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6.6 Supplementary information 
6.6.1 Supplementary tables 










Table S6-2: Wilcoxon signed rank test results for the morphological comparison. Compositions legend: H = 
Glc/Gal/HexNAc, N = Man/Gal, F = Fucose, S = NeuAc (as sodiated species). P-values and q-values < 0.05 are 
highlighted in green. 
Composition m/z Myx vs Int (n = 11) Myx vs RC (n = 4) Int vs RC (n = 5) 
 [M+Na]+ p-value q-value p-value q-value p-value q-value 
H6N2 1419.48 0.5830 0.7212 0.2500 0.4688 0.6250 0.7212 
H7N2 1581.53 0.3575 0.5959 0.2500 0.4688 0.1875 0.4688 
H8N2 1743.58 0.5416 0.7212 0.1250 0.4688 0.1250 0.4688 
H9N2 1905.63 0.7609 0.8152 0.2500 0.4688 0.1875 0.4688 
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 The work presented in this thesis describes the improvement and application of on-
tissue chemistry for in-situ biomolecular analysis using matrix assisted-laser 
desorption/ionization mass spectrometry imaging (MALDI-MSI). We have proposed new 
methodologies, applying on-tissue (enzymatic) chemistry, to increase the molecular 
information obtained in a MALDI-MSI analysis. We have also developed an automated 
histology-guided MSI platform, based on state-of-the-art image processing tools, to 
facilitate high mass and spatial resolution MALDI-MSI while maintaining reasonable 
data loads and acquisition times. We have shown the importance of these methods in a 
clinical biomarker discovery study on myxoid liposarcoma tissues. The following section 
will summarize, discuss, and provide future perspectives on the reported developments. 
7.1 Technical developments 
7.1.1 Improving and innovating on-tissue chemistry for MALDI-
MSI analysis of proteins and post-translational protein 
modifications   
Since its introduction in 2006 by Shimma et al. (Shimma et al., 2006) on-tissue 
digestion has become increasingly popular in the MSI community, owing to its ability to 
increase proteome coverage and aid the (in-situ) identification of peptides/proteins. 
Moreover, it enables the proteomic analysis of formalin-fixed, paraffin-embedded 
(FFPE) tissues by MALDI-MSI, thereby greatly increasing the number of patient 
samples available for clinical MSI studies.  
 The use of proteolytic enzymes in bottom-up proteomics has been frequently 
investigated, especially with regard to the repeatability and quantification of the 
analysis (Brownridge and Beynon, 2011). Only a small number of studies have been 
conducted into the fundamentals and reproducibility of on-tissue enzymatic digestion, 
even though a workshop organized by the European MSI network COST Action BM1104 
specifically focusing on comparing different on-tissue digestion methods found very 
little consensus. Diehl et al. have previously published a study on the effect of different 
parameters during on-tissue digestion, including the protease, the incubation time, and 
the MALDI matrix. However, this study was mostly focused on improving the spatial 
resolution, and the quality and repeatability of the MSI images (Diehl et al., 2015). Two 
more recent studies by Erich et al. and De Sio et al. have compared multiple previously 
published on-tissue digestion sample preparation methods and tested the relative 
repeatability of those methods (Erich et al., 2016; Sio et al., 2015). Erich et al. 
proposed an automated, user-independent, computational approach to provide a more 
objective evaluation of the repeatability of MALDI-MSI (Erich et al., 2016). In Chapter 
2, we investigated the spatiotemporal dynamics of on-tissue enzymatic digestion. The 
investigation was based on the analysis of three sample groups with varying incubation 
times (1,5 h, 3 h, and 18 h), resulted in the finding that longer digestion times 
improved the repeatability of the on-tissue digestion. Additionally, it was found that 
differences in the chemical background of distinct morphological regions, specifically 
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the white and grey matter in mouse brain, resulted in differences in digestion 
efficiency. These sample preparation artifacts disappeared with the use of longer 
incubation times, supporting the hypothesis that longer incubation times improve the 
repeatability of on-tissue digestion experiments by ensuring a more complete digestion 
for all morphological regions.  
 The on-tissue digestion dynamics study focused on the global differences between 
the three incubation times by comparing the number of peaks in the total average 
spectra. Additional insight into the digestion dynamics was obtained by tracing the 
digestion of Myelin Basic Protein (MBP, MBP_MOUSE) throughout the tissue and the 
duration of the digestion. In order to reduce ionization bias and increase the 
comparability of the different datasets (n = 27, nine replicates per incubation time), 
three proteolytic fragments of MBP were selected and isotopically-labeled reference 
standard (ILRS) peptides were synthesized and sprayed homogeneously onto the 
tissue. The MBP fragments included two ‘limit peptides’ (end product of the proteolytic 
digestion), and one ‘missed-cleavage peptide’. The fragments were chosen in such a 
manner that the full digestion of the missed-cleavage peptide resulted in one of the 
limit peptides, so that relative intensity differences between the two peptides could be 
used to represent the efficiency of the digestion (with the proviso that other proteins 
might have different digestion efficiencies and other tissue types might affect the 
digestion dynamics). Also, it should be taken into account that the results were 
obtained for analysis from fresh frozen tissues; the dynamics of on-tissue digestion for 
FFPE tissues may well differ. While this study provides useful insight into the dynamics 
of on-tissue digestion, additional investigations spanning more proteins, more tissue 
types and tissue formats would be needed for a complete understanding of the factors 
affecting the dynamics of on-tissue digestion. Nevertheless the methodology reported 
here, to obtain quantitative data of digestion rate (for one cleavage site) from different 
tissue regions, presents the methodology that should be expanded for all future 
investigations. 
 The extensive work performed in the field of proteomics over the last two decades 
is an invaluable resource for the improvement and adaptation of MALDI-MSI methods. 
As described above, adaptation of the bottom-up proteomics approach led to the 
introduction of on-tissue digestion MALDI-MSI. As is the case in LC-MS/MS-based 
bottom-up proteomics, on-tissue proteolytic digestion is predominantly performed using 
trypsin. Due to its cleavage specificity, C-terminal of the basic amino acid residues 
arginine and lysine, trypsin produces proteolytic peptides with intrinsically positively 
charged C-termini that are detected with high sensitivity by mass spectrometry 
(Brownridge and Beynon, 2011; Vandermarliere et al., 2013).However, previous work 
in the proteomics field has also concluded that the use of different enzymes (even with 
a shared cleavage specificity) can lead to increased proteome coverage (Choudhary et 
al., 2003; Hohmann et al., 2009). In Chapter 3 and Chapter 5 we describe two 
different multi-enzyme approaches; Chapter 3 describes the combination of several 
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proteolytic enzymes with lysine and arginine cleavage specificity, and how the use of 
different enzymes could increase proteome coverage as well as protein sequence 
coverage; Chapter 5 describes a multimodal MSI approach, in which sequential on-
digestions were performed with the glycosidase PNGase F and trypsin in order to 
analyze both N-linked glycans and proteolytic peptides in two sequential MALDI-MSI 
analyses, but from the same FFPE tissue section. While the methodology proposed in 
Chapter 3 is dependent on the analysis of multiple tissue sections (although the 
analysis with the combination of trypsin/Lys-C is based on the same principle), the 
methodology in Chapter 5 requires only a single tissue section for the acquisition of 
two datasets on two closely related molecular classes. The benefit is that the 
information obtained in both datasets originates from exactly the same morphological 
and histological features. It should be noted that the MALDI-MS analysis of N-glycans 
can be improved further by performing a linkage-specific sialic acid derivatization. This 
derivatization stabilizes the otherwise labile sialic acid residues, enables the 
differentiation between the isobaric α2,3- and α2,6-linked sialic acids, and reduces the 
adverse effects on positive-mode ionization of the negative charge of native sialic acids 
(Holst et al., 2016). A potential complication is the dimethylamidation derivatization 
reaction modifies all free carboxylic acid (COOH) groups, and therefore also affects 
protein C-termini and acidic amino acid residues. The exact derivatization-induced 
changes of the proteins were not characterized in detail, but which could complicate 
the identification of proteolytic fragments from the same FFPE tissue section. 
Nevertheless, the sequential on-tissue digestion approach has proven itself a useful 
tool for N-glycan MALDI-MSI as is described in Chapter 5.  
7.1.2 Histology-guided MALDI-MSI    
Recent technological advances, mainly the development of an ultrafast MALDI-TOF-MS 
platform, and resolution for MALDI-FTICR-MS analysis, have made high spatial 
resolution and high mass resolution analysis readily available for MSI. However, the 
increased cellular and chemical specificity achieved by the high-resolution analysis 
come at the cost of data acquisition time and data load. Especially in the field of clinical 
MSI where large patient tissue series need to be analyzed, this imposes challenges on 
both the MSI infrastructure and data management systems. To overcome these 
challenges, we have developed a histology-guided MSI (HG-MSI) platform based on an 
automated image registration pipeline in Chapter 4. The image registration pipeline 
registers a high-resolution annotated histological image of a tissue section to a lower 
resolution image of an adjacent tissue section, prepared for MALDI-MSI analysis. 
Following the image registration, the annotation borders are reproduced on the low-
resolution image, enabling the exclusive MSI analysis of the a priori selected regions of 
interest. In a study on a small tissue cohort the HG-MSI approach resulted in a 
reduction of data acquisition time and data load of 80%, and thereby improving the 
applicability of high spatial and mass resolution MSI for clinical research. 
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 The prior histological specification of the HG-MSI approach is well suited for 
applications in which an a priori histological specification is possible, meaningful, and 
needed, e.g. the analysis of tumor progression based on cellular dedifferentiation or 
other specific morphological hallmarks. The tool is especially useful for those 
applications where high spatial resolution, or high mass resolution is required, but at 
the same time impractical or limited by extremely large pixel counts and/or slow data 
acquisition speeds. Chapter 4 describes the application of the HG-MSI platform for the 
analysis of proteolytic peptides from FFPE tissues using an ultrahigh mass resolution 
MALDI-FTICR-MS instrument manufactured by Bruker Daltonics. To ensure this tool can 
become a valuable asset for the MSI community it is vendor neutral, applicable to all 
MSI modalities (e.g. SIMS, DESI, LESA, etc.), and freely available online. 
 The analysis of tissue microarrays (TMA), as described in Chapter 6, offers a 
solution for the analysis of a large patient series. A TMA is an assembly of needle core 
biopsies (diameter 0.5 – 2 mm), obtained from histologically predefined tissue regions 
from many patients. The major advantages of analyzing TMAs are that a large number 
of patient samples can be rapidly compared; the experimental variance is reduced 
substantially as all needle cores are prepared during the same sample preparation and 
analyzed together; and a substantial histological pre-selection of tissue regions has 
already taken place.  
7.2 Clinical application  
7.2.1 The molecular background of tumor progression in myxoid 
liposarcoma    
The methods described in this thesis, and especially those in Chapters 4 and 5, were 
ultimately designed for their application in clinical research. Chapter 6 describes the 
application of the multimodal MSI method described in Chapter 5 in a study focusing 
on the molecular characterization of tumor progression in myxoid liposarcoma (MLS). 
We have demonstrated an association between a higher abundance of high-mannose 
type glycans, and highly branched complex-type glycans with MLS tumor progression. 
While this phenomenon was not previously described for MLS or any other 
mesenchymal tumor, it was described for several other tumor types, including 
colorectal cancer, breast cancer, and ovarian cancer. High-mannose type glycans are 
found both intra- and extracellular. However, the MALDI-MSI experiments in Chapter 
6 were not performed at a spatial resolution needed to discriminate between intra- or 
extracellular molecules. Therefore, the results presented in Chapter 6 should be 
validated with independent techniques such as immunohistochemistry to provide 
additional information on the exact location of the N-glycans in the cellular 
environment. Further insights into the changes associated with MLS progression could 
be garnered by also including protein and lipid MSI data as well as an in-depth analysis 
of the proteome, to further unravel the relevant pathways and molecular alterations 
leading to the advanced stages of MLS. 
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7.3 Future work   
This thesis describes the optimization and application of on-tissue digestion MALDI-MSI 
to improve its applicability in clinical research. Since the introduction of MSI, the 
identification of detected molecules has been one of the major challenges. Especially in 
clinical studies and/or biomarker discovery studies, the identity of the detected 
molecules is paramount to obtain valuable biological insights about the nature of the 
potential MSI-based biomarkers. One of the advantages of applying the on-tissue 
digestion method to in situ protein analysis is that it aids protein identification. The 
work described in the thesis shows that the number of protein identities that could be 
assigned to m/z features increased substantially with high mass resolution MSI. 
However, it should be noted that approximately only 10-15% of all peaks in the MSI 
average spectra were assigned with a peptide identity, and which did not include many 
of the high intensity peaks. The solution to improve the peptide identification rate in 
MSI is multifaceted.  
 First, in FFPE tissues, formalin is used to cross-link proteins and does so by 
connecting the basic amino acids lysine, arginine & histidine within and between 
proteins. For the analysis of proteins in FFPE tissue, formalin-fixation is reversed by a 
process called antigen retrieval. However, the reversal of the formalin fixation is often 
not complete and results in irregular, and predominantly uncharacterized remnants of 
the formalin fixation attached to the peptides/proteins. This results in both a large 
number of unmatched MS/MS spectra during the database search following LC-MS/MS 
analysis, and a large number of unassigned peaks in the MSI average spectrum. In 
order to utilize the full potential of proteomic MSI from FFPE tissue a thorough 
characterization of the formalin-induced modifications should be performed. However, 
previous attempts, and the fact that the majority of the bottom-up proteomics field 
remains distant from FFPE tissue, indicate the enormous challenges it encompasses. 
Alternatively, targeted offline LC-MS/MS approaches, based on MSI peak lists, could aid 
in additional identity assignments. 
 Second, the digested proteome with its large number of (near-)isobaric proteolytic 
fragments, is an extremely complex sample and results in a very complex mass 
spectrum containing many overlapping isotope envelopes. The spectra are further 
complicated by the presence of adducts. Tissues are a salt-rich environment, and 
although the tissues are washed during sample preparation, various salt-adducts (Na+, 
2Na-H+, K+, 2K-H+) are commonly detected in MSI analyses, as is described in 
Chapter 5. While the removal of adduct peaks from the mass spectra is a possible 
solution to simplify the spectra, the preferred strategy would be to reduce adduct 
formation during the analysis by applying additional washes, or using a more salt 
resistant MALDI matrix that reduces the adduct formation. Wang et al. recently 
reported that the matrix (E)-propyl α-cyano-4-hydroxyl cinnamylate, formed by the 
reaction of the regular peptide MALDI matrix α-cyano-4-hydroxycinnamic acid with 
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propyl alcohol, displayed high salt tolerance for intact protein analysis (Wang et al., 
2015b). We synthesized this matrix but preliminary MALDI-MSI experiments using on-
tissue digestion revealed the matrix exhibited an increased propensity to form salt 
adducts.  
 Third, the peptide identity assignments described in Chapter 3 and Chapter 5 of 
this thesis were all performed on the basis of accurate mass. While the use of this 
method provides a lot of valuable information on the potential identities of the detected 
molecules, the preferred method would involve the acquisition of their tandem MS 
spectra directly from the tissue section. While this approach is commonly described in 
literature using low mass resolution MALDI-TOF-MS platforms, its availability for high 
mass resolution MS systems is very limited. To improve the true peptide identification 
in MSI, mass spectrometers should be equipped with improved quadrupole technology, 
allowing a more specific selection of m/z features for fragmentation, leading to a more 
accurate identification directly from tissue.  
 The additional work described above would improve our basic understanding of the 
samples we work with, which will ultimately result in more specific and more efficient 
methods better suited for the MSI analysis of FFPE tissues. Nevertheless, the impact of 
MSI on clinical research rapidly increased over the last years, improved methodology 
and technology will ascertain further establishment of MSI in clinical research, and 
might result in an implementation of MSI in molecular diagnostics in the future. 
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acid 
CID  Collision-induced dissociation 
CMC Carboxymethyl cellulose 
COX7A Cytochrome C oxidase 7A2 
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DC  Direct current 
DESI Desorption electrospray 
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HG-MSI Histology-guided mass 
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HIAR Heat-induced antigen retrieval 
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dissociation 
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LESA Liquid extraction surface 
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LMJ-SSP Liquid microjunction surface 
sampling 
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MALDI Matrix-assisted laser 
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mmu Millimass units 
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MS  Mass spectrometry 
MSI  Mass spectrometry imaging 
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OCT  Optimal cutting temperature 
OS  Osteosarcoma 
PC  Phosphatidylcholines 
PEG  Polyethylene glycol 





catalytic subunit alpha isoform  
PNGase F Peptide N-glycosidase F 
ppm Parts-per-million 
PTEN Phosphatase and tensin 
homolog 
qTOF Quadrupole-time-of-flight 
RC  Round cell MLS 
RF  Radio frequency 
ROI  Region of interest 
SA  Sinapic acid 
SIMS Secondary ion mass 
spectrometry 
S/N  Signal-to-noise 
SPE  Solid phase extraction 
SPTN1 Spectrin-1 
SqCC Squamous cell carcinoma 
STS  Soft tissue sarcoma 
TCEP Tris(2-carboxyethyl)phosphine 
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 In dit proefschrift staat een aantal verbeteringen en toepassingen van in-situ 
chemie beschreven. In-situ chemie wordt gebruikt als monster voorbewerkingsmethode 
voor de biomoleculaire analyse met behulp van “matrix-assisted laser 
desorption/ionisation” (MALDI) “mass spectrometry imaging” (MSI). In de beschreven 
methoden worden enzymatische reacties direct toegepast op weefselcoupes om de 
moleculaire informatie, verkregen via de MALDI-MSI-analyse, te verrijken. Ook staat 
een geautomatiseerd histologie-gedreven MSI-platform beschreven dat gebruik maakt 
van moderne beeld bewerkingsalgoritmen. Dit nieuwe platform maakt het mogelijk MSI 
met hoge beeld- en massaresolutie toe te passen met behoud van werkbare data 
acquisitie tijden en data grootte. Tenslotte hebben we het belang van deze methoden 
aangetoond in een klinische studie naar de tumor progressie van myxoid liposarcoom. 
Hieronder volgen een samenvatting en een discussie van de gepresenteerde resultaten, 
alsmede een uiteenzetting van de toekomstperspectieven van het in dit proefschrift 
beschreven werk. 
Technologische ontwikkelingen 
De verbetering en innovatie van in-situ chemie voor MALDI-MSI-
analyse van eiwitten en post-translationele eiwitmodificaties  
In 2006 werd de in-situ enzymatische digestie met trypsine door Shimma et al. 
(Shimma et al., 2006) geïntroduceerd. Na haar introductie is de techniek snel populair 
geworden onder de gebruikers van MSI. De in-situ enzymatische digestie maakt het 
mogelijk om een groter deel van het proteoom te analyseren met MSI, helpt bij de 
identificatie van eiwitten/peptiden, en maakt de eiwitanalyse van formaline gefixeerd 
en daarna in paraffine ingebed (FFPE) weefsel mogelijk. Dit laatste zorgt ervoor dat er 
veel meer patiëntmateriaal beschikbaar komt voor klinische MSI-studies. 
 Het gebruik van proteolytische enzymen in oplossing, de herhaalbaarheid van de 
enzymatische digestie en de effecten van de enzymatische digestie op kwantitatieve, 
“bottom-up” eiwitanalyse is veelvuldig bestudeerd (Brownridge en Beynon, 2011). 
Tijdens een bijeenkomst van een werkgroep georganiseerd door het Europese MSI-
netwerk COST Actie BM1104, gericht op de vergelijking van MSI resultaten verkregen 
na in-situ eiwit digestie, werd maar weinig overeenstemming gevonden in de behaalde 
resultaten verkregen met verschillende in-situ enzymatische digestie methoden 
ontwikkeld in verschillende laboratoria. Desondanks is er maar een klein aantal studies 
uitgevoerd naar de fundamenten en de herhaalbaarheid van de enzymatische digestie 
op weefselcoupes. Diehl et al., beschrijven bijvoorbeeld het effect van verschillende 
experimentele parameters op de in-situ enzymatische digestie, waaronder de keuze van 
het proteolytisch enzym, de incubatietijd en de MALDI-matrix. Deze studie was met 
name gericht op het verbeteren van de beeldresolutie en de kwaliteit en 
reproduceerbaarheid van de door MSI geproduceerde visualisaties van moleculaire 
distributies (Diehl et al., 2015). In twee recentere studies door Erich et al. en De Sio et 
al. werden reeds gepubliceerde in-situ enzymatische digestie methoden vergeleken en 
158 Appendix 
 
de herhaalbaarheid van deze methoden getest (Erich et al., 2016; Sio et al., 2015). 
Erich et al. omschreven ook een geautomatiseerd en gebruikersonafhankelijk algoritme 
om een objectievere beoordeling van de herhaalbaarheid van een MALDI-MSI-
experiment te geven (Erich et al., 2016). In Hoofdstuk 2 hebben wij de dynamiek van 
de in-situ enzymatische digestie in zowel plaats als tijd onderzocht. Deze studie was 
gebaseerd op de MSI-analyse van drie groepen monsters na enzymatische digestie met 
variërende trypsine incubatietijden (1.5 uur, 3 uur, en 18 uur). Deze analyses leidden 
tot de bevinding dat langere incubatietijden resulteerden in een betere herhaalbaarheid 
van de in-situ enzymatische digestie. Ook werd geconcludeerd dat het gevarieerde 
chemische “landschap” van verschillende morfologische gebieden in het muis brein, de 
witte en grijze stof bijvoorbeeld, effect had op de digestie efficiëntie. Deze artefacten 
van de monster voorbewerking verdwenen wanneer langere incubatietijden werden 
gebruikt. Hiermee werd de hypothese bevestigd dat langere incubatietijden de 
herhaalbaarheid van de in-situ enzymatische digestie bevorderen. Deze verbeterde 
herhaalbaarheid komt voort uit een completere eiwitdigestie in alle morfologische 
gebieden. 
 Tijdens de studie naar de dynamiek van de in-situ enzymatische digestie werd 
gekeken naar de globale verschillen in de massaspectra na het toepassen van de drie 
incubatietijden. Deze verschillen werden bepaald door het vergelijken van het totaal 
aantal pieken in de gemiddelde spectra. Ook werd de digestiedynamiek bestudeerd 
door het volgen van de digestie van het eiwit Myelin Basic Protein (MBP, MBP_MOUSE) 
gedurende de volledige lengte van de incubatietijd door het hele weefsel. Om ionisatie 
effecten te reduceren en de verschillende datasets (n = 27, negen replicaties per 
incubatietijd) meer vergelijkbaar te maken werden drie proteolytische fragmenten van 
MBP geselecteerd en gesynthetiseerd als isotoop-gelabelde referentie standaard (ILRS) 
peptiden. Deze ILRS-peptiden werden vervolgens homogeen op de weefsels 
aangebracht als interne standaard. Onder de gekozen MBP-fragmenten waren twee 
zogenaamde ‘limiet peptiden’ (eindproducten van de proteolytische digestie), en één 
‘intermediair peptide’ (partieel geknipt digestie product). De fragmenten waren zodanig 
gekozen dat de volledige digestie van het intermediair peptide resulteerde in een van 
de geselecteerde limiet peptiden. Op deze manier kon de digestie efficiëntie bepaald 
worden door middel van de verschillen in relatieve intensiteit tussen de limiet en 
intermediair peptiden. De berekende digestie efficiëntie is mogelijk anders voor andere 
eiwitten, en ook het gebruik van andere weefseltypen kan de digestie dynamiek 
beïnvloeden. De hier gepresenteerde resultaten volgden uit de analyse van 
diepgevroren weefsel. Het gebruik van FFPE-weefsel kan de dynamiek van de in-situ 
digestie mogelijk veranderen. Deze studie geeft een nuttig inzicht in de dynamiek van 
de in-situ enzymatische digestie, maar om een volledig beeld te krijgen van alle 
factoren die de dynamiek van eiwitdigestie op een weefselcoupe beïnvloeden zal een 
grootschalige studie met meer verschillende weefseltypen en meer eiwitten moeten 
worden uitgevoerd. Desalniettemin kan de methodiek die in Hoofdstuk 2 beschreven 
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wordt, namelijk het verkrijgen van kwantitatieve data over de enzymatische 
digestiesnelheid (voor één knip locatie) in verschillende morfologische gebieden in het 
weefsel, voor de gehele studie naar andere weefsels en eiwitten toegepast worden. 
 De grote hoeveelheid onderzoek die de afgelopen twee decennia in het proteomics-
veld is gedaan heeft geresulteerd in een onuitputtelijke bron van informatie die kan 
worden gebruikt voor het aanpassen, verbeteren en ontwikkelen van MALDI-MSI-
methoden. Zoals eerder beschreven heeft de aanpassing van de bottom-up proteomics 
aanpak geleid tot de introductie van de in-situ enzymatische digestie als 
monsteropwerking voor MALDI-MSI-analyse. Net zoals in eiwitstudies op basis van 
digestie in vloeistof wordt de in-situ digestie voornamelijk met trypsine uitgevoerd. De 
reden hiervoor is de restrictiespecificiteit van het enzym: trypsine knipt eiwitten aan de 
C-terminale zijde van de basische aminozuren arginine en lysine. Hierdoor produceert 
trypsine proteolytische fragmenten met een intrinsiek positief geladen C-terminus. Dit 
zorgt voor een hogere detectiegevoeligheid in de massaspectrometrie analyse in 
positieve ion modus (Brownridge en Beynon, 2011; Vandermarliere et al., 2013). 
Onderzoek in het proteomics-veld heeft ook uitgewezen dat het gebruik van meerdere 
proteolytische enzymen (zelfs met gedeelde specificiteit voor dezelfde aminozuren) kan 
leiden tot een diepere analyse van het proteoom (Choudhary et al., 2003; Hohmann et 
al., 2009). In Hoofdstuk 3 en Hoofdstuk 5 worden twee verschillende methodieken 
beschreven waarbij meerdere enzymen in-situ worden gebruikt; Hoofdstuk 3 
beschrijft de combinatie van verschillende proteolytische enzymen met een specificiteit 
voor arginine en lysine en hoe het gebruik van deze enzymen zowel de totale 
hoeveelheid geanalyseerde eiwitten alsmede de eiwit-aminozuursequentiedekking 
beïnvloedt; Hoofdstuk 5 beschrijft een multimodale MSI methode waarin twee 
opvolgende in-situ enzymatische digesties worden uitgevoerd. De eerste digestie wordt 
gedaan met de glycosidase PNGase F en de tweede digestie met de protease trypsine. 
Deze sequentiële digestie maakt het mogelijk om achtereenvolgens N-glycanen en 
proteolytische peptiden te analyseren vanaf hetzelfde weefsel. De methode beschreven 
in Hoofdstuk 3 is afhankelijk van de analyse van meerdere weefselcoupes, terwijl 
voor de methode beschreven in Hoofdstuk 5 maar een enkele weefselcoupe nodig is 
voor de analyse van de twee datasets. Het voordeel van het de methode beschreven in 
Hoofdstuk 5 is dat de moleculaire informatie die verkregen wordt in beide datasets 
zijn origine vindt in exact dezelfde morfologische gebieden van het weefsel. Hierdoor 
beschrijven de twee datasets de moleculaire informatie van dezelfde histopathologische 
karakteristieken van deze weefsels. Hierbij moet wel vermeld worden dat de MALDI-
MS-analyse van N-glycanen verbeterd kan worden door middel van een bindings-
specifieke derivatisering van de siaalzuren. Deze procedure stabiliseert de normaliter 
labiele siaalzuren, zorgt ervoor dat de isobare α2,3- en α2,6-gebonden siaalzuren van 
elkaar onderscheiden kunnen worden en reduceert de negatieve effecten die het 
negatief geladen siaalzuur heeft op de ionisatie van positieve ionen (Holst et al., 2016). 
De chemische dimethylamidatie-reactie, die voor de derivatisatie wordt uitgevoerd, 
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reageert met alle vrije carboxylgroepen (COOH) en heeft als bijkomend effect dat ook 
de C-termini van eiwitten en de zijgroepen van zure aminozuren worden gemodificeerd. 
De exacte modificaties van de eiwitten ten gevolge van de derivatisatie zijn niet in 
detail gekarakteriseerd en zullen ervoor zorgen dat de in-situ identificatie van de 
proteolytische fragmenten van hetzelfde FFPE-weefsel moeilijker wordt. Desalniettemin 
is in Hoofdstuk 5 aangetoond dat de sequentiële in-situ digestie een bruikbare en 
waardevolle techniek is voor de analyse van N-glycanen. 
Histologie-gedreven MALDI-MSI 
Recente technologische ontwikkelingen, met name de ontwikkeling van een ultrasnel 
MALDI-TOF-MS-platform, en de verbeterde resolutie van MALDI-FTICR-MS-analyse, 
hebben ervoor gezorgd dat MSI met hoge beeld- en massaresolutie beschikbaar kwam. 
De toename in cellulaire en chemische specificiteit, als resultaat van de hoge beeld en 
massaresolutie, gaat ten koste van de data acquisitie tijd en data grootte. Vooral in het 
klinisch MSI-onderzoek levert dit uitdagingen op voor de MSI-infrastructuur en data 
managementsystemen door de grote weefselreeksen van patiëntmateriaal die gemeten 
worden. Om de data-acquisitietijd en -grootte binnen de perken te houden hebben we 
in Hoofdstuk 4 een histologie-gedreven MSI (HG-MSI) platform ontwikkeld gebaseerd 
op een serie geautomatiseerde beeldregistratie algoritmen. Tijdens de beeldregistratie 
wordt een geannoteerd histologisch beeld van een weefselcoupe, opgenomen met een 
hoge beeldresolutie, ge-co-registreerd aan een ander beeld van een opeenvolgende 
coupe, opgenomen met een lagere beeldresolutie. Deze tweede weefselcoupe is 
opgewerkt voor MALDI-MSI-analyse. Na deze beeldregistratie worden de contouren van 
de annotaties gereproduceerd op het lage-resolutie beeld van de MSI-weefselcoupe. 
Dit geeft de mogelijk om exclusief de a priori geselecteerde regionen van interesse 
(ROIs) met MSI te analyseren en daarmee de data acquisitie tijd en grootte te 
verminderen. Het succes van het platform werd aangetoond door de analyse van een 
kleine weefselreeks met behulp van het HG-MSI-platform. Deze analyse resulteerde in 
een reductie van de data grootte en acquisitietijd van ongeveer 80% in vergelijking 
met de analyse van de volledige weefselcoupes. Met het gebruik van het HG-MSI-
platform is de toepassing en het routinematig gebruik van MSI met hoge beeld- en 
massaresolutie in klinisch onderzoek een stap dichterbij gekomen. 
 De strategie toegepast in de HG-MSI-methode, waarbij de histopathologische 
specificatie van het weefsel is gedaan voorafgaand aan de MSI-analyse, is zeer 
geschikt voor toepassingen waar de a priori histologische specificatie mogelijk, 
betekenisvol, en/of nodig is. Een voorbeeld hiervan is de analyse van tumor progressie, 
gebaseerd op cellulaire differentiatie of andere specifieke morfologische 
karakteristieken. Een ander voorbeeld is de toepassing van MSI waar hoge 
beeldresolutie of hoge massaresolutie nodig is, maar onpraktisch is door een te groot 
aantal te analyseren pixels, of een langzame data acquisitie. Hoofdstuk 4 beschrijft de 
toepassing van het HG-MSI-platform voor de analyse van proteolytische peptiden van 
FFPE-weefsels, gebruik makende van een Bruker Daltonics MALDI-FTICR-MS-
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instrument dat met ultrahoge massaresolutie meet. Om ervoor te zorgen dat het HG-
MSI platform bruikbaar en waardevol zou zijn voor de hele MSI-gemeenschap is ervoor 
gezorgd dat het gebruikt kan worden met massaspectrometers van alle producenten, 
met alle MSI-modaliteiten (SIMS, DESI, LESA, etc.), en dat het gratis/vrij beschikbaar is 
op het internet.  
 De analyse van tissue microarrays (TMAs), zoals beschreven in Hoofdstuk 6, is 
een andere oplossing voor het analyseren van grote reeksen patiëntweefsels. Een TMA 
is een verzameling van “punches” (diameter 0.5 – 2 mm), genomen uit specifieke 
gebieden van weefselblokken na histopathologische analyse van de weefsels. De 
voordelen van de analyse van een TMA zijn dat je de weefsels van een groot aantal 
patiënten in een kort tijdsbestek kunt vergelijken en dat de experimentele variantie 
aanzienlijk wordt verminderd, omdat de weefsels afkomstig van verschillende patiënten 
op hetzelfde moment dezelfde monsteropwerking ondergaan en samen worden 
geanalyseerd.  
Klinische applicatie  
De moleculaire achtergrond van tumor progressie in myxoid 
liposarcoom    
De methoden beschreven in dit proefschrift, met name deze in Hoofdstukken 4 en 5, 
werden ontwikkeld voor toepassing in klinisch onderzoek. Hoofdstuk 6 beschrijft de 
toepassing van de multimodale MSI-methode omschreven in Hoofdstuk 5 in een 
studie waarin de moleculaire achtergrond van tumor progressie in myxoid liposarcoom 
(MLS) werd onderzocht. In deze studie werd aangetoond dat er een associatie bestaat 
tussen de progressie van MLS en een hogere aanwezigheid van het type mannose-rijke 
glycanen en het type complexe glycanen met een verhoogd aantal antennes. Deze 
moleculaire veranderingen werden niet eerder beschreven voor MLS of andere 
mesenchymale tumoren, maar wel voor colorectaal-, borst-, en eierstoktumoren. 
Mannose-rijke glycanen worden zowel intra- als extracellulair aangetroffen. De MALDI-
MSI-analyse in Hoofdstuk 6 werd echter uitgevoerd met een beeldresolutie die het 
niet mogelijk maakt om het verschil te kunnen zien tussen intra- en extracellulaire 
moleculen. Om de gevonden resultaten te valideren en verdere informatie te 
verzamelen over de precieze locatie van de glycanen in het cellulaire milieu zullen 
experimenten met complementaire technieken, zoals immunohistochemie, moeten 
worden uitgevoerd. Verdere inzichten in de moleculaire achtergrond van MLS-
tumorprogressie zouden ook gehaald kunnen worden uit extra MSI-analyses van lipiden 
en eiwitten. Ook een diepgaande analyse van het proteoom zou van toegevoegde 
waarde kunnen zijn en inzicht kunnen geven over de moleculaire veranderingen die ten 
grondslag liggen aan de progressie van MLS. 
162 Appendix 
 
Toekomstperspectief   
In dit proefschrift wordt de optimalisatie en toepassing van in-situ enzymatische 
digestie in combinatie met MALDI-MSI beschreven om de toepassing hiervan in klinisch 
onderzoek te bevorderen. Sinds de introductie van MSI is het koppelen van een 
moleculaire identiteit aan een gedetecteerde m/z waarde een van de grootste 
uitdagingen. Voor klinische studies en studies waarin men tracht biomarkers te vinden 
is de identiteit van de gedetecteerde moleculen van essentieel belang om de 
biologische achtergrond van de biomarker te doorgronden. Eén van de voordelen van 
het toepassen van de in-situ enzymatische eiwit digestie vóór de analyse met MALDI-
MSI, is dat het de identificatie van de eiwitten achteraf bevorderd. Het werk 
beschreven in dit proefschrift laat zien dat het aantal verschillende geïdentificeerde 
eiwitten, toegekend aan pieken in het MSI-massaspectrum, aanzienlijk toeneemt 
wanneer de MSI-analyse met hoge massaresolutie wordt uitgevoerd. Hier moet echter 
wel bij vermeld worden dat slechts 10-15% van het totale aantal pieken in het MSI-
massaspectrum geïdentificeerd kon worden. Ook bleven de pieken met de hoogste 
intensiteit vaak ongeïdentificeerd. Door de complexiteit van het probleem, heeft de 
oplossing die resulteert in een hoger aantal peptide identificaties verschillende facetten. 
 In FFPE-weefsel wordt formaldehyde gebruikt om eiwitten aan elkaar te koppelen. 
Deze koppeling vindt plaats door de verbinding van de basische aminozuren lysine, 
arginine en histidine. Om het mogelijk te maken eiwitten in FFPE-weefsels te 
analyseren moeten deze verbindingen verbroken worden tijdens een 
antigeenherwinning. Het proces van de formaline fixatie is echter niet volledig 
reversibel, en de eiwitten blijven vaak achter met onregelmatige, en veelal niet 
gekarakteriseerde moleculaire modificaties. Deze modificaties resulteren in een groot 
aantal niet-geïnterpreteerde MS/MS-spectra na de LC-MS/MS-analyse, wat een groot 
aantal ongeïdentificeerde pieken in het MSI-massaspectrum ten gevolge heeft. Om het 
volledige potentieel van eiwit MSI van FFPE-weefsels te benutten zouden de formaline-
geïnduceerde modificaties grondig gekarakteriseerd moeten worden. Eerdere pogingen, 
en het feit dat de meerderheid van het bottom-up proteomics veld ver weg blijft van 
FFPE-weefsels, geven aan dat dit een enorme uitdaging behelst. Een alternatief om de 
hoeveelheid identificaties te vergroten zou zijn om doelmatige LC-MS/MS-analyses te 
doen, gebaseerd op de pieklijsten verkregen uit de MSI-analyse. 
 Verder is het enzymatisch gedigesteerde proteoom een zeer complex geheel en 
resulteert, mede door het grote aantal isobare proteolytische peptiden, in een 
uitermate complex massaspectrum met veel overlappende isotooppatronen. De 
massaspectra worden nog complexer gemaakt door de aanwezigheid van 
zoutcomplexen. Weefsels hebben een zoutrijk milieu, en zoals beschreven in 
Hoofdstuk 5 wordt een variëteit aan peptide-zoutcomplexen, zoals Na+, 2Na-H+, K+, 
2K-H+ waargenomen. Dit terwijl er vóór de eiwitanalyse een aantal spoel stappen in de 
monstervoorbewerking zijn opgenomen om zouten en lipiden uit het weefsel te 
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verwijderen. Na de MSI-analyse zou het identificeren en verwijderen van de 
zoutcomplex-pieken uit het massaspectrum een oplossing kunnen bieden om het 
massaspectrum minder complex te maken. Het zou echter beter zijn om de 
daadwerkelijke formatie van de zoutcomplexen te voorkomen. Dit zou bereikt kunnen 
worden door het toepassen van additionele weefsel spoel stappen, of door het 
toepassen van een meer zout resistente MALDI-matrix die de vorming van 
zoutadducten tegengaat. Wang et al. hebben recentelijk gepubliceerd over de matrix 
(E)-propyl α-cyano-4-hydroxylcinnamylaat, gevormd door de reactie van de reguliere 
MALDI-matrix α-cyano-4-hydroxycinnamic acid met een propyl-alcohol, welke een hoge 
zouttolerantie heeft voor de analyse van intacte eiwitten (Wang et al., 2015b). Nadat 
we deze MALDI-matrix gesynthetiseerd hadden en hier proteolytische peptiden mee 
hebben geanalyseerd, toonden de preliminaire resultaten een verhoogd aantal 
zoutcomplexen. 
 De toegekende peptide identiteiten, beschreven in Hoofdstuk 3 en Hoofdstuk 5 
van dit proefschrift werden allen gedaan op basis van de accurate massa van de 
moleculen. Hoewel de beschreven methode waardevolle informatie geeft over de 
potentiële identiteit van de gedetecteerde moleculen, heeft in-situ fragmentatie en 
directe tandem MS-analyse vanaf het weefsel de voorkeur. Deze aanpak is veelvuldig 
beschreven in de literatuur met gebruik van massaspectrometers met lage massa 
resolutie (zoals MALDI-TOF-MS-platformen), maar de beschikbaarheid van deze 
techniek voor instrumenten met hoge massaresolutie is erg beperkt. Om de definitieve 
identificatie van peptiden te doen met behulp van MSI zullen massaspectrometers 
moeten worden uitgerust met verbeterde quadrupole technologie, zodat een 
specifiekere selectie van ionen kan plaatsvinden, wat uiteindelijk zal leiden tot een 
meer accurate peptide identificatie direct vanaf het weefsel. 
 Het additionele werk wat hierboven beschreven is zal ons inzicht in de moleculaire 
histologie van de weefsels waarmee we werken drastisch vergroten, wat uiteindelijk zal 
resulteren in meer specifieke en efficiënte methoden die nog beter geschikt zijn voor de 
MSI-analyse van FFPE-weefsel. Ondanks de huidige tekortkomingen van de techniek is 
de impact van MSI op klinisch onderzoek de laatste jaren enorm toegenomen. 
Verbeterde methoden en meer geavanceerde technologie zullen deze impact met 
zekerheid gaan vergroten wat de implementatie van MSI in klinisch onderzoek zal 
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